In the united states patent and trademark office
Chimeric VSV-G proteins combining Indiana and Cocal VSV-G domains enhance viral fusion and host cell membrane interaction, addressing the need for novel VSV-G variants with improved therapeutic potential.
Patent Information
- Application Number
- PCT/US2026/026770
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
There is an ongoing need for novel vesicular stomatitis virus glycoprotein (VSV-G) variants for therapeutic use, particularly in enhancing viral fusion and host cell membrane interaction.
Development of chimeric VSV-G proteins comprising domains from Indiana and Cocal VSV-G, including signal peptide, lateral, trimerization, pleckstrin homology, fusion, and transmembrane domains, with specific amino acid modifications to enhance binding and fusion capabilities.
The chimeric VSV-G proteins demonstrate improved viral fusion and host cell membrane interaction, leading to increased production of delivery particles and potential therapeutic applications.
Smart Images

Figure US2026026770_12112026_PF_FP_ABST
Abstract
Description
ATTORNEY DOCKET No.: AZL-007WOIN THE UNITED STATES PATENT AND TRADEMARK OFFICEVSVG VARIANTSCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 800,180 filed May 5, 2025, which is hereby incorporated in its entirety by reference for all purposes.REFERENCE TO AN ELECTRONIC SEQUENCE LISTING
[0002] The contents of the electronic sequence listing (AZL_007USPR_SeqList_ST26.xml; Size: 393,684 bytes; and Date of Creation: May 1, 2025) are herein incorporated by reference in their entirety.FIELD OF THE DISCLOSURE
[0003] The present disclosure relates to vesicular stomatitis virus glycoprotein (VSV-G) chimeras and other variants. Also provided are compositions, such as delivery particles, comprising these recombinant VSV-G proteins, as well as methods of use thereof.BACKGROUND
[0004] Viral fusion proteins facilitate enveloped virus infection. These proteins mediate fusion between the virus envelope and host cellular membrane to release the viral genome into cells. Vesicular stomatitis virus glycoprotein (VSV-G) is a type III viral fusion protein. Native VSV-G binds to the low-density lipoprotein receptor (LDL-R) and its family members.
[0005] There is an ongoing and unmet need for novel VSV-G variants for therapeutic use.SUMMARY
[0006] Provided herein is a chimeric vesicular stomatitis virus glycoprotein G (VSV-G) comprising: a) one or more Indiana VSV-G domains; and b) one or more Cocal VSV-G domains.
[0007] In some aspects, the chimeric VSV-G comprises an immature VSV-G comprising: a) a signal peptide (SG), a lateral domain (DI), a trimerization domain (Dll), and a pleckstrin homology domain (Dill) from an Indiana VSV-G; and b) a fusion domain (DIV) and a transmembrane domain (TM) from a Cocal VSV-G.1IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0008] In some aspects, the chimeric VSV-G comprises a mature VSV-G comprising: a) a lateral domain (DI), a trimerization domain (DII), and a pleckstrin homology domain (Dill) from an Indiana VSV-G; and b) a fusion domain (DIV) and a transmembrane domain (TM) from a Cocal VSV-G.
[0009] Also provided herein is a chimeric VSV-G comprising: a) one or more Indiana VSV-G domains; b) one or more Cocal VSV-G domains; and c) a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.
[0010] In some aspects, the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of the respective domains of the amino acid sequence of SEQ ID NO: 1. In some aspects, the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of the respective domains of the amino acid sequence of SEQ ID NO: 307.
[0011] In some aspects, the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of the respective domains of the amino acid sequence of SEQ ID NO: 309. In some aspects, the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of the respective domains of the amino acid sequence of SEQ ID NO: 13.
[0012] In some aspects, the chimeric VSV-G comprises a signal peptide (SG), a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM). In some aspects, the chimeric VSV-G comprises a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM). In some aspects, each respective domain comprises either an Indiana VSV-G domain or a Cocal VSV-G domain. In some aspects, the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Indiana VSV-G. In some aspects, the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Cocal VSV-G. In some aspects, the chimeric VSV-G comprises 3 domains from Indiana VSV-G and 2 domains from Cocal VSV-G, not inclusive of the signal peptide (SG).2IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0013] In some aspects: (a) the Indiana VSV-G SG domain comprises amino acids 1-16 of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (b) the Indiana VSV-G DI domain comprises two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (c) the Indiana VSV-G DII domain comprises three segments comprising amino acids 35-52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (d) the Indiana VSV-G Dill domain comprises two segments comprising amino acids 53-69 and 198-275, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (e) the Indiana VSV-G DIV domain comprises amino acids 70-197 of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; and (f) the Indiana VSV-G TM domain comprises amino acids 425-512 of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307.
[0014] In some aspects: (a) the Indiana VSV-G SG domain comprises SEQ ID NO: 3; (b) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5 or comprising SEQ ID NO: 4 and 311, respectively; (c) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (d) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10 or comprising SEQ ID NO: 312 and 10, respectively; (e) the Indiana VSV-G DIV domain comprises SEQ ID NO: 11; and (f) the Indiana VSV-G TM domain comprises SEQ ID NO: 12.
[0015] In some aspects: (a) the Cocal VSV-G SG domain comprises amino acids 1-17 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; (b) the Cocal VSV-G DI domain comprises two segments comprising amino acids 18-35 and 328-399, respectively, of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; (c) the Cocal VSV-G DII domain comprises three segments comprising amino acids 36-53, 277-327, and 400-425, respectively, of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13: (d) the Cocal VSV-G Dill domain comprises two segments comprising amino acids 53-69 and 199-276, respectively, of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; (e) the Cocal VSV-G DIV domain comprises amino acids 71-198 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ 3IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOID NO: 309 or SEQ ID NO: 13; and (f) the Cocal VSV-G TM domain comprises amino acids 426-513 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13.
[0016] In some aspects: (a) the Cocal VSV-G SG domain comprises SEQ ID NO: 15; (b) the Cocal VSV-G DI domain comprises two segments comprising SEQ ID NO: 16 and 17 or comprising SEQ ID NO: 16 and 313, respectively; (c) the Cocal VSV-G DII domain comprises three segments comprising SEQ ID NO: 18, 19, and 20, respectively; (d) the Cocal VSV-G Dill domain comprises two segments comprising SEQ ID NO: 21 and 22 or comprising SEQ ID NO: 314 and 22, respectively; (c) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and (f) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
[0017] Also provided herein is a chimeric VSV-G comprising: (a) an Indiana VSV-G SG domain comprising amino acids 1-16 of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (b) an Indiana VSV-G DI domain comprising two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (c) an Indiana VSV-G DII domain comprising three segments comprising amino acids 35-52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (d) an Indiana VSV-G Dill domain comprising two segments comprising amino acids 53-69 and 198-275, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (e) a Cocal VSV-G DIV domain comprising amino acids 71-198 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; and (f) a Cocal VSV-G TM domain comprising amino acids 426-513 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13.
[0018] In some aspects: (a) the Indiana VSV-G SG domain comprises SEQ ID NO: 3; (b) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5 or comprising SEQ ID NO: 4 and 311, respectively; (c) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (d) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10 or comprising SEQ ID NO: 312 and 10, respectively; (e) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and (f) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.4IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0019] In some aspects: (a) the Indiana VSV-G SG domain comprises SEQ ID NO: 3; (b) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5, respectively; (c) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (d) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10, respectively; (e) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and (f) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
[0020] Also provided herein is a chimeric VSV-G comprising: (a) an Indiana VSV-G DI domain comprising two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (b) an Indiana VSV-G DII domain comprising three segments comprising amino acids 35-52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (c) an Indiana VSV-G Dill domain comprising two segments comprising amino acids 53-69 and 198-275, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (d) a Cocal VSV-G DIV domain comprising amino acids 71-198 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; and (e) a Cocal VSV-G TM domain comprising amino acids 426-513 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13.
[0021] In some aspects: (a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5 or comprising SEQ ID NO: 4 and 311, respectively; (b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10 or comprising SEQ ID NO: 312 and 10, respectively; (d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and (e) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
[0022] In some aspects: (a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5, respectively; (b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10, respectively; (d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and (c) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
[0023] In some aspects, the Indiana VSV-G domain has one or more of the sequences of any one of SEQ ID NO: 3-12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the Cocal VSV-G domain has one5IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOor more of the sequences of any one of SEQ ID NOs: 15-24, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
[0024] In some aspects, the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 139, 156, 158, 162, 164, 166, 141, 145, 147, 149, 153, 155, 161, 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 139, 156, 158, 162, 164, 166, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171, 173, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 139, 162, 153, 155, 182, 196, and 169, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the chimeric VSV-G comprises the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the chimeric VSV-G consists of the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the chimeric VSV-G comprises the sequence of SEQ ID NO: 306, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the chimeric VSV-G consists of the sequence of SEQ ID NO: 306, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
[0025] In some aspects, the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 2, optionally between 80% and 90% or between 85% and 90% sequence identity. In some aspects, the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 14, optionally between 80% and 90% or between 85% and 90% sequence identity. In some aspects, the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 2 and between about 70% and about 90% sequence identity with SEQ ID NO: 14, optionally between 80% and 90% or between 85% and 90% sequence identity with respect to both SEQ ID NO: 2 and SEQ ID NO: 14.
[0026] In some aspects, one or more of the Indiana VSV-G domains comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding Indiana VSV-G domain of SEQ ID NO: 1. In some aspects, one or more of the Cocal VSV-G domains comprise 1, 2, 3, 4, 5, 6, 7,6IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO8, 9, or 10 amino acid mutations compared to the corresponding Cocal VSV-G domain of SEQ ID NO: 13.
[0027] In some aspects, the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated. In some aspects, the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine. In some aspects, the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine. In some aspects, the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated to a residue wherein the chimeric VSV-G binding to a LDL receptor is reduced or eliminated. In some aspects, the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated. In some aspects, the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine. In some aspects, the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 SEQ ID NO: 310 is substituted with a glutamine. In some aspects, the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated to a residue wherein the chimeric VSV-G binding to a LDL receptor is reduced or eliminated. In some aspects, the lysine residue corresponding to residue number 47 and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 are each mutated, respectively. In some aspects, the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine. In some aspects, the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine. In some aspects, the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine. In some aspects, the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine. In some aspects, the lysine residue corresponding to residue number 47 and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 are each mutated, respectively, to a residue wherein the chimeric VSV-G binding to a LDL receptor is reduced or eliminated. In some aspects, the chimeric VSV-G has a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.7IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0028] In some aspects, the chimeric VSV-G comprises a TS, T, or S substitution contained in any oneofSEQ ID NO: 27-78, 133, 230, and 231. In some aspects, the chimeric VSV-G comprises a TS pair contained in any one of SEQ ID NO: 27-78, 133, 230, and 231. In some aspects, the chimeric VSV-G does not comprise an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2 and / or does not comprise a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.
[0029] Also provided herein is a chimeric VSV-G comprising: a) one or more domains having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; and b) one or more domains having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain, wherein the chimeric VSV-G has less than least 90% sequence identity with an Indiana VSV-G or a Cocal VSV-G, optionally between about 70% and about 90% sequence identity with SEQ ID NO: 2 and between about 70% and about 90% sequence identity with SEQ ID NO: 14, optionally between 80% and 90% or between 85% and 90% sequence identity with respect to both SEQ ID NO: 2 and SEQ ID NO: 14.
[0030] In some aspects, the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 1. In some aspects, the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 13.
[0031] In some aspects, the SG domain comprises SEQ ID NO: 3, the DI domain comprises SEQ ID NO: 4 and 5, the DII domain comprises SEQ ID NO: 6, 7, and 8, the Dill domain comprises SEQ ID NO: 9 and 10, the DIV domain comprises SEQ ID NO: 11, and / or the TM domain comprises SEQ ID NO: 12. In some aspects, the SG domain comprises SEQ ID NO: 15, the DI domain comprises SEQ ID NO: 16 and 17, the DII domain comprises SEQ ID NO: 18, 19, and 20, the Dill domain comprises SEQ ID NO: 21 and 22, the DIV domain comprises SEQ ID NO: 23, and / or the TM domain comprises SEQ ID NO: 24.
[0032] In some aspects, the chimeric VSV-G comprises a signal peptide (SG), a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM). In some aspects, the chimeric VSV-G comprises a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain8IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(DIV), and a transmembrane domain (TM). In some aspects, each domain is an Indiana VSV-G domain or a Cocal VSV-G domain. In some aspects, the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Indiana VSV-G. In some aspects, the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Cocal VSV-G.
[0033] In some aspects, the Indiana VSV-G domain has the sequence of any one of SEQ ID NO: 3-12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the Cocal VSV-G domain has the sequence of any one of SEQ ID NOs: 15-24, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
[0034] In some aspects, the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 141, 145, 147, 149, 153, 155, 161, 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171, 173, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 162, 139, 153, 155, 182, 196, and 169, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the chimeric VSV-G comprises the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
[0035] In some aspects, the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 1. In some aspects, the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 13.
[0036] In some aspects, the Indiana VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 1. In some aspects, the Cocal VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 13. In some aspects, the chimeric VSV-G has a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2. In some aspects, the chimeric VSV-G has an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2. In some aspects, the chimeric VSV-G has a deletion of the lysine amino acid9IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOcorresponding to position 47 of SEQ ID NO: 2. In some aspects, the chimeric VSV-G comprises a TS, T, or S substitution contained in any one of SEQ ID NO: 27-78, 133, 230, and 231. In some aspects, the chimeric VSV-G comprises a TS pair contained in any one of SEQ ID NO: 27-78, 133, 230, and 231. In some aspects, the chimeric VSV-G does not comprise an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2 and / or does not comprise a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.
[0037] Also provided herein is an isolated nucleic acid, the isolated nucleic acid encoding any one of the chimeric VSV-Gs described herein.
[0038] Also provided herein is a vector encoding any one of the isolated nucleic acids described herein, optionally wherein the vector comprise a promoter operably linked to the isolated nucleic acid encoding the chimeric VSV-G.
[0039] Also provided herein is a host cell comprising any one of the isolated nucleic acids or the vectors described herein.
[0040] Also provided herein is a method of producing a delivery particle, the method comprising contacting a host cell with the isolated nucleic acid or the vector described herein and one or more components for viral production or virus-like particle production, or plasmids encoding the same. In some aspects, the one or more components for viral production or virus-like particle production comprise one or more viral structural proteins, optionally wherein the one or more viral structural proteins comprise a Gag protein, a Pol protein, a Gag-Pol fusion protein, or a plasmid encoding the same, further optionally a plasmid encoding each of the Gag protein a Pol protein. In some aspects, the method produces an increased amount of the delivery particles relative to the amount of delivery particles produced using an Indiana VSV-G under equivalent conditions. In some aspects, the method produces at least a 3-fold increase in the amount of the delivery particles relative to the amount of delivery particles produced using an Indiana VSV-G In some aspects, the delivery particle is a virus-like particle (“VLP”),
[0041] A VSV-G trimer comprising any one of the chimeric VSV-Gs described herein.
[0042] A viral envelope comprising any one of the chimeric VSV-Gs or VSV-G trimers described herein.
[0043] A delivery particle comprising any one of the chimeric VSV-Gs or VSV-G trimers described herein.
[0044] Also provided herein is a delivery particle comprising a chimeric VSV-G comprising: a) one or more domains having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 10IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO100% sequence identity with an Indiana VSV-G domain; and b) one or more domains having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain.
[0045] Also provided herein is a delivery particle comprising a chimeric VSV-G comprising: a) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; b) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain; and c) a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.
[0046] Also provided herein is a delivery particle comprising a chimeric VSV-G comprising: a) a lateral domain (DI), a trimerization domain (DII), and a pleckstrin homology domain (Dill) from an Indiana VSV-G; and b) a fusion domain (DIV) and a transmembrane domain (TM) from a Cocal VSV-G.
[0047] In some aspects, the delivery particle comprising the chimeric VSV-G wherein (a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5 or comprising SEQ ID NO: 4 and 311, respectively; (b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10 or comprising SEQ ID NO: 312 and 10, respectively; (d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and (e) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
[0048] In some aspects, the delivery particle comprising the chimeric VSV-G wherein (a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5, respectively; (b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10, respectively; (d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and (e) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
[0049] Also provided herein is a delivery particle comprising: a) a chimeric VSV-G comprising: i) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; and ii) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain; b) a targeting moiety on the surface of the delivery particle; and c) a pay load encapsidated within the particle.
[0050] Also provided herein is a delivery particle comprising: a) a chimeric VSV-G comprising: i) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%11IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOsequence identity with an Indiana VSV-G domain; and ii) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain; b) a targeting moiety on the surface of the delivery particle; and c) a gene-editing system encapsidated within the delivery particle.
[0051] Also provided herein is a delivery particle comprising: a) a chimeric VSV-G comprising: i) a lateral domain (DI), a trimerization domain (DII), and a pleckstrin homology domain (Dill) from an Indiana VSV-G; and ii) a fusion domain (DIV) and a transmembrane domain (TM) from a Cocal VSV-G; b) a targeting moiety on the surface of the delivery particle; and c) a payload encapsidated within the particle, optionally wherein the payload comprises a gene-editing system.
[0052] In some aspects, the delivery particle comprises the chimeric VSV-G wherein (a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5 or comprising SEQ ID NO: 4 and 311, respectively; (b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10 or comprising SEQ ID NO: 312 and 10, respectively; (d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and (c) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
[0053] In some aspects, the delivery particle comprises the chimeric VSV-G wherein (a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5, respectively; (b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10, respectively; (d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and (e) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
[0054] In some aspects, the delivery particle comprises the chimeric VSV-G wherein the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 1. In some aspects, the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 13.
[0055] In some aspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G comprises a signal peptide (SG), a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM). In some aspects, the chimeric VSV-G comprises a lateral domain (DI), a trimerization domain 12IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM). In some aspects, each domain is an Indiana VSV-G domain or a Cocal VSV-G domain. In some aspects, the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Indiana VSV-G. In some aspects, the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Cocal VSV-G.
[0056] In some aspects, the delivery particle comprises the chimeric VSV-G wherein the Indiana VSV-G domain has the sequence of any one of SEQ ID NO: 3-12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the Cocal VSV-G domain has the sequence of any one of SEQ ID NOs: 15-24, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
[0057] In some aspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 141, 145, 147, 149, 153, 155, 161, 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171, 173, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 162, 139, 153, 155, 182, 196, and 169, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G comprises the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
[0058] In some aspects, the delivery particle comprises the chimeric VSV-G wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 1. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 13. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the Indiana VSV-G domain comprises 1, 2, 3,4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 1. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the Cocal VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 13. In some 13IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOaspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G has a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G has an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G has a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G comprises a TS, T, or S substitution contained in any one of SEQ ID NO: 27-78, 133, 230, and 231. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G comprises a TS pair contained in any one of SEQ ID NO: 27-78, 133, 230, and 231. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the chimeric VSV-G does not comprise an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2 and / or docs not comprise a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.
[0059] In some aspects, the delivery particle comprises the chimeric VSV-G wherein the SG domain comprises SEQ ID NO: 3, the DI domain comprises SEQ ID NO: 4 and 5, the DII domain comprises SEQ ID NO: 6, 7, and 8, the Dill domain comprises SEQ ID NO: 9 and 10, the DIV domain comprises SEQ ID NO: 11, and / or the TM domain comprises SEQ ID NO: 12. In some aspects, the delivery particle comprises the chimeric VSV-G wherein the SG domain comprises SEQ ID NO: 15, the DI domain comprises SEQ ID NO: 16 and 17, the DII domain comprises SEQ ID NO: 18, 19, and 20, the Dill domarn comprises SEQ ID NO: 21 and 22, the DIV domain comprises SEQ ID NO: 23, and / or the TM domain comprises SEQ ID NO: 24.
[0060] In some aspects, the targeting moiety binds to a cell surface receptor, a T cell antigen, or a tumor antigen. In some aspects, the T cell antigen comprises one or more antigens selected from the group consisting of: CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD28, 4-1BB ligand, T cell receptor (TCR) a constant chain, TCR beta constant chain, major histocompatibility complex (MHC) presenting a T cell receptor (TCR) specific peptide. In some aspects, the targeting moiety binds to each of CD3, CD28, and CD2.
[0061] In some aspects, the payload comprises a nucleic acid, a protein, a small molecule, or a combination thereof. In some aspects, the payload comprises a gene editing system, a polynucleotide encoding a transgcnc, a peptide, and / or a detectable marker.
[0062] In some aspects, the delivery particle exhibits fusogenic activity. In some aspects, the delivery particle exhibits fusogenic activity comparable to or better than that of a delivery particle comprising Indiana VSV-G.14IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0063] In some aspects, the delivery particle exhibits low off-target activity. In some aspects, the delivery particle exhibits reduced off-target activity compared to a delivery particle comprising Indiana VSV-G.
[0064] In some aspects, the delivery particle exhibits higher resistance to serum neutralization than a delivery particle comprising Indiana VSV-G. In some aspects, the delivery particle exhibits 2-fold to 10-fold higher fusogenic activity in the presence of serum than a delivery particle comprising Indiana VSV-G.
[0065] In some aspects, the delivery particle is capable of being produced at a higher titer relative to a delivery particle comprising Indiana VSV-G under equivalent conditions.
[0066] In some aspects, the delivery particle is a virus-like particle (“VLP”).
[0067] Also provided herein is a VLP comprising a chimeric VSV-G, wherein the chimeric VSV-G comprises: a) one or more Indiana VSV-G domains; and b) one or more Cocal VSV-G domains.
[0068] In some aspects, the VLP comprising the chimeric VSV-G comprises: (a) an Indiana VSV-G SG domain comprising amino acids 1-16 of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (b) an Indiana VSV-G DI domain comprising two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (c) an Indiana VSV-G DII domain comprising three segments comprising amino acids 35-52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (d) an Indiana VSV-G Dill domain comprising two segments comprising amino acids 53-69 and 198-275, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (e) a Cocal VSV-G DIV domain comprising amino acids 71-198 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; and (f) a Cocal VSV-G TM domain comprising amino acids 426-513 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13.
[0069] In some aspects, the VLP comprising the chimeric VSV-G comprises: (a) an Indiana VSV-G SG domain comprising SEQ ID NO: 3; (b) an Indiana VSV-G DI domain comprising two segments comprising SEQ ID NO: 4 and 5, respectively; (c) an Indiana VSV-G DII domain comprising three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (d) an Indiana VSV-G Dill domain comprising two segments comprising SEQ ID NO: 9 and 10, respectively; (e) a 15IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WOCocal VSV-G DIV domain comprising SEQ ID NO: 23; and (f) a Cocal VSV-G TM domain comprising SEQ ID NO: 24.
[0070] In some aspects, the VLP comprising the chimeric VSV-G comprises: (a) an Indiana VSV-G DI domain comprising two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (b) an Indiana VSV-G DII domain comprising three segments comprising amino acids 35-52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (c) an Indiana VSV-G Dill domain comprising two segments comprising amino acids 53-69 and 198-275, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (d) a Cocal VSV-G DIV domain comprising amino acids 71-198 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; and (e) a Cocal VSV-G TM domain comprising amino acids 426-513 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13.
[0071] In some aspects, the VLP comprising the chimeric VSV-G comprises: (a) an Indiana VSV-G DI domain comprising two segments comprising SEQ ID NO: 4 and 5, respectively; (b) an Indiana VSV-G DII domain comprising three segments comprising SEQ ID NO: 6, 7, and 8, respectively; (c) an Indiana VSV-G Dill domain comprising two segments comprising SEQ ID NO: 9 and 10, respectively; (d) a Cocal VSV-G DIV domain comprising SEQ ID NO: 23; and (e) a Cocal VSV-G TM domain comprising SEQ ID NO: 24.
[0072] In some aspects, the VLP is capable of being produced at a higher titer relative to a VLP comprising Indiana VSV-G under equivalent culturing conditions. In some aspects, the VLP exhibits fusogenic activity equivalent to or better than that of a VLP comprising Indiana VSV-G at an equivalent viral titer. In some aspects, the VLP exhibits activity equivalent to or better than that of a VLP comprising Indiana VSV-G following administration of an equivalent viral titer to a subject. In some aspects, the VLP comprises a payload comprising a gene editing system and the activity comprises genome editing efficiency.
[0073] In some aspects, the VLP comprises: a) a targeting moiety on the surface of the VLP; and b) a payload encapsidated within the VLP, optionally wherein the payload comprises a geneediting system.16IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0074] Also provided herein is a method of delivering a payload to a population of target cells comprising contacting the population of target cells with any one of the delivery particles or the VLPs described herein.
[0075] Also provided herein is a method of editing a population of target cells comprising contacting the population of target cells with any one of the delivery particles or the VLPs described herein.
[0076] Also provided herein is a method of modifying a population of target cells to express a transgene comprising contacting the population of target cells with any one of the delivery particles or the VLPs described herein.
[0077] In some aspects, the target cells are germ cells. In some aspects, the target cells are somatic cells. In some aspects, the target cells are cancer cells. In some aspects, the target cells are immune cells. In some aspects, the immune cells are T cells, optionally wherein the T cells are naive T cells, stimulated T cells, primary T cells (e.g., uncultured), cultured T cells, immortalized T cells, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, or natural killer T cells. In some aspects, the target cells are infected cells, autoimmune cells, or diseased cells. In some aspects, the target cells are in vivo.BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
[0078] The accompanying figures, which are incorporated herein and form a part of the specification, illustrate some, but not the only or exclusive, example embodiments and / or features. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than limiting.
[0079] FIG. 1A shows a diagram of the domain architecture of full-length precursor Indiana VSV-G mapped onto its amino acid sequence, with each domain segment identified. FIG. IB shows a diagram of the domain architecture of processed, mature Indiana VSV-G mapped onto its amino acid sequence, with each domain segment identified. FIG.1C shows a cartoon depiction of the predicted structure of VSV-G Indiana strain aligned to VSV-G Cocal strain, without the transmembrane domain, with the domains identified.
[0080] FIG. 2A shows fusogenic assay activity results for TS substitution variants 1-12, 14-26, and VSV-Gmut. FIG. 2B shows fusogenic assay activity results for TS substitution variants 27-52. From left to right for each VSV-G variant, the bars correspond to 0.5, 10, and 25 pL volumes of VLP pseudotyped with that VSV-G variant.17IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0081] FIG.3A shows the percent on-target binding, while FIG.3B shows the percent off-target binding for VSV-G variants K47del, K47del+184TS, and K47del+184TS+208TS in comparison to Indiana VSV-G (“VSV-G”) and VSV-Gmut.
[0082] FIG. 4 shows the amino acid differences between Indiana and Cocal VSV-G. The sequence on top is pre-processed Indiana VSV-G (SEQ ID NO: 1), with the differing amino acids on the bottom shown from the Cocal VSV-G sequence (SEQ ID NO: 13).
[0083] FIG.5 shows domain annotation for all Indiana-Cocal VSV-G chimeras. The domains are listed in the order SG-DI-DII-DIII-DIV-TM, with “0” corresponding to Indiana VSV-G and “1” corresponding to Cocal VSV-G. Sequence identity is shown on the left for each chimera compared to Indiana VSV-G (top bar) and Cocal VSV-G (bottom bar).
[0084] FIG. 6 shows results for fusogenic activity screening of Indiana Cocal VSV-G chimeras, compared to two Indiana-Chandipura chimeras (“IIIIAI” and “IIAIAI”), and, as controls, wildtype Indiana VSV-G (“VSV-G”), VSV-Gmut, and untreated control ("UTC").
[0085] FIG. 7A shows the results for on-target binding, and FIG. 7B shows the results for off-target binding from a fusogenic activity assay of illustrative Indiana-Cocal VSV-G chimeras compared to Indiana VSV-G (“VSV-G”), VSV-Gmut, and untreated control (“UTC”).
[0086] FIG. 8 shows the results of a serum neutralization assay for Indiana-Cocal VSV-G chimeras #5, 8, 13, 14, 19, 24, and 25 compared to Indiana VSV-G (“VSV-G”), VSV-Gmut, and untreated control (“UTC”).
[0087] FIG.9 shows the results for a fusogenic activity assay of chimera #8 and mutants thereof, compared to Indiana VSV-G (“VSV-G”) and VSV-Gmut, demonstrating high fusogenic activity and low off target binding for all chimera #8 variants. Off-target binding was statistically significantly lower than for VSV-Gmut.
[0088] FIG. 10 shows both EDV titers produced either with an Indiana strain variant VSV-Gmut or Cocal chimera 8, as assessed by sgRNA content (left panel), as well as CAR knock-in efficiency in primary T cells using the same (right panel).
[0089] FIG. 11 shows the percentage of splenic CAR T cells generated in vivo (left panel) and the percentage of splenic B cells in vivo (right panel) following in vivo editing that includes ED Vs produced either with an Indiana strain variant VSV-Gmut or Cocal chimera 8, where the EDV titer was normalized by sgRNA content.18IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WODETAILED DESCRIPTION
[0090] All publications, patents and patent applications, including any drawings and appendices, are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0091] The following description includes information that may be useful in understanding the present disclosure. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed disclosures, or that any publication specifically or implicitly referenced is prior art.Definitions
[0092] The term “a” or “an” refers to one or more of that entity, i.e. can refer to plural referents. As such, the terms “a,” “an,” “one or more,” and “at least one” are used interchangeably herein. In addition, reference to “an element” by the indefinite article “a” or “an” does not exclude the possibility that more than one of the elements is present, unless the context clearly requires that there is one and only one of the elements.
[0093] Throughout this application, the term “about” is used to indicate that a value includes the inherent variation of error for the device or the method being employed to determine the value, or the variation that exists among the samples being measured. Unless otherwise stated or otherwise evident from the context, the term “about” means within 10% above or below the reported numerical value (except where such number would exceed 100% of a possible value or go below 0%). When used in conjunction with a range or series of values, the term “about” applies to the endpoints of the range or each of the values enumerated in the series, unless otherwise indicated. As used in this application, the terms “about” and “approximately” are used as equivalents.
[0094] As used herein the term “sequence identity” refers to the extent to which two optimally aligned polynucleotides or polypeptide sequences are invariant throughout a window of alignment of residues, e.g. nucleotides or amino acids. An “identity fraction” for aligned segments of a test sequence and a reference sequence is the number of identical residues which are shared by the two aligned sequences divided by the total number of residues in the reference sequence segment, i.e. the entire reference sequence or a smaller defined part of the reference sequence. “Percent identity” is the identity fraction times 100. Comparison of sequences to determine percent identity can be accomplished by a number of well-known methods, including for example by using mathematical algorithms, such as, for example, those in the BLAST suite of sequence analysis programs. Unless noted otherwise, the term “sequence identity” in the claims refers to sequence identity as calculated by Clustal Omega® using default parameters. In some embodiments 19IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOdescribed herein, a protein domain comprises multiple non-contiguous segments of a polypeptide sequence, such that the domain is defined by the combination of these separated regions rather than by a single continuous stretch of amino acids. Unless otherwise specified, references to sequence identity or similarity between two variants of such a discontinuous domain refer to the cumulative identity across the entirety of the constituent segments. That is, the percentage identity is calculated over the combined total length of all defined segments that make up the domain, using aligned sequences that account for insertions, deletions, and conservative substitutions, in accordance with standard alignment algorithms known in the art (e.g., BLAST).
[0095] “Indiana VSV-G” refers to the glycoprotein G from the Indiana strain of the vesicular stomatitis virus (VSV). Unless otherwise specified, or clear from context, reference to Indiana VSV-G generally refers to the processed (“mature”) Indiana VSV-G protein that does not comprise a signal peptide (SEQ ID NO: 2), or a domain thereof. For example, mutations generally refer to their position within the context of the processed mature Indiana VSV-G protein and are described with reference to the numbering in SEQ ID NO: 2, e.g., mutations at K47 and R354. In the context of exchanging (“swapping”) domain sequences, as discussed in more detail throughout, the domain regions generally refer to their positional sequence boundaries within the context of the un-processed (“immature”) Indiana VSV-G protein that includes a signal peptide and arc described with reference to the numbering in SEQ ID NO: 1, e.g., amino acids 1-16 of SEQ ID NO: 1 for the signal peptide domain of Indiana VSV-G, amino acids 17-34 and 327-398 of SEQ ID NO: 1 for the lateral domain (“DI”) of Indiana VSV-G, etc.
[0096] “Cocal VSV-G” refers to the glycoprotein G from the Cocal strain of VSV. Unless otherwise specified, or clear from context, reference to Cocal VSV-G generally refers to processed (“mature”) Cocal VSV-G protein that does not comprise a signal peptide (SEQ ID NO: 14), or a domain thereof. For example, mutations generally refer to their position within the context of the processed mature Cocal VSV-G protein and are described with reference to the numbering in SEQ ID NO: 14, e.g., mutations at K47 and R354. In the context of exchanging (“swapping”) domain sequences, as discussed in more detail throughout, the domain regions generally refer to their positional sequence boundaries within the context of the un-processed (“immature”) Cocal VSV-G protein that includes a signal peptide and are described with reference to the numbering in SEQ ID NO: 13, e.g., amino acids 1-17 ofSEQ ID NO: 13 for the signal peptide domain of Cocal VS V-G, amino acids 18-35 and 328-399 of SEQ ID NO: 13 for the lateral domain (“DI”) of Cocal VSV-G, etc.
[0097] For the purposes of this disclosure, references to specific domains within a protein (e.g., SG, DI, DII, Dill, DIV, and TM) are intended to denote functional or structural regions of VSV- 20IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOG proteins based on sequence features, homology, predicted secondary or tertiary structure, and / or experimental data. The precise boundaries of these domains are not absolute and may vary depending on alignment algorithms, structural models, or biological context. As such, domain delineations provided herein are approximate and encompass variants with minor extensions, truncations, or shifts in boundary residues that do not materially affect the function or structure attributed to the domain. Unless otherwise specified, references to a domain include sequences that retain the characteristic biological activity and / or structural conformation associated with that domain.Overview
[0098] The present disclosure provides recombinant proteins comprising one or more domains from the Indiana VSV-G protein and one or more domains from and the Cocal VSV-G protein (referred to herein as “VSV-G chimeras” or “chimeric VSV-G”). In some embodiments, these VSV-G chimeras have high fusogenic activity, low off-target binding, and / or improved resistance to serum neutralization. In some embodiments, these VSV-G chimeras allow for an increase in viral particle titer when producing virus or virus-like particles, i.e., more viral particles (e.g., VLPs) are produced than when using parental VSV-G strains (e.g., an Indiana strain VSV-G) under the same conditions, representing an improvement in manufacturing capability and efficiency. Also disclosed arc modified VSV-G proteins comprising one or more amino acid mutations (referred to herein as “VSV-G mutants”). In some embodiments, these mutations improve fusion activity, specificity, and / or resistance to serum neutralization, among other advantages. Also disclosed are delivery particles comprising the VSV-G chimeras and mutants of the disclosure. The present disclosure also provides methods of using these delivery particles. The present disclosure also provides methods of producing these delivery particles.Recombinant VSV-G proteins of the disclosureVSV-G Chimeras
[0099] Provided herein are recombinant VSV-G proteins comprising at least one domain from Indiana VSV-G and at least one domain from Cocal VSV-G. Exemplary sequences of full length Indiana and Cocal VSV-G proteins are shown in Table 1, which include both wild-type strain sequences and modified (“mutant” or “mut”) sequences that include mutations that reduce, minimize, or eliminate binding of VSV-G to its native cognate receptor, LDL-R (e.g., mutations K47A, K47Q, and R354A).
[0100] In some embodiments, the VSV-G proteins described herein comprise a signal peptide. The signal peptide directs the nascent polypeptide to the endoplasmic reticulum for membrane insertion and secretion and is cleaved co-translationally. While not present in the mature 21IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOglycoprotein, the signal peptide is involved in protein targeting and expression in eukaryotic expression systems. A person of skill in the art will understand that a mature version of a protein sequence docs not comprise a signal peptide. For each recombinant VSV-G protein of the disclosure, both pre- and post-cleavage sequences are explicitly incorporated herein.Table 1: Sequences of Indiana VSV-G and Cocal VSV-G. Description SequenceImmature MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDL Indiana VSV-G NWHNDLIGTALQVKMPKSHKAIQADGWMCHASKWVTTCDFRWY (with signal GPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVT peptide) DAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTT WHSDYKVKGLCDSNL1SMD1TFFSEDGELSSLGKEGTGFRSNYFAY ETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPE GSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLS YLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAPILSRMVGMISGTT TERELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDL HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFS SWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNR LGK (SEQID NO: 1)Mature Indiana KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVK VSV-G (without MPKSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSV signal peptide) EQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVL VDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSN LISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKH WGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLI QDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTERELWDDWAPYEDV EIGPNGVLRTSSGYKFPLYMIGHGMLDSDLHLSSKAQVFEHPHIQD AASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIASFFFIIGLIIG LFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 2) Immature MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDL Indiana VSV-G NWHNDLIGTALQVKMPQSHKAIQADGWMCHASKWVTTCDFRWY mutant (with GPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVT signal peptide) DAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTT WHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFAYIncludes K47Q ETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPE and R354A GSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLS YLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAPILSRMVGMISGTT TE AEI .WDD WAPYED VEIGPNGVI .RTS SGYKFPI .YMIGHGMI .DS DI . HLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFS SWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNR LGK (SEQ ID NO: 307)Mature Indiana KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVK VSV-G mutant MPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSV (without signal EQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVL peptide) VDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSN LISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHIncludes K47Q WGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIand R354A QDVERILDYS LCQETWS KIRAGLPISP VDLS YLAPKNPGTGP AFTIIN 22IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WODescription Sequence GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDV EIGPNGVLRTSSGYKFPLYMIGHGMLDSDLHLSSKAQVFEHPHIQD AAS QLPDDESLFFGDTGLS KNPIELVEGWFS S WKSSIASFFFIIGLIIG LFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 308) Immature Cocal MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQ VSV-G (with NWHNDLLGITMKVKMPKTHKAIQADGWMCHAAKWITTCDFRWY signal peptide) GPKYITHSIHSIQPTSEQCKESIKQTKQGTWMSPGFPPQNCGYATVT DSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKCETEECETVHNST VWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSNYFA YEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECP VGATISAPTQTSVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVD LSYLAPKNPGTGPAFTIINGTLKYFETRYIRIDIDNPIISKMVGKISGS QTERELWTEWFPYEGVEIGPNGILKTPTGYKFPLFMIGHGMLDSDL HKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTG1SKNPVEL1EGWFS SWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEM SRFRK (SEQ ID NO: 309)Mature Cocal AKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLLGITMKVK VSV-G (without MPKTHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTS signal peptide) EQCKESIKQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHH VLVDEYTGEWIDSQFPNGKCETEECETVHNSTVWYSDYKVTGLCD ATLVDTEITFFSEDGKKESIGKPNTGYRSNYFAYEKGDKVCKMNY CKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQTSVD VSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPA FTIINGTLKYFETRYIRIDIDNPIISKMVGKISGSQTERELWTEWFPYE GVEIGPNGILKTPTGYKFPLFMIGHGMLDSDLHKTSQAEVFEHPHL AEAPKQLPEEETLFFGDTGISKNPVELIEGWFSSWKSTVVTFFFAIG VFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 310)Immature Cocal MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQ VSV-G mutant NWHNDLLGITMKVKMPATHKAIQADGWMCHAAKWITTCDFRWY (with signal GPKYITHSIHSIQPTSEQCKESIKQTKQGTWMSPGFPPQNCGYATVT peptide) DSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKCETEECETVHNST VWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSNYFAIncludes K47A YEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECP and R354A VGATISAPTQTSVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVD LSYLAPKNPGTGPAFTIINGTLKYFETRYIRIDIDNPIISKMVGKISGS QTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLFMIGHGMLDSDL HKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFS SWKSTVVTFFFAIGVFIEEYVVARIVIAVRYRYQGSNNKRIYNDIEM SRFRK (SEQ ID NO: 13)Mature Cocal AKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLLGITMKVK VSV-G mutant MPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTS (without signal EQCKESIKQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHH peptide) VLVDEYTGEWIDSQFPNGKCETEECETVHNSTVWYSDYKVTGLCD ATEVDTEITFFSEDGKKESIGKPNTGYRSNYFAYEKGDKVCKMNYIncludes K47A CKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQTSVD and R354A VSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPA FTIINGTLKYFETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYE GVEIGPNGILKTPTGYKFPLFMIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFSSWKSTVVTFFFAIG 23IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WODescription Sequence VFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO:14)
[0101] The VSV-G glycoprotein can be divided into six domains: a signal peptide (“SG”), lateral domain (“DI”), trimerization domain (“DII”), pleckstrin homology domain (“Dill”), fusion domain (“DIV”), and transmembrane (“TM”) domain. Some of these domains are non-continuous within the amino acid sequence of VSV-G, as delineated in, e.g. , FIG. 1A-1B. While the sequence is discontinuous, the domain architecture of VSV-G proteins disclosed herein is referred to in shorthand in the following order: SG-DI-DII-DIII-DIV-TM (pre-signal peptide cleavage) or DI-DII-DIII-DIV-TM (post-signal peptide cleavage). FIG. 1C shows the predicted structure of VSV-G Indiana strain aligned to VSV-G Cocal strain, without the transmembrane domain, illustrating the domains are formed in three dimensional space from polypeptides segments that are non-continuous in the linear amino acid sequence of VSV-G.
[0102] Sequences of the domains from Indiana and Cocal VSV-G are shown in Table 2. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an Indiana domain and a Cocal domain from Table 2. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a domain from Table 2. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a domain having at least 90% sequence identity to a domain from Table 2. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to a domain from Table 2. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to a domain from Table 2.Table 2: Sequences of Indiana and Cocal VSV-G domains. Description SEQ ID Sequence Corresponding Position in NO Respective VSV-G Indiana SG 3 MKCLLYLAFLFIGVNC Amino Acids 1-16 of SEQ domain ID NO: 1Indiana DI 4 KFTIVFPHNQKGNWKNVP Amino Acids 17-34 of SEQ domain, ID NO: 1segment 1Indiana DI 311 GTGPAFTIINGTLKYFETRYIRVDIAA Amino Acids 327-398 of domain, PILSRMVGMISGTTTERELWDDWAP SEQ ID NO: 1 segment 2 YEDVEIGPNGVLRTSSGYKFIndiana DI 5 GTGPAFTIINGTLKYFETRYIRVDIAA Amino Acids 327-398 of domain, PILSRMVGMISGTTTEAELWDDWAP SEQ ID NO: 307YEDVEIGPNGVLRTSSGYKF24IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WODescription SEQ ID Sequence Corresponding Position in NO Respective VSV-G segment 2with R354AIndiana DII 6 SNYHYCPSSSDLNWHNDL Amino Acids 35-52 of SEQ domain, ID NO: 1segment 1Indiana DII 7 SAPSQTSVDVSLIQDVERILDYSLCQ Amino Acids 276-326 of domain, ETWSKIRAGLPISPVDLSYLAPKNP SEQ ID NO: 1 segment 2Indiana DII 8 PLYMIGHGMLDSDLHLSSKAQVFEH Amino Acids 399-424 of domain, P SEQ ID NO: 1 segment 3Indiana Dill 312 IGTALQVKMPKSHKAIQ Amino Acids 53-69 of SEQ domain, ID NO: 1segment 1Indiana Dill 9 IGTALQVKMPQSHKAIQ Amino Acids 53-69 of SEQ domain, ID NO: 307segment 1with K47QIndiana Dill 10 ISMDITFFSEDGELSSLGKEGTGFRSN Amino Acids 198-275 of domain, YFAYETGGKACKMQYCKHWGVRLP SEQ ID NO: 1 segment 2 S GVWFEMADKDLFAAARFPECPEGSSIIndiana DIV 11 ADGWMCHASKWVTTCDFRWYGPK Amino Acids 70-197 of domain YITHSIRSFTPSVEQCKESIEQTKQGT SEQ ID NO: 1WLNPGFPPQSCGYATVTDAEAVIVQ VTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCD SNLIndiana TM 12 HIQD AAS QLPDDESLFFGDTGLS KNP Amino Acids 425-512 of domain IELVEGWFSSWKSSIASFFFIIGLIIGLF SEQ ID NO: 1LVLRVGIHLCIKLKHTKKRQIYTDIE MNRLGKCocal SG 15 MNFLLLTFIVLPLCSHA Amino Acids 1-17 of SEQ domain ID NO: 13Cocal DI 16 KFSIVFPQSQKGNWKNVP Amino Acids 18-35 of SEQ domain, ID NO: 13segment 1Cocal DI 313 GTGPAFTIINGTLKYFETRYIRIDIDNP Amino Acids 328-399 of domain, I1SKMVGK1SGSQTERELWTEWFPYE SEQ ID NO: 309 segment 2 GVEIGPNGILKTPTGYKFCocal DI 17 GTGPAFTIINGTLKYFETRYIRIDIDNP Amino Acids 328-399 of domain, IISKMVGKISGSQTEAELWTEWFPYE SEQ ID NO: 13 segment 2 GVEIGPNGILKTPTGYKFwith R354A25IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WODescription SEQ ID Sequence Corresponding Position in NO Respective VSV-G Cocal DII 18 SSYHYCPSSSDQNWHNDL Amino Acids 36-53 of SEQ domain, ID NO: 13segment 1Cocal DII 19 SAPTQTSVDVSLILDVERILDYSLCQE Amino Acids 277-327 of domain, TWS KIRS KQP VSPVDLS YLAPKNP SEQ ID NO: 13 segment 2Cocal DII 20 PLFMIGHGMLDSDLHKTSQAEVFEH Amino Acids 400-425 of domain, P SEQ ID NO: 13 segment 3Cocal Dill 314 LGITMKVKMPKTHKAIQ Amino Acids 53-69 of SEQ domain, ID NO: 309segment 1Cocal Dill 21 LGITMKVKMPATHKAIQ Amino Acids 53-69 of SEQ domain, ID NO: 13segment 1with K47ACocal Dill 22 VDTEITFFSEDGKKESIGKPNTGYRS Amino Acids 199-276 of domain, NYFAYEKGDKVCKMNYCKHAGVR SEQ ID NO: 13 segment 2 LPSGVWFEFVDQDVYAAAKLPECPVGATICocal DIV 23 ADGWMCHAAKWITTCDFRWYGPK Amino Acids 71-198 of domain YITHSIHSIQPTSEQCKESIKQTKQGT SEQ ID NO: 13WMSPGFPPQNCGYATVTDSVAVVV Q ATPHH VLVDEYTGEWIDS QFPNGK CETEECETVHNSTVWYSDYKVTGLC DATLCocal TM 24 HLAEAPKQLPEEETLFFGDTGIS KNP Amino Acids 426-513 of domain VELIEGWFS S WKSTVVTFFFAIGVFIL SEQ ID NO: 13LYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK*
[0103] In some embodiments, a recombinant VSV-G protein disclosed herein comprises an SG domain from Indiana VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an SG domain comprising the amino acid sequence of SEQ ID NO: 3. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an SG domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 3. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an SG domain having 1, 2, 3, 4, or 5 mutations compared to the amino acid sequence of SEQ ID NO: 3.
[0104] In some embodiments, a recombinant VSV-G protein disclosed herein comprises an SG domain from Cocal VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an SG domain comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an SG domain having at 26IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOleast 90% sequence identity to the amino acid sequence of SEQ ID NO: 15. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an SG domain having 1, 2, 3, 4, or 5 mutations compared to the amino acid sequence of SEQ ID NO: 15.
[0105] Domain I (DI) of the VSV-G protein is referred to as the lateral domain. As delineated in FIG. 1A-1B, the DI domain has two segments in Indiana and Cocal VSV-G. In general, wherever a VSV-G protein refers to having a DI, the VSV-G protein will include both of the DI segments. For example, a VSV-G protein having a DI domain from an Indiana VSV-G will include both KFTIVFPHNQKGNWKNVP (SEQ ID NO: 4) - which corresponds to amino acids 17-34 of full-length Indiana VSV-G (SEQ ID NO: 1) - and GTGPAFTIINGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGP NGVLRTSSGYKF (SEQ ID NO: 5) - which corresponds to amino acids 327-398 of full-length Indiana mutant VSV-G (SEQ ID NO: 307). For the avoidance of doubt, a VSV-G protein described as having an Indiana DI domain includes both of the DI segments from Indiana VSV-G instead of the corresponding respective two DI segments from Cocal VSV-G, which correspond to amino acids 18-35 and 328-399 of full-length Cocal VSV-G (SEQ ID NO: 309).
[0106] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain from Indiana VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain comprising the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 5. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having at least 90% sequence identity to the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 5. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 5. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 5.
[0107] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain from Indiana VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain comprising the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 311. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having at least 90% sequence identity to the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 311. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequences of SEQ ID NO: 4 and SEQ ID 27IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WONO: 311. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequences of SEQ ID NO: 4 and SEQ ID NO: 311.
[0108] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain from Cocal VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain comprising the amino acid sequences of SEQ ID NO: 16 and SEQ ID NO: 17. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having at least 90% sequence identity to the amino acid sequences of SEQ ID NO: 16 and SEQ ID NO: 17. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having about 80, 81, 82, 83, 84, 85, 86, 87. 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequences of SEQ ID NO: 16 and SEQ ID NO: 17. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequences of SEQ ID NO: 16 and SEQ ID NO: 17.
[0109] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain from Cocal VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain comprising the amino acid sequences of SEQ ID NO: 16 and SEQ ID NO: 313. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having at least 90% sequence identity to the amino acid sequences of SEQ ID NO: 16 and SEQ ID NO: 313. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having about 80, 81, 82, 83, 84. 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequences of SEQ ID NO: 16 and SEQ ID NO: 313. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DI domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequences of SEQ ID NO: 16 and SEQ ID NO: 313.
[0110] Domain II (DII) of VSV-G is referred to as the trimerization domain. As delineated in FIG. 1A-1B, the DII domain has three segments in Indiana and Cocal VSV-G. In general, wherever a VSV-G protein refers to having a DII, the VSV-G protein will include all three of the DII segments. For example, a VSV-G protein having a DII domain from an Indiana VSV-G will include SNYHYCPSSSDLNWHNDL (SEQ ID NO: 6) - which corresponds to amino acids 35-52 of full-length Indiana VSV-G (SEQ ID NO: 1) SAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNP (SEQ ID NO: 7) - which corresponds to amino acids 276-326 of full-length Indiana VSV-G (SEQ ID NO: 1) -and PLYMIGHGMLDSDLHLSSKAQVFEHP (SEQ ID NO: 8) - which corresponds to amino 28IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOacids 399-424 of full-length Indiana VSV-G (SEQ ID NO: 1). For the avoidance of doubt, a VSV-G protein described as having an Indiana DII domain includes all three of the DII segments from Indiana VSV-G instead of the corresponding respective three DII segments from Cocal VSV-G, which correspond to amino acids 36-53, 277-327, and 400-425 of full-length Cocal VSV-G (SEQ ID NO: 309).
[0111] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DII domain from Indiana VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DII domain comprising the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DII domain having at least 90% sequence identity to the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DII domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DII domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.
[0112] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DII domain from Cocal VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DII domain comprising the amino acid sequences of SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DII domain having at least 90% sequence identity to the amino acid sequences of SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DII domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequences of SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DII domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequences of SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20.
[0113] Domain III (Dill) of VSV-G is referred to as the plcckstrin homology domain. As delineated in FIG. 1A-1B, the Dill domain has two segments in Indiana and Cocal VSV-G. In general, wherever a VSV-G protein refers to having a Dill, the VSV-G protein will include both of the Dill segments. For example, a VSV-G protein having a Dill domain from an Indiana VSV-G will include both IGTALQVKMPQSHKAIQ (SEQ ID NO: 9) - which corresponds to amino 29IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOacids 53-69 of full-length Indiana mutant VSV-G (SEQ ID NO: 307) - and ISMDITFFSEDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEM ADKDLFAAARFPECPEGSSI (SEQ ID NO: 10) - which corresponds to amino acids 327-398 of full-length Indiana VSV-G (SEQ ID NO: 1). For the avoidance of doubt, a VSV-G protein described as having an Indiana Dill domain includes both of the Dill segments from Indiana VSV-G instead of the corresponding respective two Dill segments from Cocal VSV-G, which correspond to amino acids 53-69 and 199-276 of full-length Cocal VSV-G (SEQ ID NO: 309).
[0114] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain from Indiana VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain comprising the amino acid sequences of SEQ ID NO: 9 and SEQ ID NO: 10. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having at least 90% sequence identity to the amino acid sequences of SEQ ID NO: 9 and SEQ ID NO: 10. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequences of SEQ ID NO: 9 and SEQ ID NO: 10. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequences of SEQ ID NO: 9 and SEQ ID NO: 10.
[0115] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain from Indiana VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain comprising the amino acid sequences of SEQ ID NO: 312 and SEQ ID NO: 10. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having at least 90% sequence identity to the amino acid sequences of SEQ ID NO: 312 and SEQ ID NO: 10. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequences of SEQ ID NO: 312 and SEQ ID NO: 10. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequences of SEQ ID NO: 312 and SEQ ID NO: 10.
[0116] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain from Cocal VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain comprising the amino acid sequences of SEQ ID NO: 21 and SEQ ID NO: 22. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having at least 90% sequence identity to the amino acid sequences of SEQ ID NO:30IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO21 and SEQ ID NO: 22. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequences of SEQ ID NO: 21 and SEQ ID NO: 22. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequences of SEQ ID NO: 21 and SEQ ID NO: 22.
[0117] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain from Cocal VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain comprising the amino acid sequences of SEQ ID NO: 314 and SEQ ID NO: 22. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having at least 90% sequence identity to the amino acid sequences of SEQ ID NO: 314 and SEQ ID NO: 22. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequences of SEQ ID NO: 314 and SEQ ID NO: 22. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a Dill domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequences of SEQ ID NO: 314 and SEQ ID NO: 22.
[0118] Domain IV (DIV) of VSV-G is referred to as the fusion domain. As delineated in FIG.1A-1B, the DIV domain has one segment in Indiana and Cocal VSV-G. For example, a VSV-G protein having a DIV domain from an Indiana VSV-G can include ADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPP QSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHS DYKVKGLCDSNL (SEQ ID NO: 11), which corresponds to amino acids 70-197 of full-length Indiana VSV-G (SEQ ID NO: 1). For the avoidance of doubt, a VSV-G protein described as having an Indiana DIV domain includes the DIV segment from Indiana VSV-G instead of the corresponding respective DIV segment from Cocal VSV-G, which corresponds to amino acids 71-198 of full-length Cocal VSV-G (SEQ ID NO: 309).
[0119] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DIV domain from Indiana VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DIV domain comprising the amino acid sequence of SEQ ID NO: 11. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DIV domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 11. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DIV domain having about 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino 31IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOacid sequence of SEQ ID NO: 11. In some embodiments, a recombinant VS V-G protein disclosed herein comprises a DIV domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequence of SEQ ID NO: 11.
[0120] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DIV domain from Cocal VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DIV domain comprising the amino acid sequence of SEQ ID NO: 23. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DIV domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 23. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DIV domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 23. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a DIV domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequence of SEQ ID NO: 23.
[0121] The transmembrane (TM) domain of VSV-G is located C-terminally. See, e.g., FIG. 1A-1B. For example, a VSV-G protein having a TM domain from an Indiana VSV-G can include HIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIASFFFIIGLIIGLFLVLRVGIH LCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 12), which corresponds to amino acids 425-512 of full-length Indiana VSV-G (SEQ ID NO: 1). For the avoidance of doubt, a VSV-G protein described as having an Indiana TM domain includes the TM segment from Indiana VSV-G instead of the corresponding respective TM segment from Cocal VSV-G, which corresponds to amino acids 426-513 of full-length Cocal VSV-G (SEQ ID NO: 309).
[0122] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a TM domain from Indiana VSV-G. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a TM domain comprising the amino acid sequence of SEQ ID NO: 12. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a TM domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 12. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a TM domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 12. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a TM domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequence of SEQ ID NO: 12.
[0123] In some embodiments, a recombinant VSV-G protein disclosed herein comprises a TM domain from Cocal VSV-G. In some embodiments, a recombinant VSV-G protein disclosed32IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOherein comprises a TM domain comprising the amino acid sequence of SEQ ID NO: 24. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a TM domain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 24. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a TM domain having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 24. In some embodiments, a recombinant VSV-G protein disclosed herein comprises a TM domain having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mutations compared to the amino acid sequence of SEQ ID NO: 24.
[0124] In some embodiments, a recombinant VSV-G protein of the disclosure comprises 1, 2, 3, 4, or 5 domains from Indiana VSV-G. In some embodiments, a recombinant VSV-G protein of the disclosure comprises 1, 2, 3, 4, or 5 domains from Cocal VSV-G. In some embodiments, a recombinant VSV-G protein of the disclosure comprises an SG, DI, DII, Dill, DIV, and TM domain. In some embodiments, a recombinant VSV-G protein of the disclosure comprises an SG, DI, DII, Dill, DIV, and TM domain, wherein each domain is from either Indiana VSV-G or Cocal VSV-G. In some embodiments, a recombinant VSV-G protein of the disclosure comprises an SG, DI, DII, Dill, DIV, and TM domain, wherein each domain has at least 90% sequence identity to the corresponding domain from Indiana VSV-G or Cocal VSV-G. In some embodiments, a recombinant VSV-G protein of the disclosure comprises an SG, DI, DII, Dill, DIV, and TM domain, wherein each domain has at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity with the corresponding domain from Indiana VSV-G or Cocal VSV-G. In some embodiments, a recombinant VSV-G protein of the disclosure comprises an SG, DI, DII, Dill, DIV, and TM domain, wherein each domain has about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% sequence identity with the corresponding domain from Indiana VSV-G or Cocal VSV-G.
[0125] In some embodiments, a Indiana VSV-G SG domain comprises amino acids 1-16 of a full-length Indiana VSV-G protein.
[0126] In some embodiments, a Indiana VSV-G DI domain comprises two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein.
[0127] In some embodiments, a Indiana VSV-G DII domain comprises three segments comprising amino acids 35-52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein.
[0128] In some embodiments, a Indiana VSV-G Dill domain comprises two segments comprising amino acids 53-69 and 198-275, respectively, of a full-length Indiana VSV-G protein.33IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WO
[0129] In some embodiments, a Indiana VSV-G DIV domain comprises amino acids 70-197 of a full-length Indiana VSV-G protein.
[0130] In some embodiments, a Indiana VSV-G TM domain comprises amino acids 425-512 of a full-length Indiana VSV-G protein.
[0131] In some embodiments, a Cocal VSV-G SG domain comprises amino acids 1-17 of a full-length Cocal VSV-G protein.
[0132] In some embodiments, a Cocal VSV-G DI domain comprises two segments comprising amino acids 18-35 and 328-399, respectively, of a full-length Cocal VSV-G protein.
[0133] In some embodiments, a Cocal VSV-G DII domain comprises three segments comprising amino acids 36-53, 277-327, and 400-425, respectively, of a full-length Cocal VSV-G protein.
[0134] In some embodiments, a Cocal VSV-G Dill domain comprises two segments comprising amino acids 53-69 and 199-276, respectively, of a full-length Cocal VSV-G protein.
[0135] In some embodiments, a Cocal VSV-G DIV domain comprises amino acids 71-198 of a full-length Cocal VSV-G protein.
[0136] In some embodiments, a Cocal VSV-G TM domain comprises amino acids 426-513 of a full-length Cocal VSV-G protein.Exemplary chimeras of the disclosure
[0137]
[0138] In some embodiments, a chimera of the disclosure comprises an amino acid sequence as disclosed in Table 3, which provides full-length sequences of exemplary chimeras, including SG domains. The chimera ID corresponds to the shorthand domain annotation described herein, SG-DI-DII-DIII-DIV-TM, where “0” corresponds to Indiana and “1” corresponds to Cocal. Mature sequences for these chimeras (without signal peptides) are provided in SEQ ID NO: 199 to SEQ ID NO: 228, which correspond sequentially, using domain annotation SG-DI-DII-DIII-DIV-TM, to chimeras 000001, 000010, 000011, 000100, 000101, 000110, 000111, 001000, 001001, 001010, 001011, 001100, 001101, 001110, 001111, 010000, 010001, 010010, 010011, 010100, 010101, 010110, 010111, 011000, 011001, 011010, 011011, 011100, 011101, 011110, 100001, 100010, 100011, 100100, 100101, 100110, 100111, 101000, 101001, 101010, 101011, 101100, 101101, 101110, 101111, 110000, 110001, 110010, 110011, 110100, 110101, 110110, 110111, 111000, 111001, 111010, 111011, 111100, 111101, and 111110, where “0” corresponds to Indiana and “1” corresponds to Cocal. Each of the chimeras in Table 3 also includes the K47Q34IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOand R354A mutations disclosed herein for the Indiana VSV-G domains and K47A and R354A for the Cocal VSV-G domains.Table 3: Exemplary Indiana- Cocal chimeras of the disclosure Chimera Chimera Amino Acid Sequence & SEQ ID NOID structure000001 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTAL QVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLY MIGHGMLDSDLHLS S KAQ VFEHPHL AE APKQLPEEETLFFGDTGIS KNPVELIEGWFS SWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 137)000010 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLTQDVERTLDYSLCQETWSKTRAGLPLSPVDLSYLAPKNPGTGPAFTTINGTLKYFE TRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFS SWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 138)8 000011 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRY1RVD1AAP1LSRMVGM1SGTTTEAELWDDWAPYEDVE1GPNGVLRTSSGYKFPLY MIGHGMLDSDLHLS S KAQ VFEHPHL AE APKQLPEEETLFFGDTGIS KNPVELIEGWFS SWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 139)000100 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNY1CPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPSQT SVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP L YMIG I IGMLDSDLI ILSS KAQ VFEI IPI IIQD A AS QLPDDESLFFG DTG LSKNPIEL VEG WFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 140)9 000101 MKCLLYLAFLHGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKY 35IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structure FETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGW FSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 141)1 000110 MKCLLYLAFLHGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPS QTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTL KYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGY KFPL YMIG I IGMLDSDLI ILS S KAQ VFEI IPI IIQD A AS QLPDDESLFFGDTG LS KNPIEL V EGWFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK(SEQ ID NO: 142)000111 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPS QTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTL KYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGY KFPL YMIGHGMLDSDLHLS S KAQ VFEHPHL AE APKQLPEEETLFFGDTGIS KNPVELI EGWFSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK(SEQ ID NO: 143)001000 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTAL QVKMPQSIIKAIQADGWMCIIASKWVTTCDFRWYGPKYITIISIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL FMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGW FSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 144)10 001001 MKCLLYLAFLHGVNCKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTAL QVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL FMIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWF SSWKSTVVTFFFAIGVHLLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 145)001010 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL36IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structure FMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGW FS S WKS SI ASFFFIIGLIIGLFL VLR VGIHLCIKLKHTKKR QI YTDIEMNRLG K (SEQ ID NO: 146)11 001011 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL FMIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWF SSWKSTVVTFFFAIGVHLLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 147)001100 MKCLLYLAFLHGVNCKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQT SVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLK YFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKF PLFMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEG WFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 148)12 001101 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPIIIIVLVDEYTGEWVDSQFINGK CSNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQT SVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLK YFETRYIRVDIAAPILSRMVCTMISGTTTEAELWDDWAPYEDVEICTPNGVLRTSSGYKF PLFMIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEG WFSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK(SEQ ID NO: 149)001110 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPT QTSVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGT LKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGY KFPLFMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELV EGWFSSWKSSIASFFFIIGLIIGLFLVLRVCTIHLCIKLKHTKKRQIYTDIEMNRLGK(SEQ ID NO: 150)001111 MKCLLYLAFLFIGVNCKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPT QTSVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGT LKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLFMICTHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIE37IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structure GWFSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK(SEQ ID NO: 151)010000 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTAL QVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEICTPNCTILKTPTGYKFPLYMI GHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSS WKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 152)13 010001 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTAL QVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLYMI GHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFSSW KSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 153)010010 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVIINSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLYMI GHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFCTDTGLSKNPIELVECTWFSS WKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 154)14 010011 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSNYIIYCPSSSDLNWIINDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETCTGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLYMI GHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFSSW KSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 155)3 010100 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLLGITM KVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAFA YEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPSQTS VDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNCTILKTPTGYKFPLYMIGHGMLDSDLHLS S KAQ VFEHPHIQD A AS QLPDDESLFFGDTGLS KNPIEL VEGWFS38IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structureSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 156)010101 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLLGITM KVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAFA YEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPSQTS VDV SLIQD VERILDY SLC QETWSKIR AGLPISP VDLS YL APKNPGTGPAFTIINGTLK YF ETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNCTILKTPTGYKFPLY MIGHGMLDSDLHLS S KAQ VFEHPHL AE APKQLPEEETLFFGDTGIS KNPVELIEGWFS SWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 157)4 010110 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLLGITM KVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDCTKKESICTKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPSQT SVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFS SWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 158)010111 MKCLLYLAFLFICTVNCKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLLGITM KVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVIINSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPSQT SVDVSLIQDVERILDYSLCQETWSKIRACTLPISPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLY MICTHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTCTISKNPVELIECTWFS SWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 159)011000 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSSYIIYCPSSSDQNWIINDLIGTAL QVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETCTGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLFM IGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSS WKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 160)15 011001 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTAL QVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNCTILKTPTGYKFPLFMIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFSS39IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structureWKSTVVTFFFAIGVHLLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 161)5 011010 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLFM IGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSS WKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 162)011011 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLFM IGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFSS WKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 163)6 011100 MKCLLYLAFLHGVNCKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLLGITM KVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVI INSTTWI ISD YKVKGLCDSNLVDTEITFFSEDG KKESIGKPNTG YRSNAFA YEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQTS VDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLF MIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVECTWF SSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 164)011101 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSSYIIYCPSSSDQNWIINDLLGITM KVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSD YKVKGLCDSNLVDTEITFFSEDG KKESIGKPNTGYRSNAFA YEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQTS VDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLF MIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFS SWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 165)7 011110 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLLGITM KVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQT SVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLK YFETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLFMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGW40IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structureFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 166)011111 MKCLLYLAFLFIGVNCKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLLGITM KVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQT SVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLK YFETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPL FMIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWF SSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 167)100000 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTA LQVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFS SWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 168)25 100001 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTA LQVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPT VI INSTTWI ISDYKVKGLCDSNLISMDITFFSEDGELSSLG KEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFS SWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 169)100010 MNFLLLTFI VLPLC SI I AKFTI VFPI INQKGNWKNVPSN YI I YCPS S SDLNWI INDLIG TA LQVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIK QTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGK CETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYF AYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTS VDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGW FSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 170)26 100011 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTA LQVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIK QTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGK CETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYF AYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTS VDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWF41IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structureSSWKSTVVTFFFAIGVHLLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 171)100100 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPSQT SVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEG WFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 172)27 100101 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPSQT SVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGW FSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 173)16 100110 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVIINSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPS QTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTL KYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGY KFPL YMIGHGMLDSDLHLS S KAQ VFEHPHIQD A AS QLPDDESLFFGDTGLS KNPIEL V EGWFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK(SEQ ID NO: 174)100111 MNFLLLTFIVLPLCSIIAKFTIVFPIINQKGNWKNVPSNYIIYCPSSSDLNWIINDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPS QTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTL KYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGY KFPLYMIGHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELI EGWFSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK(SEQ ID NO: 175)101000 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTA LQVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLFMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGW42IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structureFSSWKSSIASFEFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 176)28 101001 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTA LQVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQHNGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL FMIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWF SSWKSTVVTFFFAIGVHLLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 177)17 101010 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTA LQVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIK QTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGK CETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYF AYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTS VDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LFMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEG WFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 178)29 101011 MNFLLLTFIVLPLC SH AKFTIVFPHNQKGNWKNVPSS YHYCPSS SDQNWHNDLIGTA LQVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIK QTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGK CETEECETVIINSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYF AYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTS VDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LFMICTHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGW FSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 179)18 101100 MNFLLLTFIVLPLC SI I AKFTIVFPI INQKGNWKNVPSS YI IYCPSS SDQNWI INDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFESEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQT SVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAETIINGTLK YFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKF PLFMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEG WFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 180)101101 MNFLLLTFIVLPLCSHAKETIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQT SVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLK YFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLEMIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFEGDTGISKNPVELIEG43IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structureWFSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK(SEQ ID NO: 181)19 101110 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPT QTSVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGT LKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGY KFPLFMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELV EGWFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK(SEQ ID NO: 182)101111 MNFLLLTFIVLPLCSHAKFTIVFPHNQKGNWKNVPSSYHYCPSSSDQNWHNDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPT QTSVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGT LKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGY KFPLFMIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIE GWFSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK(SEQ ID NO: 183)110000 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTAL QVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPT VI INSTTWI ISDYKVKGLCDSNLISMDITFFSEDGELSSLG KEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLYMI GHCTMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSS WKSSIASFFHIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 184)30 110001 MNFLLLTFIVLPLCSIIAKFSIVFPQSQKGNWKNVPSNYIIYCPSSSDLNWIINDLIGTAL QVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQHNGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWCTVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLYMI GHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFSSW KSTVVTFFFAIGVHLLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 185)20 110010 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSS44IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structureWKSSIASFFFUGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 186)110011 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSV DVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFE TRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLYMI GHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFSSW KSTVVTFFFAIGVHLLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 187)110100 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPSQT SVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFS SWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 188)110101 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNYICPTVI INSTTWI ISD YKVKG LCDSNLVDTEITFFSEDG KKESIG KPNTG YRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPSQT SVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKY FETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFS SWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 189)110110 MNFLLLTFIVLPLCSIIAKFSIVFPQSQKGNWKNVPSNYIIYCPSSSDLNWIINDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPS QTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTL KYFETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEG WFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 190)110111 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSNYHYCPSSSDLNWHNDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPS QTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTL KYFETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLYMIGHGMLDSDLHLSSKAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGW45IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structureFSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 191)111000 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTAL QVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQHNGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLFM IGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSS WKSSIASFFHIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 192)31 111001 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTAL QVKMPQSHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIE QTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGKC SNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLFM IGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFSS WKSTVVTFFFAIGVHLLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 193)23 111010 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVIINSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLFM IGHCTMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVECTWFSS WKSSIASFFHIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 194)111011 MNFLLLTFIVLPLCSIIAKFSIVFPQSQKGNWKNVPSSYIIYCPSSSDQNWIINDLIGTAL QVKMPQSHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQ TKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNGKC ETEECETVHNSTVWYSDYKVTGLCDATLISMDITFFSEDGELSSLGKEGTGFRSNYFA YETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPTQTSV DVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLKYF ETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLFM IGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFSS WKSTVVTFFFAIGVHLLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 195)24 111100 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQT SVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLK YFETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPLFMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGW46IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WOChimera Chimera Amino Acid Sequence & SEQ ID NOID structureFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 196)111101 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLLGIT MKVKMPATHKAIQADGWMCHASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESI EQTKQGTWLNPGFPPQSCGYATVTDAEAVIVQVTPHHVLVDEYTGEWVDSQFINGK CSNYICPTVHNSTTWHSDYKVKGLCDSNLVDTEITFFSEDGKKESIGKPNTGYRSNAF AYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPTQT SVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGTLK YFETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKFPL FMIGHGMLDSDLHKTSQAEVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWF SSWKSTVVTFFFAIGVHLLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 197)111110 MNFLLLTFIVLPLCSHAKFSIVFPQSQKGNWKNVPSSYHYCPSSSDQNWHNDLLGIT MKVKMPATHKAIQADGWMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESI KQTKQGTWMSPGFPPQNCGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQFPNG KCETEECETVHNSTVWYSDYKVTGLCDATLVDTEITFFSEDGKKESIGKPNTGYRSN AFAYEKGDKVCKMNYCKHAGVRLPSGVWFEFVDQDVYAAAKLPECPVGATISAPT QTSVDVSLILDVERILDYSLCQETWSKIRSKQPVSPVDLSYLAPKNPGTGPAFTIINGT LKYFETRYIRIDIDNPIISKMVGKISGSQTEAELWTEWFPYEGVEIGPNGILKTPTGYKF PLFMIGHGMLDSDLHKTSQAEVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEG WFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 198)8 Mature 000011 KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADG (no SG) WMCHAAKWITTCDFRWYGPKYITHSIHSIQPTSEQCKESIKQTKQGTWMSPGFPPQN CGYATVTDSVAVVVQATPHHVLVDEYTGEWIDSQEPNGKCETEECETVHNSTVWYS D YKVTGLCDATLISMDITFFSEDG ELSSLG KEGTGFRSNYFAYETGG KACKMQYCKI I WGVRLPSGVWFEMADKDLFAAARFPECPEGSSISAPSQTSVDVSLIQDVERILDYSLC QETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAPILSRMV GMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMIGHGMLDSDLHLSS KAQVFEHPHLAEAPKQLPEEETLFFGDTGISKNPVELIEGWFSSWKSTVVTFFFAIGVFILLYVVARIVIAVRYRYQGSNNKRIYNDIEMSRFRK (SEQ ID NO: 306)
[0139] In some embodiments, a recombinant VS V-G protein of the disclosure comprises an amino acid sequence from Table 3. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having at least 90% sequence identity to an amino acid sequence from Table 3. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to an amino acid sequence from Table 3.
[0140] In some embodiments, a recombinant VSV-G protein of the disclosure comprises the amino acid sequence of any one of SEQ ID NO: 137-198. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NO: 137-198. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having about 80,47IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequence of any one of SEQ ID NO: 137-198.
[0141] In some embodiments, a recombinant VSV-G protein of the disclosure comprises the amino acid sequence of any one of SEQ ID NO: 199-228. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NO: 199-228. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequence of any one of SEQ ID NO: 199-228.
[0142] In some embodiments, a recombinant VSV-G protein of the disclosure comprises the amino acid sequence of any one of chimera #3 (SEQ ID NO: 156); chimera #4 (SEQ ID NO: 158); chimera #5 (SEQ ID NO: 162); chimera #6 (SEQ ID NO: 164); chimera #7 (SEQ ID NO: 166); chimera #8 (SEQ ID NO: 139); chimera #9 (SEQ ID NO: 141); chimera #10 (SEQ ID NO: 145); chimera #11 (SEQ ID NO: 147); chimera #12 (SEQ ID NO: 149); chimera #13 (SEQ ID NO: 153); chimera #14 (SEQ ID NO: 155); chimera #15 (SEQ ID NO: 161); chimera #16 (SEQ ID NO: 174); chimera #17 (SEQ ID NO: 178); chimera #18 (SEQ ID NO: 180); chimera #19 (SEQ ID NO: 182); chimera #20 (SEQ ID NO: 186); chimera 110100 (SEQ ID NO: 188); chimera 111010 (SEQ ID NO: 194); chimera #24 (SEQ ID NO: 196); chimera #25 (SEQ ID NO: 169); chimera #26 (SEQ ID NO: 171); chimera #27 (SEQ ID NO: 173); chimera #28 (SEQ ID NO: 177); chimera #29 (SEQ ID NO: 179); chimera #30 (SEQ ID NO: 185); and chimera #31 (SEQ ID NO: 193). In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 141, 145, 147, 149, 153, 155, 161, 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 141, 145, 147, 149, 153, 155, 161, 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193.
[0143] In some embodiments, a recombinant VSV-G protein of the disclosure comprises the amino acid sequence of any one of chimera #3 (SEQ ID NO: 156); chimera #4 (SEQ ID NO: 158); chimera #5 (SEQ ID NO: 162); chimera #6 (SEQ ID NO: 164); chimera #7 (SEQ ID NO: 166); chimera #8 (SEQ ID NO: 139); chimera #11 (SEQ ID NO: 147); chimera #13 (SEQ ID NO: 153); chimera #14 (SEQ ID NO: 155); chimera #15 (SEQ ID NO: 161); chimera #16 (SEQ ID NO: 174); chimera #17 (SEQ ID NO: 178); chimera #19 (SEQ ID NO: 182); chimera #20 (SEQ ID 48IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WONO: 186); chimera 110100 (SEQ ID NO: 188); chimera 111010 (SEQ ID NO: 194); chimera #24 (SEQ ID NO: 196); chimera #25 (SEQ ID NO: 169); chimera #26 (SEQ ID NO: 171); chimera #27 (SEQ ID NO: 173); chimera #29 (SEQ ID NO: 179); chimera #30 (SEQ ID NO: 185); and chimera #31 (SEQ ID NO: 193). In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171, 173, 179, 185, and 193. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171, 173, 179, 185, and 193.
[0144] In some embodiments, a recombinant VSV-G protein of the disclosure comprises the amino acid sequence of any one of chimera #5 (SEQ ID NO: 162); chimera #8 (SEQ ID NO: 139); chimera #13 (SEQ ID NO: 153); chimera #14 (SEQ ID NO: 155); chimera #19 (SEQ ID NO: 182); chimera#24(SEQID NO: 196); and chimera #25 (SEQ ID NO: 169). In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NO: 162, 139, 153, 155, 182, 196, and 169. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequence of any one of SEQ ID NO: 162, 139, 153, 155, 182, 196, and 169.
[0145] In some embodiments, a recombinant VSV-G protein of the disclosure comprises the amino acid sequence of chimera #8 (SEQ ID NO: 139). In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 139. In some embodiments, a recombinant VSV-G protein disclosed herein comprises an amino acid sequence having about 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to the amino acid sequence of SEQ ID NO: 139.
[0146] In some embodiments, a recombinant VSV-G protein of the disclosure comprises the amino acid sequence of chimera #8 with a K47 deletion (precursor SEQ ID NO: 229; mature SEQ ID NO: 232). In some embodiments, a recombinant VSV-G protein of the disclosure comprises the amino acid sequence of chimera #8 with a D121S mutation (precursor SEQ ID NO: 230; mature SEQ ID NO: 233). In some embodiments, a recombinant VSV-G protein of the disclosure comprises the amino acid sequence of chimera #8 with an E421T mutation (precursor SEQ ID 49IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WONO: 231; mature SEQ ID NO: 234). In some embodiments, a recombinant VSV-G protein of the disclosure comprises the amino acid sequence of chimera #8 (SEQ ID NO: 139) with one or more of: K47 deletion, D121S, and E421T.VSV-G Mutants
[0147] In some aspects, the present disclosure provides recombinant VSV-G proteins comprising one or more mutations compared to a wildtype VSV-G sequence. In some embodiments, a chimera of the disclosure comprises any one or more of the mutations disclosed herein. Unless otherwise specified, the residue numbering of the mutations disclosed herein is provided in the context of the mature Indiana VSV-G protein sequence (SEQ ID NO: 2). One of skill in the art is able to determine the corresponding position of an amino acid in SEQ ID NO: 2 in a different VSV-G sequence.
[0148] In some embodiments, a chimeric VSV-G protein herein comprises mutations to a residue wherein the chimeric VSV-G binding to a LDL receptor is reduced or eliminated. Such mutations can include, but are not limited to, mutations at positions K47 and R354 corresponding to the positions of the amino acid in SEQ ID NO: 2. Without wishing to be bound by theory, mutations that reduced or eliminate binding to a LDL receptor, which is the native cognate ligand of VSV-G, can reduce, minimize or eliminate off-target binding to cells without disrupting the fusogenic activity of VSV-G, e.g., VSV-G brought into the proximity of a target member through means other than binding to an LDL receptor can still mediate membrane fusion. Accordingly, in general, any mutations to VSV-G (e.g., mutations at positions K47 and / or R354, such as K47Q and / or R354A substitutions) can be used in the chimeric VSV-G chimeras described herein.
[0149] In some embodiments, a chimeric VSV-G protein herein includes where a lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated to a residue wherein the chimeric VSV-G binding to a LDL receptor is reduced or eliminated. In some embodiments, a chimeric VSV-G protein herein includes where an arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated to a residue wherein the chimeric VSV-G binding to a LDL receptor is reduced or eliminated. In some embodiments, a chimeric VSV-G protein herein includes where a lysine residue corresponding to residue number 47 and an arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 arc each mutated, respectively, to a residue wherein the chimeric VSV-G binding to a LDL receptor is reduced or eliminated. In general, substitutions at positions K47 and / or R354 can be any mutation that reduces or eliminates VSV-G binding to an LDL receptor, such as K47Q, R354A, R354Q, and combinations thereof.50IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0150] In some embodiments, a chimeric VSV-G protein herein includes where a lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated. In some embodiments, a chimeric VSV-G protein herein includes where a lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine. In some embodiments, a chimeric VSV-G protein herein includes where a lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine.
[0151] In some embodiments, a chimeric VSV-G protein herein includes where an arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated. In some embodiments, a chimeric VSV-G protein herein includes where an arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine. In some embodiments, a chimeric VSV-G protein herein includes where an arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or residue number ### of SEQ ID NO: 310 is substituted with a glutamine.
[0152] In some embodiments, a chimeric VSV-G protein herein includes where a lysine residue corresponding to residue number 47 and an arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 are each mutated, respectively. In some embodiments, a chimeric VSV-G protein herein includes where a lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine and an arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine. In some embodiments, a chimeric VSV-G protein herein includes where a lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine and an arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine. In some embodiments, a chimeric VSV-G protein herein includes where a lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine and an arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine. In some embodiments, a chimeric VSV-G protein herein includes where a lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine.
[0153] In some embodiments, a recombinant VSV-G protein herein comprises a K47Q mutation compared to the mature Indiana VSV-G protein (SEQ ID NO: 2). In some embodiments, a recombinant VSV-G protein herein comprises a glutamine (Q) at the position that aligns with the lysine (K) at position 47 of SEQ ID NO: 2.51IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0154] In some embodiments, a recombinant VSV-G protein herein comprises an R354A mutation compared to the mature Indiana VSV-G protein (SEQ ID NO: 2). In some embodiments, a recombinant VSV-G protein herein comprises an alanine (A) at the position that aligns with the arginine (R) at position 354 of SEQ ID NO: 2.
[0155] In some embodiments, a recombinant VSV-G protein herein comprises a K47Q and an R354A mutation compared to the mature Indiana VSV-G protein (SEQ ID NO: 2). In some embodiments, a recombinant VSV-G protein herein comprises a glutamine (Q) at the position that aligns with the lysine (K) at position 47 and an alanine (A) at the position that aligns with the arginine (R) at position 354 of SEQ ID NO: 2. SEQ ID NO: 25 (prc-cursor) and SEQ ID NO: 26 (mature) correspond to the immature and mature forms of Indiana VSV-G, respectively, with these two mutations, referred to herein as “VSV-Gmut”.
[0156] In some embodiments, a recombinant VSV-G protein herein comprises a K47 deletion compared to the mature Indiana VSV-G protein (SEQ ID NO: 2). In some embodiments, a recombinant VSV-G protein herein comprises a deletion at the position that aligns with the lysine (K) at position 47 of SEQ ID NO: 2.
[0157] In some embodiments, a recombinant VSV-G protein herein does not comprise a K47Q mutation compared to the mature Indiana VSV-G protein (SEQ ID NO: 2). In some embodiments, a recombinant VSV-G protein herein does not comprises a glutamine (Q) at the position that aligns with the lysine (K) at position 47 of SEQ ID NO: 2. In some embodiments, a recombinant VSV-G protein herein comprises a lysine (K) at the position corresponding to position 47 of SEQ ID NO: 2. In some embodiments, a recombinant VSV-G protein herein docs not comprise an R354A mutation compared to the mature Indiana VSV-G protein (SEQ ID NO: 2). In some embodiments, a recombinant VSV-G protein herein does not comprise an alanine (A) at the position that aligns with the arginine (R) at position 354 of SEQ ID NO: 2. In some embodiments, a recombinant VSV-G protein herein comprises an arginine (R) at the position corresponding to position 354 of SEQ ID NO: 2. In some embodiments, a recombinant VSV-G protein herein comprises a K47 deletion and does not comprise an R354A mutation. In some embodiments, a recombinant VSV-G protein herein comprises a K47 deletion and comprises an arginine (R) at the position corresponding to position 354 of SEQ ID NO: 2.
[0158] In some embodiments, a recombinant VSV-G protein herein comprises a TS substitution, e.g., as disclosed in Example 1 herein. A “TS pair” or “TS substitution,” as described herein, refers to consecutive threonine and serine amino acid residues within a recombinant VSV-G protein, wherein one or both of the amino acids have been introduced as substitutions in the VSV-G protein52IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOsequence. A TS pair can be referred to by the amino acid position (n) of the threonine (T) residue within the sequence, such that the amino acid position of the serine (S) residue will be n+1, as follows: nTS. Unless otherwise noted, the amino acid position (n) of the T within the TS pair is given with respect to the mature Indiana VSV-G sequence, SEQ ID NO: 2.
[0159] In some embodiments, a recombinant VSV-G protein of the disclosure comprises a TS substitution disclosed in Table 4, shown in the context of the mature VSV-Gmut sequence. In Table 4, TS pairs are bolded and underlined. Some of the pairs incorporate a pre-existing “T” or “S” within the VSV-Gmut sequence, identifiable via comparison with the mature VSV-Gmut sequence (SEQ ID NO: 26). In some embodiments, a recombinant VSV-G protein of the disclosure comprises one or more of the TS pairs shown in Table 4.Table 4: TS substitution mutations incorporated into mature VSV-Gmut.Var# SequenceTS-1 KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTSLQVKMPQSHKAIQADGWMCHAS KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFTSGKCSTSICPTVHNSTSWHSDYKVKGLCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKS SIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 27)TS-2 KFTIVFPHNQKGNWKNVPSNYHYCPTSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS KWVTSCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTSHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELS SLG KEGTGFRSN YF A YETGGK AC KM Q YC KHWG VRLPSG VWFEM ADKDLF A A ARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVCTMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLTSNPIELVEGWFSSWKS STASFFFITGI JTGT.FI .VERVGIHECIKEKHTKKRQIYTDIEMNREGK (SEQ ID NO: 28)TS-3 KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTSLNPGFPPQSCGYATVTDAEAVIV TSTPIIIIVLVDEYTSEWVDSQFINGKCSNYICPTVIINSTTWIISDYKVKGLCDSNLISMDITFFSE DGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMICTHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWTSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 29)TS-4 KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTSQGTWLNPGFPPQSCGYATVTDAEAVIV QVTSHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVTSLCDSNLISMDITFFSE DGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMTSKDLFAAARFPEC PEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIING TLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNCTVLRTSSGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIA SFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 30)TS-5 KFTI VFPI INQKGNWKNVPSNYI IYCPSSSDLNWI INDLIGTALQVKMPQSI IKAIQADG WMCI IASKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTTSGTWLNPGFPPQSCGYATVTDAEAVIV 53IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOVar# Sequence QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSTSKVKGLCDSNLISMDITFFSE DGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAATSFPEC PEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIING TLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSTSSSIA SFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 31)TS-6 KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKTSQADGWMCHA SKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATSTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELS SLGKEGTGFR SN YF A YETGGK AC KM Q YC KHWG VRLPSG VWFEM ADKDLFA A ARFP ECPEGTSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGIIGMLDSDLIILSSKAQVFEIIPIIIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSTSKSS IASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 32)TS-7 KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEATS VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHTSYKVKGLCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETTSKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFTSWKSS IASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 33)TS-8 KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHTSLIGTALQVKMPQSHKAIQADGWMCHAS KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKTSGLCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTSTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTSLSKNPIELVEGWFSSWKS SIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 34)TS-9 KFTIVFPTSQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDTSLISMDITFFS EDG ELS SLG KEGTG FRSN YF A YETGG K AC KM Q YC KI IWG VRLPSG VWFEM ADKDLFA A ARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKITSGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWTSSWKS SIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 35)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 10 KWVTTCDFRWYGPKYITHSIRSFTSSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQ VTPI II I VL VDE YTG EW VDS QFING KC SNYICPTVI INSTTWI ISD YK VKG LCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKTSGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSI ASFFFITSLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 36)TS- KFTIVFPHNQKGNWKNVPTSYHYCPSSSDLNWHNDLIGTALQVKMPQSHKATSADGWMCHAS 11 KWVTTCDFRWYGPKYITIISIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELS SLG KEGTGFRSN YF A YETGGK AC KM QYCTSWG VRLPSG VWFEM ADKDLFA A ARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINCTTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELTSDWAPYEDVEIGPNCTVLRTSSGYKFPLY54IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOVar# Sequence MIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIA SFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 37)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 12 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPTSCGYATVTDAEAVI VQTSPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELS SLG KEGTGFRSN YF A YETGGK AC KM Q YC KHWG VRLPSG VWFEM ADKDLF A A ARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFTSWKS SITSFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 38)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 13 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCTSSIEQTKQGTWLNPGFPPQSCGYATVTDAEAVIV QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCTSNLISMDITFFSE DGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSG VWFEM ADKDLF AAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPITSVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDETSFFGDTGLSKNPIELVEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 39)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKATQADGWMCHTS 14 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATTSDAEAVIV QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSE DGELSSLGKEGTGFRSNYFAYTSGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSI ASFTSIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 40)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPTSHKAIQADGWMCHAS 15 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKTSFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDTSLFFGDTGTSKNPIELVEGWFSSWKSS IASFFFIIGLIIGLFLVLRVGIIILCIKLKIITKKRQIYTDIEMNRLGK (SEQ ID NO: 41)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 16 KWVTTCDFRWYGPKYITHSIRSFTPTSEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICP'1'VHNSTTWHSDYKVKGLCDSNLISMDITFFS TSGELSSLGKEGTGFRSNYFAYETSGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGIIGMLDSDLIILSSKAQVFEIIPIIIQDATSQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 42)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 17 KWV'n’CDFRWYGPKYrrHSlRSFTPSVEQCKTSlEQlKQG'rWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELS SLG KEGTGFRSN YF A YETGGK AC KM QYC KHWG VRLPSG VWFEM ADKDLF A A ARFT SCPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAATSLPDDESLFFGDTTSSKNPIELVEGWFSSWKS SIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 43)TS- KFT1VFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDL1GTALQVKMPQSHKA1QADGWMCTSS18 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI55IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOVar# Sequence VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISTSITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELTSGWFSSWKS SIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 44)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 19 KWVTTCDFRWYGPKYITHSITSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAETSIV QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLITSDITFFSE DGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGIIGMLDSDLIILSSKAQVFEIIPIIIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSTSKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 45)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 20 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELS SLG KEGTGFRSN YF A YETGGK AC KM Q YC K.HWG VRLPSG VWFEM ADK.DLFA A ARFP ECPEGSSISAPSTSSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFTSTGLSKTSIELVEGWFSSWKSS IATSFFHGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 46)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 21 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTSAEAVIV QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSE DGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CTSGSSISAPTSTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSTSPIELVEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 47)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 22 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESITSTKQGTWLNPGFPPQSCGYATVTDAEAVIV QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSE DGELSSLG KEGTG FRSNYFA YETGGK ACKMQYCKI IWG VRLPSG VWFEM ADKDLFAAARFPE CPEGSSITSPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILTSMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPTSLVEGWFSSWKSS IASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 48)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 23 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPTSSCGYATVTDAEAVI VQ VTPI II I VL VDE YTG EW VDS QFING KC SNYICPTVI INSTTWI ISD YK VKG LCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFTSARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPITSVTSWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 49)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHTS 24 KWVTTCDFRWYGPKYITIISIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELSSLGKEGTSFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAATSFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL56IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOVar# Sequence YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSI ASTSHIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 50)TS- KFTIVFPHNQKGNWTSVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 25 KWVTTCDFRWYGPKYTSHSIRTSTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELS SLG KEGTGFRSN YF A YETGGK AC KM Q YC KHWG VRLPSG VWFEM ADKDLF A A ARFP ECPETSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKS SIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 51)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 26 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKTSGLCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKTSKMQYCKHWGVRLPSGVWFEMADKDLFATSRFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIETSEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 52)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDENWHNDEIGTAEQVKMPQSHKATQADGWMCHAS 27 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSTSKVKGLCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHTSVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLTSGDTGLSKNPIELVEGWTSSWKSS IASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 53)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 28 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMTSGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDATSQLTSDESLFFGDTGLSKNPIELVEGWFSSWKT SIASFFFIIGLIIGLFLVLRVGIIILCIKLKIITKKRQIYTDIEMNRLGK (SEQ ID NO: 54)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 29 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVlPHHVLVDEY'rGEWVDSQFINGKCSNYlCPTVHTSlTWHSDYKVKGLCDSNLISMDrrFFS EDGELSSLGKEGTGFRSNYFAYETSGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISTSTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLY MIGIIGMLDSDLIILSSKAQVFEIIPIIIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIA SFFFIITSIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 55)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQTSGWMCHAS 30 KWV'n’CDFRWYGPKYrrHSlRSFTPSVTSCKESlEQ'rKQG'rWLNPGFPPQSCGYATVlDAEAVlV QVTPHHVLVDEYTGEWVDSTSINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSE DGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGP AFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTTSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 56)TS- KFT1VFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDL1GTALQVKMPQSHKA1QADGWMCHAT31 SWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDATSVIV57IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOVar# Sequence QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSE DGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETSYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIA SFFFTSGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 57)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 32 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYTSPTVHNSTTWHSDYKVKGLCDSNLISMDITFF SEDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCTSTWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGIIGMLDSDLIILSSKAQVFEIIPIIIQDAASQLPDTSSLFFGDTGLSKNPIETSEGWFSSWKSS IASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 58)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 33 KWTSTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVIV QVTPHHVLVDEYTGEWVDSQTSNGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELSSLGKTSTGFRSNYFAYETGGTSCKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 59)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 34 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTTSEAVIV QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSE DGELSSLGKEGTGFRSTSFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPEC PEGSSISAPSQTSTSVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIING TLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIA SFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKTSIYTDIEMNRLGK (SEQ ID NO: 60)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDTSWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 35 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTTSNPGFPPQSCGYATVTDAEAVIV QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTSHSDYKVKGLCDSNLISMDITFFSE DGELSSLG KEGTG FRSNYFAYETGGK ACKMQYCKI IWG VRLPSG VWFEM ADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSI ASFFFIIGTSIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 61)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 36 KWVTTCDFRWYGPKYITHSIRSFTTSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQ VTPI II I VL VDE YTG EW VDS QFING KC SNYICPTVI INSTTWTSD YKVKTSCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELTSGWFSSWKS SIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 62)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 37 KWVTTCDFRWYGPKYITIISIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDTSVKGLCDSNLISMDITFFS EDGELS SLG KEGTGFRSN YF A YETGGK AC KM Q YC KHWG VRLPSG VWFEM ADKDLTS A ARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVTSAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL58IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOVar# Sequence YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDTSLFFGDTGLSKNPIELVEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 63)TS- KFTIVFPHNTSGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 38 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELS SLG KEGTGFRSN YF A YETGGK AC KM Q YC KHWG VRLPSG VWFEM ADKDLF A A ARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLTSKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKS SIASFTSIIGTSIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 64)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 39 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYTSVTDAEAVIV QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSE DGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPTSSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHTSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNTSELVEGWFSSWKSS IASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 65)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDENWHNDEIGTTSQVKMPQSHKATQADGWMCHAS 40 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLTSMDITFF SEDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGTSSSWKSS IASFFFIIGLITSLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 66)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 41 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVTSLCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFATSRFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSTSPIELVEGWFSSWKTSI ASFFFIIGLIIGLFLVLRVGIIILCIKLKIITKKRQIYTDIEMNRLGK (SEQ ID NO: 67)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 42 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICP'1'VHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELSSLGKETSGFRSNYFAYETGGKACKMQYCKHWGVRLTSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGTSISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWTSYEDVEIGPNGVLRTSSGYKFPL YMIGIIGMLDSDLIILSSKAQVFEIIPIIIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 68)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 43 KWV'n’CDFRWYGPKYrrHSlRSFTPSVEQCKESlEQ'rKQG'rWLNPGFPPQSCGYAlVlDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNTSSMDITFF SEDGELSSLGKEGTGFRTSYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTETSLWDDWAPYEDVTSGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKS SIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 69)TS- KFT1VFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDL1GTALQVKMPQSHKA1QADGWMCHAS44 KWVTTCDFRWYGPKYITHSIRSFTPSTSQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVIV59IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOVar# Sequence QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTTSSDYKVKGLCDSNLISMDITFFSED GELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPECP EGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLATSNPGTGPAFTIINGT LKYFETRYIRVDIAAPILSRMVGMISGTTTEATSWDDWAPYEDVEIGPNGVLRTSSGYKFPLYMI GHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSIASF FHIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 70)TS- KFTIVFPHNQKGNWKNVPSNYTSCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 45 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIETSKQGTWLNPGFPPQSCGYATVTDAEAVIV QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSE DGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGIIGMLDSTSIILSSKAQVFEIIPIIIQDAASQLPDDESLFFGDTGTSKNPIELVEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 71)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 46 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGTSACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELTSDWAPYEDVEIGPNGVLRTSSGYKFPLY MIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFTSTGLSKNPIELVEGWFSSWKSTS ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 72)TS- KFTIVFPHNQTSNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 47 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELSSLTSEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFPE CPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYTSPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSTSSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 73)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 48 KWVTTTSFRWYGTSYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVIV QVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFSE DGELSSLG KEGTG FRSNYFAYETGGK ACKMQYCKI IWG VRLPSG VWFEM ADKDLFAAARFPE CPEGSSISATSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIIN GTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDETSFFGDTGLSKNPIELVEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 74)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLTSTALQVKMPQSHKAIQADGWMCHA 49 SKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSTSYATVTDAEAVI VQ VTPI II I VL VDE YTG EW VDS QFING KC SNYICPTVI INSTTWI ISDTS VKG LCDSNLISMDITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPTSDVEIGPNGVLRTSSGYKFPL YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKSSI ASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 75)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 50 KWVTTCDFRWYGPKYITIISIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELSSTSKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMATSDLFAAARFPE CPEGSSISTSSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTIINGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFPL60IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WOVar# Sequence YMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNTSELVEGWFSSWKSS IASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 76)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKTSQADGWMCHA 51 SKWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISMDITFFS EDGELS SLG KEGTGFRSN YF A YETGGK AC KM Q YC KHWG VRLPSG VWFEM ADKDLF A A ARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP LYMIGHGMLDSDLHLSSKAQVFEHPHIQDAASQLPDDESLFFGDTGLSKNPIELVEGWFSSWKS SIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 77)TS- KFTIVFPHNQKGNWKNVPSNYHYCPSSSDLNWHNDLIGTALQVKMPQSHKAIQADGWMCHAS 52 KWVTTCDFRWYGPKYITHSIRSFTPSVEQCKESIEQTKQGTWLNPGFPPQSCGYATVTDAEAVI VQVTPHHVLVDEYTGEWVDSQFINGKCSNYICPTVHNSTTWHSDYKVKGLCDSNLISTSITFFS EDGELSSLGKEGTGFRSNYFAYETGGKACKMQYCKHWGVRLPSGVWFEMADKDLFAAARFP ECPEGSSISAPSQTSVDVSLIQDVERILDYSLCQETWSKIRAGLPISPVDLSYLAPKNPGTGPAFTII NGTLKYFETRYIRVDIAAPILSRMVGMISGTTTEAELWDDWAPYEDVEIGPNGVLRTSSGYKFP L YMIGHGMLDSDLHLS SK AQ VFEHPHIQD A A S QLPDDESLFFGDTGLS KNPIEL VEGWFS S WKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK (SEQ ID NO: 78)
[0160] In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 184TS pair. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 208TS pair. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 120TS pair. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 421TS pair. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 428TS pair. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 432TS pair. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 442TS pair.
[0161] In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 121 S substitution. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 42 IT substitution. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 429S substitution. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 436S substitution. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 442T substitution. In some embodiments, a recombinant VSV-G protein of the disclosure comprises a 445T substitution.
[0162] In some embodiments, a recombinant VSV-G protein of the disclosure comprises a mutation from any one of the following publications: WO 2019 / 057974; WO 2022 / 183072; WO 2023 / 114884; and WO 2024 / 1079959. Each of these publications is incorporated by reference herein in its entirety for all purposes.61IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WODelivery Particles
[0163] The present disclosure provides delivery particles comprising: (a) a recombinant VSV-G protein of the disclosure on the surface of the delivery particle; and (b) a payload comprised by the delivery particle.
[0164] lierein, “delivery particle” refers to a microscopic structure, engineered or naturally occurring, designed to encapsulate, protect, and / or transport pay loads (e.g., nucleic acids, proteins, drugs, or other therapeutic molecules) to target cells and / or tissues. In some embodiments, the recombinant VSV-G proteins of the present disclosure are comprised by, associated with, or incorporated into delivery particles. In some embodiments, the delivery particle is selected from the list consisting of: virus-like particles (VLPs), liposomes, exosomes, lipid nanoparticles (LNPs), micelles, and membrane vesicles. In some embodiments, the recombinant VSV-G protein is embedded within or anchored to the delivery particle. In some embodiments, the recombinant VSV-G protein is incorporated into the delivery particle as a surface-displayed moiety. In some embodiments, the recombinant VSV-G protein is incorporated into the delivery particle as a transmembrane component. In some embodiments, the delivery particle comprises additional functional components such as targeting ligands, stabilizers, or excipients to enhance delivery, specificity, or bioavailability. In some embodiments, a delivery particle of the disclosure comprises a targeting polypeptide that provides for specific binding to a target cell, thereby facilitating delivery of its payload to a particular target cell.
[0165] In some embodiments, the delivery particle is a vims-like particle (“VLP”). As used herein, the term “enveloped delivery vehicle,” “EDV,” “vims like particle,” and “VLP” are synonymous and refer to a vector comprising a group-specific antigen (gag) protein fragment and a lipid membrane. In some embodiments, the surface display of the recombinant VSV-G protein increases fusion activity, improves on target binding, and / or decreases off-target binding. EDVs may be used to delivery one or more cargo molecules to a cell. In some cases, an EDV also comprises a targeting polypeptide that provides for specific binding to a target cell, thereby facilitating delivery of its cargo a particular target cell. In some cases, EDVs are used to encapsidate or otherwise carry a cargo protein, for example, a polynucleotide-guided nuclease. In instances where the cargo protein is a polynucleotide-guided nuclease, the EDV may also encapsidate a guide polynucleotide. In some cases, EDVs are used to encapsidate nucleic acids, for example, a homology-directed repair (HDR) template and / or a nucleic acid with a coding sequence for a protein of interest, e.g., a CRISPR / Cas nuclease. Examples of EDVs can be found in Hamilton, Jennifer R et al. “Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering.” Cell reports vol. 35,9 (2021): 109207.62IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOdoi: 10.1016 / j .celrep.2021.109207; Hamilton, Jennifer R et al. “In vivo human T cell engineering with enveloped delivery vehicles.” Nature Biotechnology, 10.1038 / s41587-023-02085-z. 11 Jan.2024, doi:10.1038 / s41587-023-02085-z; and U.S. Patent Application Publication No.2022 / 0403379.
[0166] EDVs comprise a fragment of a gag protein, which can be present as part of a fusion with another component such as a nuclease and / or a targeting protein. In general, a naturally occurring gag protein comprises (1) a matrix (MA) polypeptide that binds to cell membranes and directs virions to the cell surface, (2) a capsid (CA) polypeptide that forms an inner shell of a virus, and (3) a nuclcocapsid (NC) polypeptide that binds directly to virion genomic material (e.g., RNA). A gag precursor can be expressed from viral genomic RNA as a single polypeptide that is later proteolytically cleaved to produce an MA polypeptide, a capsid polypeptide, and an NC polypeptide that are each separate from the others. A naturally-occurring gag protein also contains a (1) p2 polypeptide between the CA and NC polypeptides that plays a role in ordered vims assembly and infectivity, (2) a pl polypeptide between the NC polypeptide and a p6 polypeptide that may play a role in vims infectivity, and (3) a p6 polypeptide that plays a role in the late steps of viral replication. Gag proteins are discussed in detail in Olson, Erik D, and Karin Musier-Forsyth. “Retroviral Gag protein-RNA interactions: Implications for specific genomic RNA packaging and virion assembly.” Seminars in cell & developmental biology vol. 86 (2019): 129-139. doi:10.1016 / j.semcdb.2018.03.015; Hill, Melissa K et al. “Proline residues within spacer peptide p 1 are important for human immunodeficiency vims type 1 infectivity, protein processing, and genomic RNA dimer stability.” Journal of virology vol. 76,22 (2002): 11245-53. doi: 10.1128 / jvi.76.22.11245-11253.2002; Schmalen, Adrian et al. “The N-Terminus of the HIV-1 p6 Gag Protein Regulates Susceptibility to Degradation by IDE.” Vimses vol. 10,12 710. 12 Dec. 2018, doi:10.3390 / vl0120710: Newman, John L et al. “Flexibility in the P2 domain of the HIV-1 Gag polyprotein.” Protein science : a publication of the Protein Society vol. 13,8 (2004): 2101-7. doi: 10.1110 / ps.04614804.
[0167] An EDV gag protein fragment can be derived from a lentiviral gag protein or a retroviral gag protein. For example, the lentiviral gag protein can be selected from the group consisting of a bovine immunodeficiency vims gag protein, a simian immunodeficiency vims gag protein, a feline immunodeficiency vims gag protein, a human immunodeficiency vims (HIV) gag protein, an equine infection anemia vims gag protein, and a caprine arthritis encephalitis vims gag protein. In some embodiments, the gag protein is derived from an HIV gag protein.
[0168] The gag protein fragment in some embodiments can comprise an MA polypeptide and a CA polypeptide, and optionally does not compromise the NC polypeptide. The gag protein 63IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOfragment in some embodiments can also comprise a pl polypeptide, a p2 polypeptide, and / or a p6 polypeptide. The MA polypeptide, CA polypeptide, pl polypeptide, p2 polypeptide, and p6 polypeptide can be derived from any lentiviral gag protein or retroviral gag protein. The polypeptides of the gag protein fragment can each be of a different origin and the polypeptides may be combined in a single synthetic gag protein fragment. In some embodiments, the gag protein fragment polypeptides are derived from an HIV gag protein.
[0169] In an EDV, a Gag polyprotein can be both in the form of a fusion protein (e.g., Gag-Cas9) and as a separate polypeptide (e.g., as typically expressed by a native HIV-1 Gag-Pol gene). An EDV can include separate vectors (e.g., plasmids) that separately express Gag polyprotcin in a fusion protein and as a separate polypeptide (e.g., separate vectors encoding each of Gag-Cas9 and Gag-Pol).
[0170] In some embodiments, the EDV includes a Pol polyprotein and / or processed domains thereof. As discussed, a Pol polyprotein can be expressed from a Gag-Pol gene, including an HIV-1 Gag-Pol gene. In some embodiments, the processed domains of the Pol polyprotein includes a protease domain, a reverse transcriptase domain, and an integrase, which can be subsequently processed during maturation into separate domains.
[0171] In some embodiments, a Pol polyprotein includes inactivating mutations in the integrase domain (e.g., a D64 mutation, such as D64V) . In some embodiments, a Pol polyprotein includes inactivating mutations in both the reverse transcriptase domain (e.g., a DI 85 mutation, such as D185) and the integrase domain (e.g., a D64 mutation, such as D64V). An illustrative example of a Pol polyprotcin with a D64V mutation is shown in SEQ ID NO: 6. In some embodiments, such as “two particle’' EDV systems described herein, each EDV species includes a Pol polyprotein with an inactivating mutation in the integrase domain (e.g., D64V). In some embodiments, a Pol polyprotein includes inactivating mutations in the reverse transcriptase domain (e.g., a D185 mutation, such as D185A). EDVs with a Pol polyprotein includes inactivating mutations in the reverse transcriptase domain are generally limited to EDVs that deliver a polynucleotide-guided nuclease (e.g., a Cas9 endonuclease) without the need for reverse transcription of a cargo.
[0172] In some embodiments, a Pol polyprotein includes a full or partial deletion in the reverse transcriptase domain. In some embodiments, a Pol polyprotein includes a full or partial deletion in the integrase domain. In some embodiments, a Pol polyprotein includes a full or partial deletions in both the reverse transcriptase domain and the integrase domain.
[0173] In some embodiments, the Gag polyprotein includes an HIV-1 Gag polyprotein and / or the Pol polyprotein includes and HIV-1 Pol polyprotein.64IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0174] In some embodiments, the delivery particle is a lipid nanoparticle (“LNP”). In some embodiments, the LNP comprises phospholipids and / or ionizable lipids. In some embodiments, the LNP comprises additional lipid components, such as a sterol and / or a conjugated lipid.Payloads
[0175] In some embodiments, a recombinant VSV-G of the disclosure is incorporated into a delivery particle, e.g. , a VLP, comprising a payload. In some embodiments, the payload comprises one or more biologically active components, recombinant proteins, nucleic acids, therapeutic agents, small molecules, and / or adjuvants. In some embodiments, the payload comprises a gene editing system, a polynucleotide encoding a transgcnc, a peptide, and / or a detectable marker. In some embodiments, the delivery particle comprises a nucleic acid molecule, such as a DNA, RNA, or a chemically modified nucleic acid. In some embodiments, the payload comprises a protein, polypeptide, enzyme, and / or peptide. In some embodiments, the delivery particle comprises a payload protein that is displayed on the surface or encapsulated within the particle. In some embodiments, the payload comprises a therapeutic molecule such as a small molecule drug, peptide, or antibody.
[0176] Examples of delivery particles and payloads useful in conjunction with the recombinant VSV-G proteins of the disclosure can be found in Hamilton, Jennifer R et al. “Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering.” Cell reports vol.35,9 (2021): 109207. doi:10.1016 / j.celrep.202L 109207; Hamilton, Jennifer R et al. “In vivo human T cell engineering with enveloped delivery vehicles.” Nature Biotechnology, 10.1038 / s4I587-023-02085-z. 11 Jan. 2024, doi:10.1038 / s41587-023-02085-z; and U.S. Patent Application Publication No. 2022 / 0403379, each of which is incorporated by reference herein in its entirety for all purposes.
[0177] In some embodiments, the payload comprises a nucleic acid. In some embodiments, the nucleic acid encodes a transgene (e.g., a CAR, an engineered TCR, an antibody). In some embodiments, the nucleic acid is non-encoding (e.g., a gRNA or siRNA). In some embodiments, the nucleic acid payload is a lentiviral genome comprising a nucleic acid encoding a transgene flanked by inverted terminal repeats (ITRs). Particles with such pay loads are described in the art, see e.g., WO 2020 / 102709, incorporated herein by reference.
[0178] A payload can include a homology-directed repair, e.g., for use in editing a genome. The term “homology-directed repair” or “HDR” refers to a cellular process in which cut or nicked ends of a DNA strand (e.g., a genome) are repaired by polymerization from a nucleic acid template (an “HDR template”) that includes sequences that are homologous to the cut or nicked DNA strand.65IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOThus, the original sequence is replaced with a sequence on the HDR template. An HDR template (e.g., with an exogenous transgene flanked by regions of homologous sequences) can be introduced into a cell to obtain a specific HDR-induccd change of the sequence at a target site.
[0179] The terms “modifying,” “editing,” and the like, used in the context of modifying a genome of a cell, refers to inducing a structural change in the sequence of the genome at a target genomic region. As used herein, the terms “gene modification,” “gene editing,” and the like refer to transient or permanent genetic modification in a target cell following introduction of molecules, e.g., nucleic acids and / or proteins, of the present disclosure, into the cell. The genetic modification can be accomplished by contacting a target cell with one or more vectors that can deliver the nucleic acids and / or proteins for introducing the genetic modification and inserting the nucleic acids into the genome of the cell. The choice of method is generally dependent on the type of cell being transformed and the circumstances under which the transformation is taking place (i.e. in vitro, ex vivo, or in vivo). In some embodiments, the gene modification is performed, for example, by inducing a double stranded break within a target genomic region, or a pair of single stranded nicks on opposite strands and flanking the target genomic region. Methods for inducing single or double stranded breaks at or within a target genomic region include the use of a polynucleotide-guided nuclease (e.g., transcription activator-like effector nuclease (TALEN), a zinc finger nuclease, a mcganuclcasc, Cas9 nuclease domain, or derivative thereof), and a guide polynucleotide (e.g., a guide RNA or pair of guide RNAs) directed to the target genomic region.
[0180] The terms “chimeric antigen receptor” and “CAR” refer to artificial multi-module molecules capable of triggering or inhibiting the activation of an immune cell which generally but not exclusively include an extracellular domain (e.g., a ligand / antigen binding domain), a transmembrane domain and one or more intracellular signaling domains. The term CAR is not limited specifically to CAR molecules but also includes CAR variants. CAR variants include split CARs wherein the extracellular portion (e.g., the ligand binding portion) and the intracellular portion (e.g., the intracellular signaling portion) of a CAR are present on two separate molecules. CAR variants also include ON-switch CARs which are conditionally activatable CARs, e.g., including a split CAR wherein conditional hetero-dimerization of the two portions of the split CAR is pharmacologically controlled. CAR variants also include bispecific CARs, which include a secondary CAR binding domain that can either amplify or inhibit the activity of a primary CAR. CAR variants also include inhibitory chimeric antigen receptors (iCARs) which may, e.g., be used as a component of a bispecific CAR system, where binding of a secondary CAR binding domain results in inhibition of primary CAR activation. CAR molecules and derivatives thereof (i.e., CAR variants) are described, e.g., in PCT Application No. US2014 / 016527; Fedorov et al. Sci Transl 66IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOMed (2013) ;5(215):215ral72; Glienke et al. Front Pharmacol (2015) 6:21; Kakarla & Gottschalk 52 Cancer J (2014) 20(2): 151-5; Riddell et al. Cancer J (2014) 20(2):141-4; Pegram et al. Cancer J (2014) 20(2): 127-33; Cheadle ct al. Immunol Rev (2014) 257( 1):91 -106; Barrett et al. Annu Rev Med (2014) 65:333-47; Sadelain et al. Cancer Discov (2013) 3(4):388-98; Cartellieri et al., J Biomed Biotechnol (2010) 956304.
[0181] In some embodiments, the payload comprises a polynucleotide-guided nuclease. Where the cargo protein is a polynucleotide-guided nuclease, in some embodiments, the payload also comprises a guide polynucleotide. In some embodiments, the payload comprises a nucleic acid with a coding sequence for a protein of interest. In some embodiments, the payload comprises a CRISPR / Cas nuclease.
[0182] In some embodiments, the payload comprises a protein. In some embodiments, the protein is a nuclease, an antibody, or a peptide drug. In some embodiments, the nuclease is a CRISPR / Cas enzyme or a fusion protein comprising a CRISPR / Cas enzyme. Suitable CRISPR / Cas enzymes are known in the art. In some embodiments, the CRISPR / Cas enzyme is a type II CRISPR / Cas enzyme. In some embodiments, the type II CRISPR / Cas enzyme is a Cas9 polypeptide. In some embodiments, the CRISPR / Cas enzyme is a type V CRISPR / Cas effector polypeptide, e.g., Casl2a, Casl2b, Casl2c, Casl2d, or Casl2e. In some embodiments, the CRISPR / Cas enzyme is a type VI CRISPR / Cas enzyme, e.g., Casl3a, Casl3b, Casl3c, or Casl3d. In some embodiments, the CRISPR / Cas enzyme is a Casl4 polypeptide, e.g., Casl4a, a Casl4b, or Casl4c. Also suitable for use is a variant CRISPR / Cas enzyme, where the variant CRISPR / Cas enzyme has reduced nucleic acid cleavage activity.
[0183] Also suitable for use is a CRISPR / Cas fusion polypeptide comprising: i) a CRISPR / Cas enzyme variant with reduced nucleic acid cleavage activity; and ii) a heterologous fusion polypeptide. In some embodiments, the heterologous fusion polypeptide is a protein modifying enzyme. In some embodiments, the heterologous fusion polypeptide is a nucleic acid modifying enzyme. In some embodiments, the heterologous fusion polypeptide is a transcription factor. In some embodiments, the heterologous fusion polypeptide is a transcription activator. In some embodiments, the heterologous fusion polypeptide is a transcription repressor. In some embodiments, the nucleic acid modifying enzyme is a cytidine deaminase. In some embodiments, the nucleic acid modifying enzyme is an adenosine deaminase. In some embodiments, the nucleic acid modifying enzyme is a prime editor.
[0184] In some embodiments, the payload comprises a nuclease. In some embodiments, the nuclease is a homing nuclease polypeptide; a Fokl polypeptide; a transcription activator-like67IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOeffector nuclease (TALEN) polypeptide; a MegaTAL polypeptide; a meganuclease polypeptide; a zinc finger nuclease (ZFN); an ARCUS nuclease; or the like. The meganuclease can be engineered from an LADLIDADG homing endonuclease (LHE). A mcgaTAL polypeptide can comprise a TALE DNA binding domain and an engineered meganuclease. See, e.g., WO 2004 / 067736 (homing endonuclease); Urnov et al. (2005) Nature 435:646 (ZFN); Mussolino et al. (2011) Nucl. Acids Res. 39:9283 (TALE nuclease); Boissel et al. (2013) Nucl. Acids Res.42:2591 (MegaTAL).
[0185] In some embodiments, the payload comprises more than one component. For example, in some embodiments, a payload comprises a nucleic acid and a protein. For example, the payload may comprise a CRISPR / Cas enzyme and one or more gRNAs (e.g., a gene editing system). In some embodiments, the payload comprises a CRISPR / Cas enzyme and a nucleic acid encoding a transgene (e.g., a CAR, engineered TCR, or antibody), such as an HDR template. In some embodiments, the payload comprises a CRISPR / Cas enzyme, a gRNA (e.g., a sgRNA), and an HDR template encoding a transgene (e.g., a CAR). In some embodiments, the delivery particle comprises a gag protein fragment that is covalently linked to the CRISPR / Cas enzyme as a single polypeptide (i.e., a fusion protein). Particles with such payloads are described in the art, see e.g., WO 2020 / 102709, incorporated herein by reference.Targeting moieties
[0186] In some embodiments, a delivery particle of the present disclosure comprises one or more targeting moieties displayed on its surface. In some embodiments, the targeting moiety facilitates selective binding. In some embodiments, the targeting moiety improves uptake by, or interaction with, a target. In some embodiments, the target is a target cell, a target tissue, or a target receptor. In some embodiments, the targeting moiety improves specificity and / or efficacy of the delivery particle.
[0187] In some embodiments, the targeting moiety is a ligand that binds to a target receptor, e.g., expressed on the surface of a target cell. In some embodiments, the ligand is a peptide, aptamer, carbohydrate, cytokine, growth factor, or small molecule. In some embodiments, the targeting moiety is derived from a naturally-occurring ligand, or is a modified or synthetic version thereof that retains or enhances receptor-binding.
[0188] In some embodiments, the targeting moiety comprises an antibody or antibody fragment. The terms "antibody" and “immunoglobulin” are used interchangeably and include an intact immunoglobulin molecule comprising four polypeptide chains: two heavy chains and two light chains connected by disulfide bonds. Immunoglobulins can be of any isotype. "Antibody68IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOfragments" comprise a portion of an intact antibody, for example, the antigen binding or variable region of the intact antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; scFv; diabodics; linear antibodies (Zapata ct al., Protein Eng. 8(10): 1057-1062 (1995)); domain antibodies (dAb; Holt et al. (2003) Trends BiotechnoL 21:484); single-chain antibody molecules; and multi-specific antibodies formed from antibody fragments. The antibodies and fragments thereof can be further conjugated to other moieties, such as members of specific binding pairs, e.g., biotin (member of biotin- avidin specific binding pair), and the like.
[0189] In some embodiments, the targeting moiety comprises a monoclonal antibody or antigenbinding fragment thereof. In some embodiments, the targeting moiety comprises a single-chain variable fragment (scFv). "Single-chain Fv" or “scFv” antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain. In some embodiments, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer -Verlag, New York, pp. 269-315 (1994). In some embodiments, the antibody or antibody fragment binds a target antigen or receptor selectively expressed on target cells. In some embodiments, the antibody or antibody fragment is genetically or chemically fused to a structural protein of the delivery particle, or is conjugated using a linker or adaptor molecule.
[0190] In some embodiments, the targeting moieties described herein comprise an antigenbinding domain (e.g., an scFv), a CD8ot stalk (e.g., SEQ ID NO: 235), and a CD8a transmembrane domain (e.g., SEQ ID NO: 236). The CD8a stalk and transmembrane domain sequences are provided in the table below.Domain AA Sequence SEQ ID NO:CD 8a stalk TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV 235HTRGLDFACD CD8a transmembrane IYIWAPLAGTCGVLLLSLVITLYC 236domain
[0191] In some embodiments, the targeting moiety comprises an scFv that binds to CD3 (“a CD3 scFv”). In some embodiments, the CD3 scFv is based on an antibody selected from UCHT, Acapatamab, OKT3, FN-18, and SP34-2 (See Sen et al. Automated Antibody De Novo Sequencing and Its Utility in Biopharmaceutical Discovery. J Am Soc Mass Spectrom. 2017 May;28(5):803-810, incorporated herein by reference in its entirety). In some embodiments, the CD3 scFv comprises, from N-terminus to C-terminus, VH domain - linker - VL domain. In some69IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOembodiments, the scFv comprises, from N-terminus to C-terminus, VL domain - linker - VH domain.
[0192] In some embodiments, the targeting moiety comprises an scFv that binds to CD5 (“a CD5 scFv”). In some embodiments, the CD5 scFv is based on an antibody selected from those described in WO 2016 / 172606, incorporated herein by reference in its entirety. In some embodiments, the CD5 scFv comprises, from N-terminus to C-terminus, VH domain - linker - VL domain. In some embodiments, the scFv comprises, from N-terminus to C-terminus, VL domain - linker - VH domain.
[0193] In some embodiments, the targeting moiety comprises an scFv that binds to CD7 (“a CD7 scFv”). In some embodiments, the CD7 scFv is based on an antibody selected from those described in WO 2003 / 051926, incorporated herein by reference in its entirety. In some embodiments, the CD7 scFv comprises, from N-terminus to C-terminus, VH domain - linker - VL domain. In some embodiments, the scFv comprises, from N-terminus to C-terminus, VL domain - linker - VH domain.
[0194] In some embodiments, the targeting moiety comprises an scFv that binds to CD27 (“a CD27 scFv”). In some embodiments, the CD27 scFv is based on an antibody selected from M2177, H2191, M2191, (see the exapsy.org / abcd database entries for ABCD_AG335, _336, and _337, respectively), varlilumab, 3C2 (See WO 2019 / 204462, incorporated herein by reference in its entirety), 2B3 (See WO 2019 / 204462, incorporated herein by reference in its entirety), hCD27.L5 (See WO 2012 / 004367, incorporated herein by reference in its entirety), and boscrolimab (Sec entry 1308 in the imgt.org / mAb-DB database). In some embodiments, the CD27 scFv comprises, from N-terminus to C-terminus, VH domain - linker - VL domain. In some embodiments, the scFv comprises, from N-terminus to C-terminus, VL domain - linker - VH domain.
[0195] In some embodiments, the targeting moiety comprises an scFv that binds to CD4 (“a CD4 scFv”). In some embodiments, the CD4 scFv is based on the ibalizumab antibody. In some embodiments, the CD4 scFv comprises, from N-terminus to C-terminus, VH domain - linker -VL domain. In some embodiments, the scFv comprises, from N-terminus to C-terminus, VL domain - linker - VH domain.
[0196] In some embodiments, the targeting moiety comprises an scFv that binds to CD28 (“a CD28 scFv”). In some embodiments, the CD28 scFv comprises, from N-terminus to C-terminus, VH domain - linker - VL domain. In some embodiments, the scFv comprises, from N-terminus to C-terminus, VL domain - linker - VH domain.70IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WO
[0197] In some embodiments, the targeting moiety comprises an scFv that binds to a TCR (“a TCR scFv”). In some embodiments, the TCR scFv is based on an antibody selected from BMA031, GL1BM, GL1BM VH28, GL1BM VH31, HEBE, HEBE H10, and HEBE H66 described in WO 2013 / 037484, incorporated herein by reference in its entirety. In some embodiments, the TCR scFv comprises, from N-terminus to C-terminus, VH domain - linker -VL domain. In some embodiments, the scFv comprises, from N-terminus to C-terminus, VL domain - linker - VH domain.
[0198] In some embodiments, the targeting moiety comprises an antigen binding domain that binds a T cell antigen, including but not limited to CD2, CD3, CD4, CD5, CD7, CD8, CD19, CD28, 4- IBB ligand, T cell receptor (TCR) a constant chain, TCR beta constant chain, major histocompatibility complex (MHC) presenting a T cell receptor (TCR) specific peptide, and combinations thereof. In some embodiments, the targeting moiety comprises an antigen binding domain that binds to each of CD3, CD28, and CD2.
[0199] Targeting moieties that target T cells can be used to specifically target T cells and subpopulations thereof. The term “T cell” refers to a lymphoid cell that typically has undergone maturation in the thymus and generally expresses a T cell receptor molecule and / or other T cell signaling molecules (e.g., the CD3 family member of proteins). T cells include, but are not limited to, naive T cells, stimulated T cells, primary T cells (e.g., uncultured), cultured T cells, immortalized T cells, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, combinations thereof, or sub-populations thereof. T cells can be CD4+, CD8+, or CD4+and CD8+. T cells can be helper cells, for example helper cells of type Thl, Th2, Th3, Th9, Thl7, or TFH. T cells can be cytotoxic T cells. Regulatory T cells can be FOXP3+or FOXP3’. T cells can be a / Beta T cells or gamma / delta T cells. In some embodiments, the T cell is a CD4+CD25hiCD1271° regulatory T cell. In some embodiments, the T cell is a regulatory T cell selected from the group consisting of Tri, Th3, CD8+CD28-, Tregl7, and Qa-1 restricted T cells, or a combination or sub-population thereof. In some embodiments, the T cell is a FOXP3+T cell. In some embodiments, the T cell is a CD4+CD25loCD127hleffector T cell. In some embodiments, the T cell is a CD4+CD25loCD127hiCD45RAhiCD45RO’ naive T cell. T cells can also include T cells or cells with immune properties of a T cell that are engineered, such as a CAR-expressing T cell. CAR-expressing T cells can include T cells that have been engineered to reduce or eliminate expression of a native T cell receptor molecule, for example, T cells with a CAR or other protein inserted into the TRAC locus that disrupts expression of a native T cell receptor. T cells with reduced or eliminated expression of a native T cell receptor are generally still capable of mediating T cell responses through other T cell signaling molecules (e.g., the CD3 family member of 71IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOproteins) and a non-native receptor (e.g., a CAR). Accordingly, targeting moieties that target T cells can be selected based on the desired T cell subpopulation.
[0200] Exemplary scFv sequences are provided below in Table 5. Linker sequences are indicated in bold and italicized text.Table 5: Targeting moiety scFvs.Target Clone name Ref. scFv sequence (AA) SEQ ID CD3 UCHT1 7a.1 EVQLQQSGPELVKPGASMKISCKASGYSFTGYTMNWVKQSHGK 237NLEWMGLINPYKGVSTYNQKFKDKATLTVDKSSSTAYMELLSL TSEDSAVYYCARSGYYGDSDWYFDVWGQGTTLTVFGGGGSGG GGSGGGGSDIQMTQTTSSLSASLGDRVTISCRASQDIRNYLNWY QQKPDGTVKLLIYYTSRLHSGVPSKFSGSGSGTDYSLTISNLEQE DIATYFCQQGNTLPWTFAGGTKLEIKS CD3 UCHT1 7a.2 DIQMTQTTSSLSASLGDRVTISCRASQDIRNYLNWYQQKPDGTV 238KLLIYYTSRLHSGVPSKFSGSGSGTDYSLTISNLEQEDIATYFCQQ GNTLPWTFAGGTKLEIKGGGGSGGGGSGGGGSEVQLQQSGPEL VKPGASMKISCKASGYSFTGYTMNWVKQSHGKNLEWMGLINP YKGVSTYNQKFKDKATLTVDKSSSTAYMELLSLTSEDSAVYYC ARSGYYGDSDWYFDVWGQGTTLTVFS CD3 OKT3 7b MQVQLLESGAELARPGASVKMSCKASGYTFTRYTMHWVKQRP 239GQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSS LTSEDSAVYYCAGYYDDHYCLDYWGQGTLVTVSSGGGGSGGG GSGGGGSDIVMTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQ QKSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAE DAATYYCQQWSSNPFTFGSGTKLEIKRS CD3 Acapatamab 7f.l EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPG 240KGEEWVARIRSKYNNYATYYADSVKDRFTLSRDDSKNTAYEQM NNLKTEDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGG GGSGGGGSGGGGSQTVVTQEPSLTVSPGGTVTLTCGSSTGAVTS GNYPNWVQQKPGQAPRGL1GGTKFLAPGTPARFSGSLLGGKAA LTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLS CD3 Acapatamab 7f.2 QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPG 241QAPRGLIGGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAE YYCVLWYSNRWVFGGGTKLTVLGGGGSGGGGSGGGGSEVQLV ESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKT EDTAVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSS CD3 N / A 7g D1QMTQSPSSLSASVGDRVT1TCRASQDIRNYLNWYQQKPGKAP 242KLLIYYTSRLESGVPSRFSGSGSGTDYTLHSSLQPEDFATYYCQQ GNTLPWTFGQGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGL VQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPT KGVSTYNQKFKDRFUSVDKSKNTAYLQMNSLRAEDTAVYYCA RSGYYGDSDWYFDVWGQGTLVTVSSS CD3 OKT3 7h.l QVQLQQSGAELARPGASVKMSCKASGYTFTRYTMHWVKQRPG 243QGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSL TSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSGGGGSGGGG SGGGG5QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQ KSGTSPKRWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAED AATYYCQQWSSNPFTFGSGTKLEINS CD3 OK.T3 7h.2 QIVLTQSPAIMSASPGEKVTMTCSASSSVSYMNWYQQKSGTSPK 244RWIYDTSKLASGVPAHFRGSGSGTSYSLTISGMEAEDAATYYCQ QWSSNPFTFGSGTKLEINGGGGSGGGGSGGGGSQVQLQQSGAE LARPGASVKMSCKASGYTFTRYTMIIWVKQRPGQGLEWIGYINP SRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSS72IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOTarget Clone name Ref. scFv sequence (AA) SEQ ID CD3 hOKT3 7i.l QVQLVQSGGGVVQPGRSLRLSCKASGYTFTRYTMHWVRQAPG 245KGLEWIGYINPSRGYTNYNQKVKDRFTISRDNSKNTAFLQMDSL RPEDTGVYFCARYYDDHYCLDYWGQGTPVTVSSGGGGSGGGG SGGGGSDIQMTQSPSSLSASVGDRVUTCSASSSVSYMNWYQQT PGKAPKRWIYDTSKLASGVPSRFSGSGSGTDYTFTISSLQPEDIAT YYCQQWSSNPFTFGQGTKLQITS CD3 hOKT3 7i.2 DIQMTQSPSSLSASVGDRVTITCSASSSVSYMNWYQQTPGKAPK 246RW1YDTSKLASGVPSRFSGSGSGTDYTFTISSEQPEDIATYYCQQ WSSNPFTFGQGTKLQITGGGGSGGGGSGGGGSQVQLVQSGGGV VQPGRSLRLSCKASGYTFTRYTMHWVRQAPGKGLEWIGYINPS RGYTNYNQKVKDRFTISRDNSKNTAFLQMDSLRPEDTGVYFCA RYYDDHYCLDYWGQGTPVTVSSS CD3 FN-18 7j-l QVQLQQSEAELARPGASVKMSCKASGYTFTDYTIHWLKQRPGQ 247GLDWIGYFNPSSESTEYNRKFKDRTILTADRSSTTAYMQLSSLTS EDSAVYYCSRKGEKLLGNRYWYFDVWGAGTSVTVSSGGGGSG GGGSGGGGSDIVMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQ KNYLAWYQQKPGQSPKLLINWASTRESGVPDRFTGSGSRTDFTL TISSVKAEDLAVYFCQQFYSYPPTFGGGTKLEIKS CD3 FN-18 7j-2 D1VMSQSPSSLAVSVGEKVTMSCKSSQSLLYSSNQKNYLAWYQ 248QKPGQSPKLLINWASTRESGVPDRFTGSGSRTDFTLTISSVKAED LAVYFCQQFYSYPPTFGGGTKLEIKGGGGSGGGGSGGGGSQVQ LQQSEAELARPGASVKMSCKASGYTFTDYTIHWLKQRPGQGLD WIGYFNPSSESTEYNRKFKDRTILTADRSSTTAYMQLSSLTSEDS AVYYCSRKGEKLLGNRYWYFDVWGAGTSVTVSSS CD3 SP34-2 7k.1 EVKLLESGGGLVQPKGSLKLSCAASGFTFNTYAMNWVRQAPGK 249GLEWVARIRSKYNNYATYYADSVKDRFTISRDDSQSILYLQMN NLKTEDTAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSAGG GGSGGGGSGGGGSQAVVTQESALTTSPGETVTLTCRSSTGAVTT SNYANWVQEKPDHLFTGLIGGTNKRAPGVPARFSGSLIGDKAAL TITGAQTEDEAIYFCALWYSNLWVFGGGTKLTVLS CD3 SP34-2 7k.2 QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPD 250HLFTGLIGGTNKRAPGVPARFSGSLIGDKAALTITGAQTEDEAIY FCALWYSNLWVFGGGTKLTVLGGGGSGGGGSGGGGSEVKLLE SGGGLVQPKGSLKLSCAASGFTFNTYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFUSRDDSQSILYLQMNNLKTED TAMYYCVRHGNFGNSYVSWFAYWGQGTLVTVSAS CD4 ibalizumab 9a.l QVQLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQ 251GLDWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLR SEDTAVYYCAREKDNYATGAWFAYWGQGTLVTVSSGGGGSGG GGSGGGGSSDIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQ KNYLAWYQQKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTL TISSVQAEDVAVYYCQQYYSYRTFGGGTKLEIKS CD4 ibalizumab 9a.2 DIVMTQSPDSLAVSLGERVTMNCKSSQSLLYSTNQKNYLAWYQ 252QKPGQSPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSVQAED VAVYYCQQYYSYRTFGGGTKLEIKSGGGGSGGGGSGGGGSSQV QLQQSGPEVVKPGASVKMSCKASGYTFTSYVIHWVRQKPGQGL DWIGYINPYNDGTDYDEKFKGKATLTSDTSTSTAYMELSSLRSE DTAVYYCAREKDNYATGAWFAYWGQGTLVTVSS CD28 N / A 15a QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQ 253GLEWMGWISAYNDNTHYAQKLQGRVTMTTDTSTSTAYMELRS LRSDDTAVYYCATQAAMDVWGQGTLVTVSSGGGGSGGGGSG GGGSSYELTQPPSASGTPGQRVTISCSGSRSNIGGNTVNWYQQLP GTAPKLLIYANDQRPSGVPDRVSGSKSGTSASLATSGLQSEDEAH YYCAAWDDRLNGVVFGGGTKLTVLS CD28 N / A 15b.l QVQLQQSGPELVKPGTSVRISCEASGYTFTSYYIHWVKQRPGQG 254LEWIGCIYPGNVNTNYNEKFKDKATLIVDTSSNTAYMQLSRMTS EDSAVYFCTRSHYGLDWNFDVWGAGTTVTVSSGGGGSGGGGSGGGGSSDIQMNQSPSSLSASLGDTITITCHASQNIYVWLNWYQQ73IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOTarget Clone name Ref. scFv sequence (AA) SEQ ID KPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIAT YYCQQGQTYPYTFGGGTKLEIKS CD28 N / A 15b.2 DIQMNQSPSSLSASLGDTITITCHASQNIYVWLNWYQQKPGNIPK 255LLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQG QTYPYTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLQQSGPEL VKPGTSVRISCEASGYTFTSYYIHWVKQRPGQGLEWIGCIYPGN VNTNYNEKFKDKATLIVDTSSNTAYMQLSRMTSEDSAVYFCTR SHYGLDWNFDVWGAGTTVTVSSS CD28 N / A 15c.l VQLQQSGAELKKPGASVKVSCKASGYTFTEYIIHWIKLRSGQGL 256EWIGWFYPGSNDIQYNAQFKGKATLTADKSSSTVYMRRDDFSG YDALPYWGQGTLVTVSAGGGG5GGGGSGGGGSSDIQMTQSPSS LSASVGDRVTITCKTNENIYSNLAWYQQKDGKSPQLLIYAATHL VEGVPSRFSGSGSGTQYSLTISSLQPEDFGNYYCQHFWGTPATFG GGTKLEIKS CD28 N / A 15c.2 DIQMTQSPSSLSASVGDRVTITCKTNENIYSNLAWYQQKDGKSP 257QLLIYAATHLVEGVPSRFSGSGSGTQYSLTISSLQPEDFGNYYCQ HFWGTPATFGGGTKLEIKGGGGSGGGGSGGGGSSVQLQQSGAE LKKPGASVKVSCKASGYTFTEYIIHWIKLRSGQGLEWIGWFYPG SNDIQYNAQFKGKATLTADKSSSTVYMRRDDFSGYDALPYWGQ GTLVTVSAS CD5 N / A 50a.1 NIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGK 258GLRWMGWINTHTGEPTYADDFKGRFAFSLETSASTAYLQINNL KNEDTATYFCTRRGYDWYFDVWGAGTTVTVSSGGGGSGGGGS GGGGSSDIKMTQSPSSMYASLGERVTITCKASQDINSYLSWFHH KPGKSPKTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSLDYEDM GIYYCQQYDESPWTFGGGTKLEMKS CD5 N / A 50a.2 D1KMTQSPSSMYASLGERVTITCKASQDINSYLSWFHHKPGKSP 259KTLIYRANRLVDGVPSRFSGSGSGQDYSLTISSLDYEDMGIYYCQ QYDESPWTFGGGTKLEMKGGGGSGGGGSGGGGSSNIQLVQSGP ELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLRWMGWI NTHTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTATYF CTRRGYDWYFDVWGAGTTVTVSSS CD5 HOLO 50b.1 QVTLKESGPGILKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGK 260GLEWLAHIWWDDDVYYNPSLKNQLTISKDASRDQVFLKITNLD TADTATYYCVRRRATGTGFDYWGQGTTLTVSSGGGGSGGGGS GGGGSSNIVMTQSHKFMSTSVGDRVSIACKASQDVGTAVAWYQ QKPGQSPKLLIYWTSTRHTGVPDRFTGSGSGTDFTLTITNVQSED LADYFCHQYNSYNTFGSGTRLELKS CD5 HOLO 50b.2 NIVMTQSHKFMSTSVGDRVSIACKASQDVGTAVAWYQQKPGQS 261PKLLIYWTSTRHTGVPDRFTGSGSGTDFTLTITNVQSEDLADYFC HQYNSYNTFGSGTRLELKGGGGSGGGGSGGGGSSQVTLKESGP GILKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAIIIW WDDDVYYNPSLKNQLTISKDASRDQVFLKITNLDTADTATYYC VRRRATGTGFDYWGQGTTLTVSSS CD5 HILI 50c.1 EVQLVESGGGVVQPGRSLRLSCTFSGFSLSTSGMGVGWIRQAPG 262KGLEWVAHIWWDDDVYYNPSLKSRLTITKDASTDTVYMELSSL RSEDTAVYYCVRRRATGTGFDYWGQGTLVTVSSGGGG5GGGG SGGGG5SNIVMTQSPSSLSASVGDRVTITCQASQDVGTAVAWYQ QKPDQSPKLLIYWTSTRHTGVPDRFTGSGSGTDFTLTISSLQPEDI ATYFCHQYNSYNTFGSGTKLEIKS CD5 HILI 50c.2 NIVMTQSPSSLSASVGDRVTITCQASQDVGTAVAWYQQKPDQSP 263KLLIYWTSTRHTGVPDRFTGSGSGTDFTLTISSLQPEDIATYFCHQ YNSYNTFGSGTKLEIKGGGGSGGGGSGGGGSSEVQLVESGGGV VQPGRSLRLSCTFSGFSLSTSGMGVGWIRQAPGKGLEWVAHIW WDDDVYYNPSLKSRLTITKDASTDTVYMELSSLRSEDTAVYYC VRRRATGTGFDYWGQGTLVTVSSS CD5 H1L3 50d.l EVQLVESGGGVVQPGRSLRLSCTFSGFSLSTSGMGVGWIRQAPG 264KGLEWVAHIWWDDDVYYNPSLKSRLTITKDASTDTVYMELSSLRSEDTAVYYCVRRRATGTGFDYWGQGTLVTVSSGGGGSGGGG 74IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOTarget Clone name Ref. scFv sequence (AA) SEQ ID SGGGGSSNIVMTQSPAFLSVTPGEKVTITCQASQDVGTAVAWYQ QKPDQSPKLLIYWTSTRHTGVPDRFTGSGSGTDFTFTISSLEAED AATYFCHQYNSYNTFGSGTKLEIKSC.D5 H1L3 50d.2 NIVMTQSPAFLSVTPGEKVTITCQASQDVGTAVAWYQQKPDQSP 265KLLIYWTSTRHTGVPDRFTGSGSGTDFTFTISSLEAEDAATYFCH QYNSYNTFGSGTKLEIKGGGGSGGGGSGGGGSSEVQLVESGGG VVQPGRSLRLSCTFSGFSLSTSGMGVGWIRQAPGKGLEWVAHI WWDDDVYYNPSLKSRLTTTKDASTDTVYMELSSLRSEDTAVYY CVRRRATGTGFDYWGQGTLVTVSSS CD5 H2L2 50e.l QVTLKESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPG 266KGLEWVAHIWWDDDVYYNPSLKSRLTITKDASKDQVVLTMTN MDPVDTATYYCVRRRATGTGFDYWGQGTLVTVSSGGGGSGGG GSGGGGSSNIVMTQSPPTLSLSPGERATLSCRASQDVGTAVAWY QQKPDQSPKLLIYWTSTRHTGVPDRFTGSGSGTDFTLTISRLEPE DE AV YFCHQYN S YNTFGSGTKLE1KSCD5 H2L2 50e.2 NIVMTQSPPTLSLSPGERATLSCRASQDVGTAVAWYQQKPDQSP 267KLLIYWTSTRHTGVPDRFTGSGSGTDFTLTISRLEPEDFAVYFCH QYNSYNTFGSGTKLEIKGGGGSGGGGSGGGGSSQVTLKESGPAL VKPTQTLTLTCTFSGFSLSTSGMGVGW1RQPPGKGLEWVAH1W WDDDVYYNPSLKSRLTITKDASKDQVVLTMTNMDPVDTATYY CVRRRATGTGFDYWGQGTLVTVSSS CD5 H3L1 50f.l QVTLKESGPVLVKPTETLTLTCTFSGFSLSTSGMGVGWIRQAPG 268KGLEWVAHIWWDDDVYYNPSLKSRL'HTKDASKDQVSLKLSSV TAADTAVYYCVRRRATGTGFDYWGQGTLVTVSSGGGGSGGGG SGGGGSSNIVMTQSPSSLSASVGDRVTITCQASQDVGTAVAWYQ QKPDQSPKLLIYWTSTRHTGVPDRFTGSGSGTDFTLTISSLQPEDI ATYFCHQYNSYNTFGSGTKLEIKS CD5 H3L1 50f.2 NIVMTQSPSSLSASVGDRVTITCQASQDVGTAVAWYQQKPDQSP 269KLLIYWTSTRHTGVPDRFTGSGSGTDFTLTISSLQPEDIATYFCHQ YNSYNTFGSGTKLEIKGGGGSGGGGSGGGGSSQVTLKESGPVLV KPTETLTLTCTFSGFSLSTSGMGVGWIRQAPGKGLEWVAHIWW DDDVYYNPSLKSRLTITKDASKDQVSLKLSSVTAADTAVYYCV RRRATGTGFDYWGQGTLVTVSSS CD5 H3L3 50g.1 QVTLKESGPVLVKPTETLTLTCTFSGFSLSTSGMGVGWIRQAPG 270KGLEWVAHIWWDDDVYYNPSLKSRLTITKDASKDQVSLKLSSV TAADTAVYYCVRRRATGTGFDYWGQGTLVTVSSGGGGSGGGG SGGGGSSNIVMTQSPAFLSVTPGEKVTITCQASQDVGTAVAWYQ QKPDQSPKLLIYWTSTRHTGVPDRFTGSGSGTDFTFTISSLEAED AATYFCHQYNSYNTFGSGTKLEIKS CD5 H3L3 50g.2 NIVMTQSPAFLSVTPGEKVTITCQASQDVGTAVAWYQQKPDQSP 271KLLIYWTSTRHTGVPDRFTGSGSGTDFTFTISSLEAEDAATYFCH Q YNS YNTFG SG TKLEIKGGGGSGGGGSGGGGSS Q VTLKESG PVL VKPTETLTLTCTFSGFSLSTSGMGVGWIRQAPGKGLEWVAHIW WDDDVYYNPSLKSRLTITKDASKDQVSLKLSSVTAADTAVYYC VRRRATGTGFDYWGQGTLVTVSSS CD7 N / A 51.a.l EVQLVESGGGLVKPGGSLKLSCAASGLTFSSYAMSWVRQTPEK 272RLEWVASISSGGFTYYPDSVKGRFTISRDNARNILYLQMSSLRSE DTAMYYCARDEVRGYLDVWGAGTTVTVSSGGGG5GGGGSGG GGSSDIQMTQTTSSLSASLGDRVTISCSASQGISNYLNWYQQKPD GTVKLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYY CQQYS KLPYTFGGGTKLEIKS CD7 N / A 51a.2 DIQMTQTTSSLSASLGDRVTISCSASQGISNYLNWYQQKPDGTV 273KLLIYYTSSLHSGVPSRFSGSGSGTDYSLTISNLEPEDIATYYCQQ YSKLPYTFGGGTKLEIKGGGGSGGGGSGGGGSSEVQLVESGGGL VKPGGSLKLSCAASGLTFSSYAMSWVRQTPEKRLEWVASISSGG FTYYPDSVKGRFTISRDNARNILYLQMSSLRSEDTAMYYCARDE VRGYLDVWGAGTTVTVSSS CD7 grisnilimab 51b.l QIQLVQSGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGK 274GLMWLGWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLK 75IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOTarget Clone name Ref. scFv sequence (AA) SEQ ID NEDTATYFCARWAYFYGSSPYFFDYWGQGTTLTVSSGGGGSGG GGSGGGGSSQAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYA NWVQEKPDHLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITG AQTEDEAIYFCALWCSNHLVFGGGTKLTVLS CD7 grisnilimab 51b.2 QAVVTQESALTTSPGETVTLTCRSSTGAVTTSNYANWVQEKPD 275HLFTGLIGGTNNRAPGVPARFSGSLIGDKAALTITGAQTEDEAIY FCALWCSNHLVFGGGTKLTVLGGGGSGGGGSGGGGSSQIQLVQ SGPELKKPGETVKISCKASGYTFTNYGMNWVKQAPGKGLMWL GWINTYTGEPTYADDFKGRFAFSLETSASTAYLQINNLKNEDTA TYFCARWAYFYGSSPYFFDYWGQGTTLTVSSS CD27 M2177 52a.1 QVQLQQSGPELVKPGASVKISCKASGYAFSSSWMNWVKQRPGK 276GLEWIGRIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLT SEDSAVYFCARSDYYGDYGFAYWGQGTLVTVSAGGGGSGGGG SGG GGSSDIVLTQSPASLAVSLGQRATISCKASQSVDYAGDSYM NWYQQKPGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLN1HPV EEEDAATYYCQQSNEDPYTFGGGTKLEIKS CD27 M2177 52a.2 DIVLTQSPASLAVSLGQRATISCKASQSVDYAGDSYMNWYQQK 277PGQPPKLLIYAASNLESGIPARFSGSGSGTDFTLNIHPVEEEDAAT YYCQQSNEDPYTFGGGTKLEIKGGGGSGGGGSGGGGSSQVQLQ QSGPELVKPGASVKISCKASGYAFSSSWMNWVKQRPGKGLEWI GRIYPGDGDTNYNGKFKGKATLTADKSSSTAYMQLSSLTSEDSA VYFCARSDYYGDYGFAYWGQGTLVTVSAS CD27 H2191 52b.1 QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYGMSW1RQAPGK 278GLEWVSYIDEGGGQTIYPDSVKGRFTISRDNAKNSLYLQMNSLR AEDTAVYYCARHRGNPFDYWGQGTLVTVSSGGGGSGGGGSGG GGSSDIQMTQSPSSLSASVGDRVTITCRASKSVSEGRWSFMHWY QQKPGKAPKLLIYVASRLESGVPSRFSGSGSGTDFTFTISSLQPED IATYYCQHSRELPWTFGQGTKVEIKS CD27 H2191 52b.2 DIQMTQSPSSLSASVGDRVTITCRASKSVSEGRWSFMHWYQQKP 279GKAPKLLIYVASRLESGVPSRFSGSGSGTDFTFTISSLQPEDIATY YCQHSRELPWTFGQGTKVEIKGGGGSGGGGSGGGGSSQVQLVE SGGGLVKPGGSLRLSCAASGFTFSSYGMSWIRQAPGKGLEWVS YIDEGGGQTIYPDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAV Y YC ARI IRGNPFD YWG QG TL VT VS S S CD27 M2191 52c.1 EVKLVESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKR 280LEWVAYISSGGGNTYYPDSVKGRFTISRDNARNTLYLQMSSLRS EDTAMYYCSRHRGNPFDYWGQGTTLTVSSGGGGSGGGGSGGG GSSDIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSFMHWYQ QKPGQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIHPVEEED AATYYCQHSRELPWTFGGGTKLEIKS CD27 M2191 52c.2 DIVLTQSPASLAVSLGQRATISCRASKSVSTSGYSFMHWYQQKP 281GQPPKLLIYLASNLESGVPARFSGSGSGTDFTLNIIIPVEEEDAAT YYCQHSRELPWTFGGGTKLEIKGGGGSGGGGSGGGGSSEVKLV ESGGGLVKPGGSLKLSCAASGFTFSSYTMSWVRQTPEKRLEWV AYISSGGGNTYYPDSVKGRFTISRDNARNTLYLQMSSLRSEDTA MYYCSRHRGNPFDYWGQGTTLTVSSS CD27 varlilumab 52d.l QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYDMHWVRQAPGK 282GLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSL RAEDCHDTAVYYCARGSGNWGFFDYWGQGTLVTVSSGGGGSG GGGSGGGGSSDIQMTQSPSSLSASVGDRVTITCRASQGISRWLA WYQQKPEKAPKSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP EDFATYYCQQCKAPPADYNTYPRTFGQGTKVEIKS CD27 varlilumab 52d.2 DIQMTQSPSSLSASVGDRVTITCRASQGISRWLAWYQQKPEKAP 283KSLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ CKAPPADYNTYPRTFGQGTKVEIKGGGGSGGGGSGGGGSSQVQ L VESGGG V VQPGRSLRLS C A ASGFTFS S YDMH W VR Q APGKGLE WVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDCHDTAVYYCARGSGNWGFFDYWGQGTLVTVSSS76IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOTarget Clone name Ref. scFv sequence (AA) SEQ ID CD27 3C2 52e.l QAQLQESGPGLVKPSETLSLTCTVSTGSISGYYWSWIRQPPGKGL 284EWIGYNYYSGSTNYNPSLKSRVTISIDTSKNQFSLKLNSVTAADT AVYYCARYPLIRGAFDYWGQGTLVTVSSGGGGSGGGGSGGGG SSDIVMTQSPLSLPVTPGEPASISCRSSQNLLHTNGYNYLDWYLQ KPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDV GVYYCMQALQTPLTFGGGTKVEIKS CD27 3C2 52e.2 DIVMTQSPLSLPVTPGEPASISCRSSQNLLHTNGYNYLDWYLQKP 285GQSPQEEIYEGSNRASGVPDRFSGSGSGTDFTEKISRVEAEDVGV YYCMQALQTPLTFGGGTKVEIKGGGGSGGGGSGGGGSSQAQLQ ESGPGLVKPSETLSLTCTVSTGSISGYYWSWIRQPPGKGLEWIGY NYYSGSTNYNPSLKSRVT1S1DTSKNQFSLKLNSVTAADTAVYYC ARYPLIRGAFDYWGQGTLVTVSSS CD27 2B3 52f.l QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPG 286QGLEWMGWINPNSGGTNSAQKFQDRVTITRVTSINTAYMELSR LRSDDTAVYFCARDRLVLPWFGE1FPDAFD1WGQGTLVTVSSGG GGSGGGGSGGGG5SEIVMTQSPATLSVSPGERATLSCRASQSIRS NLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTIS SLQSENFAVYYCQQYNNWPLTFGGGTKVEIKS CD27 2B3 52f.2 E1VMTQSPATLSVSPGERATLSCRASQSIRSNLAWYQQKPGQAP 287RLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSENFAVYYCQQ YNNWPLTFGGGTKVEIKGGGGSGGGGSGGGGSSQVQLVQSGAE VKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGWIN PNSGGTNSAQKFQDRVTITRVTSINTAYMELSRLRSDDTAVYFC ARDRLVLPWFGEIFPDAFDIWGQGTLVTVSSS CD27 hCD27.15 52g.1 EVRLQQSGADLVKPGASVKLSCTASGFIIKATYMHWVRQRPEQ 288GLEWIGRIDPANGETKYDPKFQVKATITADTSSSTAYLQLNSLTS DDTAVYYCARYAWYFDVWGAGTTVTVSSGGGGSGGGGSGGGG5SDIQMTQSPASLSASVGDTVTITCRASENIYSFLAWYHQKQG RSPQLLVYHAKTLAEGVPSRFSGSGSGTQFSLKINSLQAEDFGSY YCQHYYGSPLTFGAGTKLEVKS CD27 11CD27.15 52g.2 DIQMTQSPASLSASVGDTVTITCRASENIYSFLAWYHQKQGRSP 289QLLVYHAKTLAEGVPSRFSGSGSGTQFSLKINSLQAEDFGSYYC QHYYGSPLTFGAGTKLEVKGGGGSGGGGSGGGGSSEVRLQQSG ADLVKPGASVKLSCTASGFIIKATYMIIWVRQRPEQGLEWIGRID PANGETKYDPKFQVKATITADTSSSTAYLQLNSLTSDDTAVYYC ARYAWYFDVWGAGTTVTVSSS CD27 boserolimab 52h.l EIQLVQSGAEVKKPGASVKVSCKASGYTFTNYGMNWVKQAPG 290QGLKWMGWINTNTGEPTYAEEFKGRFTFTLDTSISTAYMELSSL RSEDTAVYYCAREGDAMDYWGQGTTVTVSSGGGGSGGGGSGG GGSSEIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQ APKRWIYDTSKLASGVPARFSGSGSGTDYSLTISSLEPEDFAVYY CQQWNSYPFTFGQGTKLEIKS CD27 boserolimab 5211.2 EIVLTQSPATLSLSPGERATLSCSASSSVSYMHWYQQKPGQAPK 291RWIYDTSKLASGVPARFSGSGSGTDYSLTTSSLEPEDFAVYYCQQ WNSYPFTFGQGTKLEIKGGGGSGGGGSGGGGSSEIQLVQSGAEV KKPGASVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGWIN TNTGEPTYAEEFKGRFTFTLDTSISTAYMELSSLRSEDTAVYYCA REGDAMDYWGQGTTVTVSSS TCR BMA031 53a.1 EVQLQQSGPELVKPGASVKMSCKASGYKFTSYVMHWVKQKPG 292QGLEWIGYINPYNDVTKYNEKFKGKATLTSDKSSSTAYMELSSL TSEDSAVHYCARGSYYDYDGFVYWGQGTLVTVSAGGGGSGGG GSGGGGSSQIVLTQSPAIMSASPGEKVTMTCSATSSVSYMHWYQ QKSGTSPKRWIYDTSKEASGVPARFSGSGSGTSYSETTSSMEAED AATYYCQQWSSNPLTFGAGTKLELKS TCR BMA031 53a.2 QIVLTQSPAIMSASPGEKVTMTCSATSSVSYMHWYQQKSGTSPK 293RWIYDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQ QWSSNPLTFGAGTKLELKGGGG5GGGGSGGGGSSEVQLQQSGPELVKPGASVKMSCKASGYKFTSYVMHWVKQKPGQGLEWIGYI77IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOTarget Clone name Ref. scFv sequence (AA) SEQ ID NPYNDVTKYNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVHY CARGSYYDYDGFVYWGQGTLVTVSAS TCR GL1BM 53b.1 QVQLVQSGAEVKKPGASVKVSCKASGYKFTSYVMHWVRQAPG 294QRLEWMGYINPYNDVTKYNEKFKGKATITRDTSANTAYMELSS LRSEDTAVYYCARGSYYDYDGFVYWGQGTLVTVSSGGGGSGG GG5GGGGSSEIVLTQSPATLSLSPGERATLSCSATSSVSYMHWY QQKPGQAPRRWIYDTSKLASGVPARFSGSGSGTDFTLTISSLEPE DF A V Y YCQQWS SNPI .TFGGGTK VEIKSTCR GL1BM 53b.2 EIVLTQSPATLSLSPGERATLSCSATSSVSYMHWYQQKPGQAPR 295RWIYDTSKLASGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQ WSSNPLTFGGGTKVEIKGGGGSGGGGSGGGGSSQVQLVQSGAE VKKPGASVKVSCKASGYKFTSYVMHWVRQAPGQRLEWMGYIN PYNDVTKYNEKFKGKATITRDTSANTAYMELSSLRSEDTAVYY CARGSYYDYDGFVYWGQGTLVTVSSS TCR GL1BM 53c.l QVQLVQSGAEVKKPGASVKVSCKASGYKFTSYVMHWVKQAPG 296 VH28 QGLEWIGYINPYNDVTKYNEKFKGRVTITRDTSASTAYMELSSL RSEDTAVYYCARGSYYDYDGFVYWGQGTLVTVSSGGGGSGGG GSGGGG5SEIVLTQSPATLSLSPGERATLSCSATSSVSYMHWYQ QKPGQAPRRW1YDTSKLASGVPARFSGSGSGTDFTLT1SSLEPED FAVYYCQQWSSNPLTFGGGTKVEIKS TCR GL1BM 53c.2 EIVLTQSPATLSLSPGERATLSCSATSSVSYMHWYQQKPGQAPR 297 VH28 RWIYDTSKLASGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQ W SSN PLTFGGGTKVE1KGGGGSGGGGSGGGGSS Q V QL V QSG AE VKKPGASVKVSCKASGYKFTSYVMHWVKQAPGQGLEWIGYIN PYNDVTKYNEKFKGRVTITRDTSASTAYMELSSLRSEDTAVYYC ARGSYYDYDGFVYWGQGTLVTVSSS TCR GL1BM 53d.1 QVQLVQSGAEVKKPGASVKVSCKASGYKFTSYVMHWVRQAPG 298 VH31 QGLEWIGYINPYNDVTKYNEKFKGRVTITRDTSASTAYMELSSL RSEDTAVYYCARGSYYDYDGFVYWGQGTLVTVSSGGGGSGGG GSGGGGSSEIVLTQSPATLSLSPGERATLSCSATSSVSYMHWYQ QKPGQAPRRWIYDTSKLASGVPARFSGSGSGTDFTLTISSLEPED FAVYYCQQWSSNPLTFGGGTKVEIKS TCR GL1BM 53d.2 EIVLTQSPATLSLSPGERATLSCSATSSVSYMHWYQQKPGQAPR 299 VH31 RWIYDTSKLASGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQ WSSNPLTFGGGTKVEIKGGGGSGGGGSGGGGSSQVQLVQSGAE VKKPGASVKVSCKASGYKFTSYVMHWVRQAPGQGLEWIGYIN PYNDVTKYNEKFKGRVTITRDTSASTAYMELSSLRSEDTAVYYC ARGSYYDYDGFVYWGQGTLVTVSSS TCR HEBE 53e.l EVQLLESGGGLVQPGGSLRLSCAASGYKFTSYVMHWVKQAPG 300KGLEWIGYINPYNDVTKYNEKFKGKATLSRDNSKNTLYLQMNS LRAEDTAVHYCARGSYYDYDGFVYWGQGTLVTVSSGGGGSGG GGSGGGGSSDIQMTQSPSTLSASVGDRVTMTCSATSSVSYMIIW YQQKPGKAPKRWIYDTSKLASGVPARFIGSGSGTEFTLTISSLQP DDFATYYCQQWS SNPLTFGGGTKVEIKS TCR HEBE 53e.2 DIQMTQSPSTLSASVGDRVTMTCSATSSVSYMHWYQQKPGKAP 301KRWIYDTSKLASGVPARFIGSGSGTEFTLTISSLQPDDFATYYCQ QWSSNPLTFGGGTKVEIKGGGGSGGGGSGGGGSSEVQLLESGG GLVQPGGSLRLSCAASGYKFTSYVMHWVKQAPGKGLEWIGYIN PYNDVTKYNEKFKGKATLSRDNSKNTLYLQMNSLRAEDTAVH YCARGSYYDYDGFVYWGQGTLVTVSSS TCR HEBEH10 53f.l EVQLQQSGPELVKPGASVKMSCKASGYKFTSYVMHWVKQAPG 302KGLEWIGYINPYNDVTKYNEKFKGKATLSRDNSKNTLYLQMNS LRAEDTAVHYCARGSYYDYDGFVYWGQGTLVTVSSGGGGSGG GGSGGGGSSDIQMTQSPSTLSASVGDRVTMTCSATSSVSYMHW YQQKPGKAPKRWIYDTSKLASGVPARFIGSGSGTEFTLTISSLQP DDFATYYCQQWS SNPLTFGGGTKVEIKS TCR HEBEH10 53f.2 DIQMTQSPSTLSASVGDRVTMTCSATSSVSYMHWYQQKPGKAP 303KRWIYDTSKLASGVPARFIGSGSGTEFTLTISSLQPDDFATYYCQQWSSNPLTFGGGTKVEIKGGGGSGGGGSGGGGSSEVQLQQSGP 78IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WOTarget Clone name Ref. scFv sequence (AA) SEQ ID ELVKPGASVKMSCKASGYKFTSYVMHWVKQAPGKGLEWIGYI NPYNDVTKYNEKFKGKATLSRDNSKNTLYLQMNSLRAEDTAV HYCARGSYYDYDGFVYWGQGTLVTVSSS TCR HEBE H66 53g.1 EVQLLQSGGGLVQPGGSLRLSCAASGYKFTSYVMHWVRQAPG 304KGLEW VG YINP YNDVTK YNEKFKGRFTLS RDNS KNTL YLQMNS LRAEDTAVYYCARGSYYDYDGFVYWGQGTLVTVSSGGGGSGG GGSGGGGSSDIQMTQSPSTLSASVGDRVTMTCSATSSVSYMHW YQQKPGKAPKRWIYDTSKLASGVPAREIGSGSGTEFTLTTSSLQP DDFATYYCQQWS SNPLTFGGGTKVEIKS TCR HEBE H66 53g.2 DIQMTQSPSTLSASVGDRVTMTCSATSSVSYMHWYQQKPGKAP 305KRWIYDTSKLASGVPARFIGSGSGTEFTLTISSLQPDDFATYYCQ QWSSNPLTFGGGTKVEIKGGGGSGGGGSGGGGSSEVQLLQSGG GLVQPGGSLRLSCAASGYKFTSYVMHWVRQAPGKGLEWVGYI NPYNDVTKYNEKFKGRFTLSRDNSKNTLYLQMNSLRAEDTAVYYCARGSYYDYDGFVYWGQGTLVTVSSS
[0201] In some embodiments, the targeting moiety comprises an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to an scFv amino acid sequence selected from those listed in Table 5, a CD8a stalk domain of SEQ ID NO: 235, and a CD8a transmembrane domain of SEQ ID NO: 236. In some embodiments, the targeting moiety comprises an scFv amino acid sequence selected from those listed in Table 5, a CD8a stalk domain of SEQ ID NO: 235, and a CD8a transmembrane domain of SEQ ID NO: 236.
[0202] In some embodiments, the delivery particle comprises a modular targeting system, wherein the targeting moiety is reversibly or non-covalently associated with the particle through an adaptor, such as a streptavidin-biotin linkage, Fc-binding domain, or lipid-conjugated anchor.
[0203] In some embodiments, the targeting moiety is selected or optimized based on its ability to engage with cell surface markers characteristic of particular tissues, such as tumor-associated antigens, tissue-specific integrins, or receptors upregulated during inflammation, infection, or fibrosis. In some embodiments, the targeting moiety enhances internalization of the particle via receptor-mediated endocytosis.Methods employing the recombinant VSV-G proteins of the disclosure
[0204] In some aspects, the present disclosure provides methods of using the recombinant VSV-G proteins and delivery particles of the disclosure. In some embodiments, the method is for therapeutic, prophylactic, or diagnostic purposes.
[0205] In some embodiments, the method is for therapeutic purposes. In some embodiments, the method comprises administering a delivery particle to a subject in need thereof, wherein the delivery particle comprises a therapeutic payload, e.g., a protein, nucleic acid, or small molecule. In some embodiments, the method comprises systemic or local administration of the delivery79IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOparticles. In some embodiments, the method comprises parenteral or enteral administration of the delivery particles.
[0206] In some embodiments, provided herein is a method of gene delivery, comprising contacting a target cell with a delivery particle comprising a nucleic acid. In some embodiments, the nucleic acid encodes a therapeutic or immunogenic protein. In some embodiments, the nucleic acid comprises DNA, RNA, a chemically modified nucleic acid, or a synthetic nucleic acid. In some embodiments, the nucleic acid is expressed in the target cell following uptake. In some embodiments, the method results in transient or sustained expression of the encoded product.
[0207] In some embodiments, the delivery particles are used for cell engineering applications. In some embodiments, the delivery particles are used to modify a target cell. In some embodiments, the method comprises contacting the target cells with the delivery particle under conditions that allow uptake of the payload. In some embodiments, the delivery particle facilitates the expression of gene editing tools, chimeric antigen receptors, or lineage-specific differentiation factors.
[0208] In some embodiments, the delivery particles are used for targeted delivery, wherein the particle comprises a targeting moiety that directs the delivery particle to a specific tissue, cell type, or disease site. In some embodiments, the method delivers a payload to a target location.
[0209] In some embodiments, the disclosure provides a method of delivering a payload to a population of target cells comprising contacting the population of target cells with a delivery particle of the disclosure.
[0210] In some embodiments, the disclosure provides a method of editing a population of target cells comprising contacting the population of target cells with a delivery particle of the disclosure.
[0211] In some embodiments, the disclosure provides a method of modifying a population of target cells to express a transgene comprising contacting the population of target cells with a delivery particle of the disclosure.
[0212] In some embodiments, a method herein can be used on any target cell type. In some embodiments, the target cell type is a germ cell, a somatic cell, a cancer cell, an immune cell, and infected cell, an autoimmune cell, or a diseased cell.Nucleic acids, expression vectors, host cells, and production methods of the disclosure
[0213] In some aspects, the present disclosure provides isolated polynucleotides encoding the recombinant VSV-G protein sequences disclosed herein. In some embodiments, the polynucleotide comprises a nucleotide sequence that encodes a polypeptide having at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% sequence identity to any 80IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOone of the amino acid sequences disclosed herein. In some embodiments, the polynucleotide encodes a polypeptide having at least 90% sequence identity to any one of the amino acid sequences disclosed herein. In some embodiments, the polynucleotide is a DNA, cDNA, or RNA molecule. In some embodiments, the polynucleotide comprises additional regulatory sequences, e.g., promoters, enhancers, untranslated regions (UTRs), and polyadenylation signals. In some embodiments, the polynucleotide is codon optimized for expression in a selected host organism. In some embodiments, the polynucleotide is synthetic, genomic, or derived from natural or recombinant sources.
[0214] Also provided arc expression vectors comprising the polynucleotides described herein. In some embodiments, the expression vector is a plasmid, phagemid, cosmid, viral vector, or other suitable vehicle capable of delivering and expressing a gene in a host cell. In some embodiments, the vector comprises operably-linked regulatory elements, including but not limited to a promoter, ribosome binding site, translation initiation sequence, introns, enhancer elements, selection markers, and / or transcriptional terminators. The vector may be configured for expression in bacterial, yeast, insect, or mammalian cells, and may include elements for episomal maintenance or genomic integration.
[0215] The disclosure further provides host cells comprising the recombinant VSV-G proteins, polynucleotides, or vectors described herein. Suitable host cells include prokaryotic cells (e.g., Escherichia coli, Bacillus subtilis) and eukaryotic cells (e.g., Saccharomyces cerevisiae, Pichia pastoris, insect cells such as Sf9, and mammalian cells such as HEK293 or CHO cells). The host cell may be genetically engineered to express the recombinant protein, and may be used for research, diagnostic, therapeutic, or industrial purposes. In some embodiments, the host cell expresses the recombinant protein in a secreted, membrane-bound, or intracellular form. The recombinant host cell may also be used in methods of producing the protein or delivery particles comprising the protein, wherein the protein or delivery particle is harvested from the culture medium, lysate, or other cellular compartment.
[0216] The present disclosure also provides methods of producing the delivery particles described herein. In general, without wishing to be bound by theory, VSV-G can be used to increase the tropism of a delivery particle (e.g., a lentiviral particle or a virus-like particle) relative to the tropism of the delivery particle without the VSV-G molecule, often through replacing the Envelope protein (glycoprotein) of a virus (e.g.. a lentivirus) with VSV-G. Generally, increasing the tropism of a vector (e.g., a lentivirus or VLP) by replacing a native Envelope protein with another Envelope protein - herein chimeric VSV-G proteins - is referred to as “pseudotyping.” Methods for pseudotyping viruses and viral-like particles - including pseudotyping using VSV-G 81IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO- are known to those skilled in the art and can generally be used with the chimeric VSV-G proteins described herein. The tropism of a delivery particle can also be modified through use of targeting moictics, as well as modifications to VSV-G, such as mutations in VSV-G that reduce or eliminate binding to a LDL receptor, both of which are described herein.
[0217] In some embodiments, the method comprises expressing one or more components of the delivery particle in a host cell. In some embodiments, the method comprises isolating delivery particles from a host cell culture. In some embodiments, the method comprises co-expression of a structural protein (e.g., lentiviral Gag and Pol proteins, such as HIV-1 Gag and Pol) and a payload, under conditions that permit self-assembly into a delivery particle. In some embodiments, the method comprises purification steps such as filtration, centrifugation, chromatography, and / or density gradient separation.
[0218] In some embodiments, use of a chimeric VSV-G described herein e.g., SEQ ID NO: 139), can result in increased production of a delivery particle (e.g., increased VLP / EDV titer) relative to delivery particle production using other VSV-G proteins, such as use of Indiana strain VSV-G. Increased titer can have several advantages, such as an increase in pcr-volumc transduction efficiency (or other downstream activities, such as CRISPR-mediated editing percentages), and also more efficient manufacturing capabilities.
[0219] In some embodiments, the method includes the incorporation or conjugation of targeting moieties onto the surface of the delivery particle, either during biosynthesis or through postproduction modification. The methods described herein are suitable for the preparation of viral vectors, virus-like particles, lipid nanoparticlcs, or other delivery systems for therapeutic, prophylactic, or diagnostic applications.REFERENCES
[0220] Each of the following publications is incorporated by reference herein in its entirety for all purposes: US 2015 / 0182617 Al; US 12,030,915 B2; WO 2019 / 057974; WO 2022 / 183072; WO 2023 / 114884; WO 2024 / 1079959; and Trobridge GD, et al., “Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells” Mol Ther 2010 Apr; 18(4):725-33.82IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WOEXAMPLESExample 1: Identifying VSV-G mutants with high fusogenic activity.Materials and Methods
[0221] VLPs comprising VSV-G are susceptible to serum neutralization. To improve resistance to serum neutralization, VSV-G mutants comprising threonine (T) and serine (S) amino acid substitutions (“TS substitutions”) at a variety of positions were generated and tested in a high-throughput screen in the presence of serum. Mutants demonstrating fusogenic activity in the presence of serum were preliminarily identified as having a degree of resistance to serum neutralization.
[0222] To validate these results and verify which regions of VSV-G are tolerant of mutations without inhibiting function, 52 variants of VSV-Gmut were generated. VSV-Gmut is a mutant VSV-G comprising K47Q and R354A mutations, which prevent the binding of the protein to its native cognate receptor, LDL-R. Precursor and mature VSV-Gmut sequences are provided in SEQ ID NO: 25 and SEQ ID NO: 26, respectively. For context, FIG. 1A-1B show the domain architecture and residue numbering of Indiana VSV-G in its pre-processed and mature forms, respectively. The mutations are numbered with respect to mature VSV-G, i.e., the numbering shown in FIG. IB.
[0223] In addition to these two mutations, each of the 52 variants was generated with up to four TS substitutions that were identified from the initial serum neutralization screen as allowing for fusogenic activity in the presence of serum. See Table 4, providing mature sequences for each of these variants. Percent on-target binding was calculated as a measure of how well each fusogen was able to facilitate payload delivery into target cells.
[0224] This validation assay was performed by generating VLPs pseudotyped with each VSV-Gmut variant (1-52) and a CD 19 targeting molecule. The VLPs packaged a lentiviral vector encoding a BFP transgene. The VLPs were used to infect a mixed population of HEK293T cells with -50% CD1 + / GFP+ (target cells) and 50% CD19- / GFP- (off-target cells). The percentage of on-target binding was calculated by dividing the number of GFP+ / BFP+ cells (i.e., target cells expressing the BFP transgene) by the total number of GFP+ cells (i.e., all target cells). This assay was performed with 0.5 pL, 10 pL, and 25 pL of VLP.Results
[0225] FIG. 2A-2B show the results of the assay. Assay results from the three volumes of VLP dosing are shown from left to right for each variant. FIG. 2A also shows the results for VSV-Gmut without any TS substitutions. As shown in the figure, several TS substitution variants 83IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOworked as well as or better than VS V-Gmut in this screen: e.g., variant 1 (SEQ ID NO: 27); variant 5 (SEQ ID NO: 31); variant 8 (SEQ ID NO: 34); variant 9 (SEQ ID NO: 35); variant 14 (SEQ ID NO: 40); variant 15 (SEQ ID NO: 41); variant 17 (SEQ ID NO: 43); variant 18 (SEQ ID NO: 44); variant 20 (SEQ ID NO: 46); variant 21 (SEQ ID NO: 47); variant 30 (SEQ ID NO: 56); variant 38 (SEQ ID NO: 64); variant 50 (SEQ ID NO: 76); variant 51 (SEQ ID NO: 77); and variant 52 (SEQ ID NO: 78).Example 2: High fusogenic activity and low off-target effects for VSV-G K47del mutant. Materials and Methods
[0226] While VSV-G is a potent facilitator of fusion to a wide range of cell types, use of this protein is hampered by its native binding to the LDL receptor, which can create undesirable off-target binding effects. The lysine residue at position 47 (K47) of VSV-G is known to be involved in binding to LDL-R. A mutant VSV-G with a deletion of this residue (“K47del,” precursor SEQ ID NO: 131; mature SEQ ID NO: 134) was generated to determine its effect on fusogenic activity and off-target binding.
[0227] Positions 184 and 208 of VSV-G arc also putative LDL-R binding sites. The inventors theorized that mutation of these residues could also prevent binding to LDL-R. These sites were found to tolerate a TS substitution in the high-throughput screen of Example 1. Two additional mutants were therefore generated with these residues mutated: K47del + MD184TS substitution (precursor SEQ ID NO: 132; mature SEQ ID NO: 135); and K47del + MD184TS + NY208TS (precursor SEQ ID NO: 133; mature SEQ ID NO: 136). None of these three mutants had a K47Q or R354A mutation.
[0228] These mutants were tested in a fusogenic activity assay in comparison to wildtype VSV-G and VSV-Gmut. VLPs pseudotyped with the VSV-G variants and a CD19 targeting molecule were generated. The VLPs packaged a lentiviral genome encoding BFP transgene. The VLPs were used to infect a mixed population of HEK293T cells with -50% CD19+ / GFP+ (target cells) and 50% CD19- / GFP- (off-target cells). The percent on-target binding was calculated by dividing the number of GFP+ / BFP+ cells (infected target cells) by the number of GFP+ cells (total target cells). The percent off-target binding was calculated by dividing the number of GFP- / BFP+ cells (infected off-target cells) over the total number of GFP- cells (total off-target cells).Results
[0229] Results of this assay are shown in FIG.3A-3B and quantified in Tables 6A and 6B. FIG.3A shows the percent on-target binding, while FIG. 3B shows the percent off-target binding for all tested VSV-G variants. All variants showed high fusogenic activity. Each of VSV-Gmut,84IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WOK47del, K47del + MD184TS, and K47del+ MD184TS + NY208TS showed lower off-target binding compared to native Indiana VSV-G (p<0.05 for K47del).Table 6A - On-Target Binding: k47del + I k47del + 184TS ii virus ( nl ) I VSV-G mut i VSV-G k47de :184TS : +208TS50 J 80.27079 i 88.19584 76.24346 8079784 79.575616 : 50.671 14 i 64.1196 47.81145 56 14618 I 50.49834\ 5.33 22.94751 30.4149 22.95647 28.38196 j 24.713581.66 9386164 13.26531 9.550917 1245136 9.5953j 0.555 | 4.159734 | 5.243209 3.896104 : 5.335068 4.342148Table 6B - Off- Target Bindingi k47del + i k47del + 184TS ii virus ( nl ) | VSV-G mut 1 VSV-G k47del184TS+208TS50 3.27 16.6 1.59 1.84 1.9716 0.97 6.08 0.56 0.67 0.595.33 0.29 1.92 0.22 0.27 0.241.66 0.11 0.66 0.093 0.12 I 0.098: 0.555 | 0.042 0.25 0.023 0.034 0.04Example 3: Generating VSV-G chimeras by shuffling Indiana and Cocal VSV-G domains. Materials and Methods
[0230] The Indiana strain of VSV-G has been the most widely used strain to date because of its high level of fusogenic activity. However, this strain suffers from susceptibility to human serum neutralization. By contrast, the Cocal strain of VSV-G has lower fusogenic activity, but higher resistance to human serum neutralization. The present inventors explored the development of chimeras of Indiana and Cocal strains of VSV-G to identify VSV-G chimeras that could lead to a fusogen with both high fusogenic activity and increased resistance to serum neutralization. To do this, domains from Indiana VSV-G (SEQ ID NO: 1) and Cocal VSV-G (SEQ ID NO: 13) were swapped. This approach was implemented to conserve the function of each of the protein domains. The K47Q and R354A mutations were also incorporated into each chimera. In some embodiments, a K47del can be employed in the context of these chimeras.85IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO
[0231] The Indiana and Cocal strains of VSV-G share 71.9% sequence identity overall. FIG.1A-1B show the domain architecture and residue numbering of Indiana VSV-G in its pre-processed and mature forms, respectively. FIG. 4 shows the amino acid differences between Indiana and Cocal VSV-G, with the differing amino acids shown from the Cocal VSV-G sequence. A comparison of the predicted protein structures of both strains of VSV-G also showed significant similarity in overall conformation. Without wishing to be bound by theory, the inventors hypothesized that the overall conformational similarity of the two strains would allow domainswapped chimeras of these strains to fold and function correctly.
[0232] Chimeric sequences were developed by generating all combinations of swapped domains from Indiana VSV-G and Cocal VSV-G. Chimeras were annotated by the origin of each domain in this order: SG-DI-DII-DIII-DIV-TM, with 0 indicating that the domain originated from Indiana- VSV-G, and 1 indicating that the domain originated from Cocal VSV-G. Using this annotation, “000000” corresponds to Indiana VSV-G, and “111111” corresponds to Cocal VSV-G. FIG.5 shows this annotation for all chimeric sequences, with sequence identity shown on the left for each chimera compared to Indiana VSV-G (top bar) and Cocal VSV-G (bottom bar). Example 4: VSV-G chimeras of the disclosure have high fusogenic activity.Materials and Methods
[0233] Domain swapped VSV-G chimeras from Example 3 were tested in a fusogenic activity screening assay. Each variant was assigned an ID number as shown in Table 7.Table 7: VSV-G chimera identifiers and sequences.Indiana-Cocal Domain Chimera IdentifierSEQ ID NOAnnotation No.010100 #3 156010110 #4 158011010 #5 162011100 #6 164011110 #7 166000011 #8 139000101 #9 141001001 #10 145001011 #11 147001101 #12 149010001 #13 15386IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WOIndiana-Cocal Domain Chimera IdentifierSEQ ID NOAnnotation No.010011 #14 155011001 #15 161100110 #16 174101010 #17 178101100 #18 180101110 #19 182110010 #20 186110100 #21 188111010 #23 194111100 #24 196100001 #25 169100011 #26 171100101 #27 173101001 #28 177101011 #29 179110001 #30 185111001 #31 193
[0234] Each of the tested Cocal / Indiana chimeras had less than 90% sequence identity with either Cocal or Indiana strains (including the signal peptide). For comparison, chimeras of Indiana VSV-G and the Chandipura strain of VSV-G were also generated: IIIIAI and IIAIAI (“I” for Indiana domain; “A” for Chandipura domain). Chandipura VSV-G shares only about 50% sequence identity with Indiana VSV-G and was expected to have lower conformational similarity and conserved domain architecture with the Indiana strain. As controls, wildtype Indiana VSV-G (“VSV-G” in FIG. 6), VSV-Gmut, and an untreated control (“UTC”) were also tested.
[0235] Percent on target binding was measured to reflect the fusogenic activity of each of these variants. The screen was performed by making VLPs composed of lentiviral vectors pseudotyped with the above VSV-G chimeras and controls, and a CD19 targeting molecule. The VEPs packaged a BFP transgene. The VLPs were used to infect a mixed population of HEK293T cells, comprising -50% CD19+ / GFP+ (target cells) and 50% CD19- / GFP- (off-target cells). VLPs were tested at 10, 25, and 50 pl. volumes. The percent on target binding was calculated by dividing the number of BFP+ / GFP+ cells by the total number of GFP+ cells.87IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WOResults
[0236] Results of this assay are shown in FIG. 6. Most of the Indiana-Cocal VSV-G chimeras exhibited fusogenic activity, with some exhibiting noticeably high activity, comparable to or exceeding that of VSV-Gmut in this assay. By contrast, the tested Indiana-Chandipura VSV-G chimeras had no detectable fusogenic activity.Example 5: VSV-G chimeras of the disclosure have high on target and low off target fusogenic activity.Materials and Methods
[0237] A few high activity Indiana-Cocal chimeras from Example 4 were selected for additional validation. They were tested for both on- and off-target activity. The tested chimeras had the following full-length sequences: chimera #5 (SEQ ID NO: 162); chimera #8 (SEQ ID NO: 139); chimera #13 (SEQ ID NO: 153); chimera #14 (SEQ ID NO: 155); chimera #19 (SEQ ID NO: 182); chimera #24 (SEQ ID NO: 196); and chimera #25 (SEQ ID NO: 169).
[0238] VLPs were pseudotyped with the VSV-G variants and a GDI 9 targeting molecule. The VLPs packaged a BEP transgcnc. The VLPs were used to infect a mixed population of HEK293T cells with -50% CD19+ / GFP+ (target cells) and 50% CD19- / GFP- (off-target cells). The percent on-target binding was calculated by dividing the number of GFP+ / BFP+ cells (infected target cells) by the number of GFP+ cells (total target cells). The percent off-target binding was calculated by dividing the number of GFP- / BFP+ cells (infected off-target cells) over the total number of GFP- cells (total off-target cells). The chimeras were compared to Indiana VSV-G (“VSV-G” in FIG.7A-7B), VSV-Gmut, and untreated control (“UTC”).Results
[0239] FIG.7A-7B show the results for on-target and off-target binding, respectively. All tested chimeras exhibited high fusogenic activity and low off-target binding.Example 6: VSV-G chimera exhibits improved resistance to serum neutralization.Materials and Methods
[0240] Indiana-Cocal VSV-G chimeras of the preceding examples were tested in a scrum neutralization assay, and compared to Indiana VSV-G (“VSV-G” in FIG. 8), VSV-Gmut, and untreated control (“UTC”).
[0241] VLPs were pseudotyped with the VSV-G variants and no targeting molecule. The VLPs packaged a BFP transgene. The VLPs were either pre-incubated with serum or without serum then used to infect a mixed population of HEK293T cells with -50% CD19+ / GFP+ (target cells) and 50% CD19- / GFP- (off-target cells). The ratio of serum to virus was 8:2. The percent on-target 88IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WObinding was calculated by dividing the number of GFP+ / BFP+ cells (infected target cells) by the number of GFP+ cells (total target cells). The percent +serum / -serum was calculated by dividing the % on target with scrum pre -incubation by the % on target without scrum prc-incubation. Off-target binding was calculated by dividing the number of GFP- / BFP+ cells (infected off-target cells) over the total number of GFP- cells (total off-target cells).Results
[0242] FIG. 8 shows the results of this assay. Chimera #8 (SEQ ID NO: 139) demonstrated a statistically significant improvement in fusogenic activity in the presence of serum (p<0.005), compared to either VSV-G or VSV-Gmut, indicating an improved resistance to human scrum neutralization.Example 7: Introducing mutations into VSV-G chimeras of the disclosure yields high on target and low off target fusogenic activity.Materials and Methods
[0243] Indiana-Cocal VSV-G chimera #8 was selected for additional mutagenesis and validation. This sequence was mutated in the following ways (residue numbering from mature protein, SEQ ID NO: 201): K47 deletion (“8 k47del”: precursor SEQ ID NO: 229, mature SEQ ID NO: 232), D121S substitution (“8 Tsubl”; precursor SEQ ID NO: 230, mature SEQ ID NO: 233), and E421T substitution (“8 Tsub2”; precursor SEQ ID NO: 231, mature SEQ ID NO: 234).
[0244] VLPs were pseudotyped with the VSV-G variants with or without a CD 19 targeting molecule. The VLPs packaged a BFP transgene. The VLPs were used to infect a mixed population of HEK293T cells with -50% CD19+ / GFP+ (target cells) and 50% CD19- / GFP- (off-target cells). The percent on-target binding was calculated by dividing the number of GFP+ / BFP+ cells (infected target cells) by the number of GFP+ cells (total target cells). The VLPs with no targeting molecule were included to assess the off-target activity of the fusogen. The chimeras were compared to Indiana VSV-G (“VSV-G” in FIG.9), and VSV-Gmut.Results
[0245] FIG.9 shows the results for this assay, as quantified in Table 8A and Table 8B (for VLPs with and without a targeting moiety, respectively), demonstrating high fusogenic activity and low off target binding for all chimera #8 variants. In fact, chimera #8 and its variants all demonstrated lower off-target binding than VSV-Gmut in this assay.Table 8A - Percent On-Target Binding with Targeting MoietyCocal chimera 8 Cocal chimera 8 Cocal chimera 8 Virus (ul) VSV-Gmut VSV-G Cocal chimera 8k47del Tsub! Tsub289IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO50 90.3 91.9 94.3 75.7 91.7 93.820 80.2 79.2 88.0 69.1 82.5 86.35 44.9 48.2 59.9 40.2 52.4 58.51 19.9 15.7 31.6 17.2 22.7 23.8Table 8B - Percent On-Target Binding without Targeting MoietyCocal chimera 8 Cocal chimera 8 Cocal chimera 8 VSV-Gmut (no VSV-G Cocal chimera 8Virus (ul) k47del Tsubl Tsub2 targeting) (no targeting) (no targeting)(no targeting) (no targeting) (no targeting) 50 42.1 98.4 15.4 11.8 12.2 25.4 20 19.5 89.6 7.4 4.9 4.4 9.6 5 5.4 55.5 2.2 1.4 0.8 3.51 1.8 24.2 0.6 0.3 0.3 0.4Example 10: Comparison of VSV-G chimeras to VSV-Gmut.Materials and Methods
[0246] In Vitro: EDVs (VLPs) that package a Gag-Cas9 editor that cuts a target locus were in produced in suspension Vector Producing Cells (VPCs) by transfecting a gag-pol packaging plasmid with a D64V integrase mutation, a VSV-Gmut (SEQ ID NO: 307) or Cocal chimera 8 (SEQ ID NO: 139) envelope plasmid, a CD3 targeting molecule plasmid and a plasmid that encodes both the Gag-Cas9 editor and corresponding sgRNA for targeting the target locus. EDVs were concentrated 300x by ultracentrifuge. EDVs and an AAV encoding a B-cell targeting CAR and EGFRt HDR template with homology arms were used to transduce primary T cells that had been pre-activated using Dynabeads 48 hours prior to transduction. EDV titer was determined using sgRNA as a proxy. Quantitation of sgRNA was performed by extracting RNA from produced EDVs and performing RT-PCR. Knock-in of the CAR and knock-out of the target locus were assessed via flow cytometry day 4 post- transduction using %EGFRt+. T-test was performed for statistical significance.
[0247] In Vivo: EDVs were produced as above. EDVs were then dosed into female NSG-MHC I / II DKO that were pre-engrafted with lxlO 7 human PBMCs 7 days prior to dosing. In addition to the EDV, mice were dosed with an AAV that delivers a CAR and EGFRt HDR template with homology arms. EDV dose is shown as sgRNA / ul on the x-axis. AAV was dosed at 3el 1 vector genomes per mouse in all but the PBS group. All mice were sacrificed on day 14 post-dose, and blood and spleens were harvested for analysis. Knock-in of the CAR and B-cell aplasia was assessed via flow cytometry day using %mCherry+ or EGFR+ and %CD19+ respectively.90IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WOResults
[0248] EDVs were produced either with an Indiana strain variant VSV-Gmut (SEQ ID NO: 307) or Cocal chimera 8 (SEQ ID NO: 139). As shown in FIG. 10 (left panel) and quantified in Table 9, EDVs produced using Cocal chimera 8 consistently produced significantly more EDV titer (approximately 3-fold) than EDVs produced using the Indiana strain variant, as assessed by sgRNA content. Without wishing to be bound by theory, the increased titer may be attributed to the fact that Cocal chimera 8 contains domain IV (fusion domain) and transmembrane domain from Cocal - which are responsible for facilitating budding from the cell surface. Thus, if Cocal has higher budding ability than Indiana, this would result in Cocal chimera 8 also demonstrating increased titers.
[0249] Next, primary T cells were transduced with an equivalent volume of EDVs produced using either Indiana strain variant VSV-Gmut or Cocal chimera 8 across a range of volumes. As shown in FIG. 10 (right panel) and quantified in Table 10, primary T cells transduced with EDVs produced using Cocal chimera 8 resulted in an increased knock-in efficiency of the CAR (at least 2-fold) compared to transduction using an equivalent volume of EDVs produced using the Indiana strain variant at all doses, consistent with the finding that EDVs produced using Cocal chimera 8 resulted in an increased EDV titer.
[0250] Next, mice were administered EDVs produced using either Indiana strain variant VSV-Gmut or Cocal chimera 8. The EDVs were titered by sgRNA content and an equivalent titer of the EDVs was administered. As shown in FIG. 11 and quantified in Table 11 and Table 12, when the EDV dose was normalized by titer, EDVs produced using Cocal chimera 8 resulted in an equivalent - if not better - functional activity in vivo, as assessed by the percentage of CAR T cells and B cell depletion.
[0251] Overall, the results demonstrate that using Cocal chimera 8 VSV-G in the production of EDVs resulted in increased EDV titer compared to using an Indiana strain VSV-G variant, while the EDVs also maintained at least the same level of functional activity.Table 9 - EDV Titer (sgRNA / uI)Replicate VSVGmut Cocal chimera 81 1.26e+012 3.03e+0122 1.36e+012 3.72e+0123 1.21e+012 2.84e+0124 1.17e+012 3.31e+0125 1.36e+012 4.16e+01291IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WO6 1.33e+012 4.5e+0127 1.31e+012 3.88e+0128 1.39c+012 3.8c+012Table 10 - CAR Knock-In % (equivalent volume EDV)CocalEDV (ul) VSVGmutChimera 825 20.4 45.68.33 21.4 462.78 20.7 47.60.93 16 39.70.31 9.3 28.10.1 4.4 15.30.03 2.8 7Table 11 - Spleen B cell % (equivalent titer EDV)VSVGmut Cocal chimera 8 VSVGmut Cocal chimera 8PBS(1.27el2) (1.27el2) (3.56el2) (3.56el2)34.9 0.75 0.05 0.1 0.0626.5 8.55 0.23 0.04 0.0533.8 6.71 22 0.13 0.07Table 12 - Spleen T cell % (equivalent titer EDV)VSVGmut Cocal chimera 8 VSVGmut Cocal chimera 8PBS(1.27el2) (1.27el2) (3.56el2) (3.56el2) 0.01 13.1 25.6 29.8 29.90.02 7.41 10.1 31.3 30.80.02 9.19 2.82 15.2 33.8INCORPORATION BY REFERENCE
[0252] All references, articles, publications, patents, patent publications, and patent applications cited herein are incorporated by reference in their entireties for all purposes. However, mention of any reference, article, publication, patent, patent publication, and patent application cited herein is not, and should not be taken as an acknowledgment or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world.92IPTS / 2003972907ATTORNEY DOCKET No.: AZL-007WONUMBERED EMBODIMENTS OF THE INVENTION
[0253] Notwithstanding the appended claims, the disclosure sets forth the following numbered embodiments:Embodiment 1. A chimeric vesicular stomatitis virus glycoprotein G (VSV-G) comprising: a) an Indiana VSV-G domain; and b) a Cocal VSV-G domain.Embodiment 2. A chimeric vesicular stomatitis virus glycoprotein G (VSV-G) comprising: a) an Indiana VSV-G domain; b) a Cocal VSV-G domain; and c) a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.Embodiment 3. The chimeric VSV-G of embodiment 1 or 2, wherein the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 1.Embodiment 4. The chimeric VSV-G of any one of embodiments 1-3, wherein the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 13.Embodiment 5. The chimeric VSV-G of any one of embodiments 1-4, wherein the chimeric VSV-G comprises a signal peptide (SG), a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM). Embodiment 6. The chimeric VSV-G of any one of embodiments 1-4, wherein the chimeric VSV-G comprises a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM).Embodiment 7. The chimeric VSV-G of embodiment 5 or 6, wherein each domain is an Indiana VSV-G domain or a Cocal VSV-G domain.Embodiment 8. The chimeric VSV-G of any one of embodiments 1-7, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Indiana VSV-G.Embodiment 9. The chimeric VSV-G of any one of embodiments 1-8, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Cocal VSV-G.Embodiment 10. The chimeric VSV-G of any one of embodiments 1-9, wherein the Indiana VSV-G domain has the sequence of any one of SEQ ID NO: 3-12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. Embodiment 11. The chimeric VSV-G of any one of embodiments 1-10, wherein the Cocal VSV-G domain has the sequence of any one of SEQ ID NOs: 15-24, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.93IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOEmbodiment 12. The chimeric VSV-G of any one of embodiments 1-11, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 141, 145, 147, 149, 153, 155, 161, 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 13. The chimeric VSV-G of any one of embodiments 1-11, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171, 173, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 14. The chimeric VSV-G of any one of embodiments 1-11, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 162, 139, 153, 155, 182, 196, and 169, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 15. The chimeric VSV-G of any one of embodiments 1-11, wherein the chimeric VSV-G comprises the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 16. The chimeric VSV-G of any one of embodiments 1-15, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 1.Embodiment 17. The chimeric VSV-G of any one of embodiments 1-16, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 13.Embodiment 18. The chimeric VSV-G of any one of embodiments 1-17, wherein the Indiana VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 1.Embodiment 19. The chimeric VSV-G of any one of embodiments 1-18, wherein the Cocal VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 13.Embodiment 20. The chimeric VSV-G of any one of embodiments 1-19, wherein the chimeric VSV-G has a glutamine at the residue cones ponding to residue number 47 of SEQ ID NO: 2. Embodiment 21. The chimeric VSV-G of any one of embodiments 1-20, wherein the chimeric VSV-G has an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2. Embodiment 22. The chimeric VSV-G of any one of embodiments 1, 3-19, and 21, wherein the chimeric VSV-G has a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.94IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOEmbodiment 23. The chimeric VSV-G of any one of embodiments 1-22, wherein the chimeric VSV-G comprises a TS, T, or S substitution contained in any one of SEQ ID NO: 27-78, 133, 230, and 231.Embodiment 24. The chimeric VSV-G of any one of embodiments 1-23, wherein the chimeric VSV-G comprises a TS pair contained in any one of SEQ ID NO: 27-78, 133, 230, and 231. Embodiment 25. The chimeric VSV-G of any one of embodiments 1-24, wherein the chimeric VSV-G does not comprise an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2 and / or does not comprise a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.Embodiment 26. A chimeric vesicular stomatitis vims glycoprotein G (VSV-G) comprising: a) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; and b) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain.Embodiment 27. The chimeric VSV-G of embodiment 26, wherein the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 1.Embodiment 28. The chimeric VSV-G of embodiment 26 or 27, wherein the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 13.Embodiment 29. The chimeric VSV-G of any one of embodiments 26-28, wherein the SG domain comprises SEQ ID NO: 3, the DI domain comprises SEQ ID NO: 4 and 5, the DII domain comprises SEQ ID NO: 6, 7, and 8, the Dill domain comprises SEQ ID NO: 9 and 10, the DIV domain comprises SEQ ID NO: 11, and / or the TM domain comprises SEQ ID NO: 12. Embodiment 30. The chimeric VSV-G of any one of embodiments 26-29, wherein the SG domain comprises SEQ ID NO: 15, the DI domain comprises SEQ ID NO: 16 and 17, the DII domain comprises SEQ ID NO: 18, 19, and 20, the Dill domain comprises SEQ ID NO: 21 and 22, the DIV domain comprises SEQ ID NO: 23, and / or the TM domain comprises SEQ ID NO: 24.Embodiment 31. The chimeric VSV-G of any one of embodiments 26-30, wherein the chimeric VSV-G comprises a signal peptide (SG), a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM). Embodiment 32. The chimeric VSV-G of any one of embodiments 26-30, wherein the chimeric VSV-G comprises a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM).95IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOEmbodiment 33. The chimeric VSV-G of embodiment 31 or 32, wherein each domain is an Indiana VSV-G domain or a Cocal VSV-G domain.Embodiment 34. The chimeric VSV-G of any one of embodiments 26-33, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Indiana VSV-G.Embodiment 35. The chimeric VSV-G of any one of embodiments 26-34, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Cocal VSV-G.Embodiment 36. The chimeric VSV-G of any one of embodiments 26-35, wherein the Indiana VSV-G domain has the sequence of any one of SEQ ID NO: 3-12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto. Embodiment 37. The chimeric VSV-G of any one of embodiments 26-36, wherein the Cocal VSV-G domain has the sequence of any one of SEQ ID NOs: 15-24, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 38. The chimeric VSV-G of any one of embodiments 26-37, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 141, 145, 147, 149, 153, 155, 161, 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 39. The chimeric VSV-G of any one of embodiments 26-37, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171, 173, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 40. The chimeric VSV-G of any one of embodiments 26-37, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 162, 139, 153, 155, 182, 196, and 169, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 41. The chimeric VSV-G of any one of embodiments 26-37, wherein the chimeric VSV-G comprises the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 42. The chimeric VSV-G of any one of embodiments 26-41, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 1.Embodiment 43. The chimeric VSV-G of any one of embodiments 26-42, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 13.96IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOEmbodiment 44. The chimeric VSV-G of any one of embodiments 26-43, wherein the Indiana VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 1.Embodiment 45. The chimeric VSV-G of any one of embodiments 26-44, wherein the Cocal VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 13.Embodiment 46. The chimeric VSV-G of any one of embodiments 26-45, wherein the chimeric VSV-G has a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2. Embodiment 47. The chimeric VSV-G of any one of embodiments 26-46, wherein the chimeric VSV-G has an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2. Embodiment 48. The chimeric VSV-G of any one of embodiments 26-45 and 47, wherein the chimeric VSV-G has a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.Embodiment 49. The chimeric VSV-G of any one of embodiments 26-48, wherein the chimeric VSV-G comprises a TS, T, or S substitution contained in any one of SEQ ID NO: 27-78, 133, 230, and 231.Embodiment 50. The chimeric VSV-G of any one of embodiments 26-49, wherein the chimeric VSV-G comprises a TS pair contained in any one of SEQ ID NO: 27-78, 133, 230, and 231. Embodiment 51. The chimeric VSV-G of any one of embodiments 26-50, wherein the chimeric VSV-G does not comprise an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2 and / or does not comprise a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.Embodiment 52. A VSV-G trimer comprising the chimeric VSV-G according to any one of embodiments 1-51.Embodiment 53. A viral envelope comprising the chimeric VSV-G according to any one of embodiments 1-51 or the VSV-G trimer of claim 52.Embodiment 54. A delivery particle comprising the chimeric VSV-G according to any one of embodiments 1-50 or the VSV-G trimer of claim 52.Embodiment 55. A delivery particle comprising a chimeric vesicular stomatitis vims glycoprotein G (VSV-G) comprising: a) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; and b) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain.Embodiment 56. A delivery particle comprising a chimeric vesicular stomatitis vims glycoprotein G (VSV-G) comprising: a) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; b) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%97IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOsequence identity with a Cocal VSV-G domain; and c) a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.Embodiment 57. A delivery particle comprising: a) a chimeric vesicular stomatitis vims glycoprotein G (VSV-G) comprising: i) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; and ii) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain; b) a targeting moiety on the surface of the delivery particle; and c) a payload encapsidated within the particle.Embodiment 58. A delivery particle comprising: a) a chimeric vesicular stomatitis vims glycoprotein G (VSV-G) comprising: i) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; and ii) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain; b) a targeting moiety on the surface of the delivery particle; and c) a gene-editing system encapsidated within the delivery particle.Embodiment 59. The delivery particle of any one of embodiments 55-58, wherein the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 1.Embodiment 60. The delivery particle of any one of embodiments 55-59, wherein the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 13.Embodiment 61. The delivery particle of any one of embodiments 55-60, wherein the chimeric VSV-G comprises a signal peptide (SG), a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM). Embodiment 62. The delivery particle of any one of embodiments 55-60, wherein the chimeric VSV-G comprises a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM).Embodiment 63. The delivery particle of embodiment 61 or 62, wherein each domain is an Indiana VSV-G domain or a Cocal VSV-G domain.Embodiment 64. The delivery particle of any one of embodiments 55-63, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Indiana VSV-G.Embodiment 65. The delivery particle of any one of embodiments 55-64, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Cocal VSV-G.Embodiment 66. The delivery particle of any one of embodiments 55-65, wherein the Indiana VSV-G domain has the sequence of any one of SEQ ID NO: 3-12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.98IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOEmbodiment 67. The delivery particle of any one of embodiments 55-66, wherein the Cocal VSV-G domain has the sequence of any one of SEQ ID NOs: 15-24, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 68. The delivery particle of any one of embodiments 55-67, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 141, 145, 147, 149, 153, 155, 161, 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 69. The delivery particle of any one of embodiments 55-67, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171. 173, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 70. The delivery particle of any one of embodiments 55-67, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 162, 139, 153, 155, 182, 196, and 169, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 71. The delivery particle of any one of embodiments 55-67, wherein the chimeric VSV-G comprises the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.Embodiment 72. The delivery particle of any one of embodiments 55-71, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 1.Embodiment 73. The delivery particle of any one of embodiments 55-72, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 13.Embodiment 74. The delivery particle of any one of embodiments 55-73, wherein the Indiana VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 1.Embodiment 75. The delivery particle of any one of embodiments 55-74, wherein the Cocal VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 13.Embodiment 76. The delivery particle of any one of embodiments 55-75, wherein the chimeric VSV-G has a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2. Embodiment 77. The delivery particle of any one of embodiments 55-76, wherein the chimeric VSV-G has an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2.99IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOEmbodiment 78. The delivery particle of any one of embodiments 55, 57-75, and 77, wherein the chimeric VSV-G has a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.Embodiment 79. The delivery particle of any one of embodiments 55-78, wherein the chimeric VSV-G comprises a TS, T, or S substitution contained in any one of SEQ ID NO: 27-78, 133, 230, and 231.Embodiment 80. The delivery particle of any one of embodiments 55-79, wherein the chimeric VSV-G comprises a TS pair contained in any one of SEQ ID NO: 27-78, 133, 230, and 231. Embodiment 81. The delivery particle of any one of embodiments 55-80, wherein the chimeric VSV-G does not comprise an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2 and / or does not comprise a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.Embodiment 82. The delivery particle of any one of embodiments 55-81, wherein the SG domain comprises SEQ ID NO: 3, the DI domain comprises SEQ ID NO: 4 and 5, the DII domain comprises SEQ ID NO: 6, 7, and 8, the Dill domain comprises SEQ ID NO: 9 and 10, the DIV domain comprises SEQ ID NO: 11, and / or the TM domain comprises SEQ ID NO: 12. Embodiment 83. The delivery particle of any one of embodiments 55-82, wherein the SG domain comprises SEQ ID NO: 15, the DI domain comprises SEQ ID NO: 16 and 17, the DII domain comprises SEQ ID NO: 18, 19, and 20, the Dill domain comprises SEQ ID NO: 21 and 22, the DIV domain comprises SEQ ID NO: 23, and / or the TM domain comprises SEQ ID NO: 24.Embodiment 84. The delivery particle of any one of embodiments 55-83, wherein the delivery particle comprises a targeting moiety that binds to a cell surface receptor, a T cell antigen, or a tumor antigen.Embodiment 85. The delivery particle of embodiment 84, wherein the T cell antigen is CD5, CD7, CD27, or CD3.Embodiment 86. The delivery particle of any one of embodiments 55-85, wherein the delivery particle comprises a pay load comprising a nucleic acid, a protein, a small molecule, or a combination thereof.Embodiment 87. The delivery particle of any one of embodiments 55-86, wherein the delivery particle comprises a payload comprising a gene editing system, a polynucleotide encoding a transgene, a peptide, and / or a detectable marker.Embodiment 88. The delivery particle of any one of embodiments 55-87, wherein the delivery particle exhibits fusogenic activity.Embodiment 89. The delivery particle of any one of embodiments 55-88, wherein the delivery particle exhibits fusogenic activity comparable to or better than that of a delivery particle comprising Indiana VSV-G.100IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOEmbodiment 90. The delivery particle of any one of embodiments 55-89, wherein the delivery particle exhibits low off target activity.Embodiment 91. The delivery particle of any one of embodiments 55-90, wherein the delivery particle exhibits reduced off target activity compared to a delivery particle comprising Indiana VSV-G.Embodiment 92. The delivery particle of any one of embodiments 55-91, wherein the delivery particle exhibits higher resistance to serum neutralization than a delivery particle comprising Indiana VSV-G.Embodiment 93. The delivery particle of any one of embodiments 55-92, wherein the delivery particle exhibits 2-fold to 10-fold higher fusogenic activity in the presence of serum than a delivery particle comprising Indiana VSV-G.Embodiment 94. The delivery particle of any one of embodiments 55-93, wherein the delivery particle is a virus-like particle ("VLP").Embodiment 95. A method of delivering a pay load to a population of target cells comprising contacting the population of target cells with the delivery particle of any one of the preceding embodiments.Embodiment 96. A method of editing a population of target cells comprising contacting the population of target cells with the delivery particle of any one of the preceding embodiments. Embodiment 97. A method of modifying a population of target cells to express a transgene comprising contacting the population of target cells with the delivery particle of any one of the preceding embodiments.Embodiment 98. The method of any one of embodiments 95-97, wherein the target cells are germ cells.Embodiment 99. The method of any one of embodiments 95-97, wherein the target cells are somatic cells.Embodiment 100. The method of any one of embodiments 95-97, wherein the target cells are cancer cells.Embodiment 101. The method of any one of embodiments 95-97, wherein the target cells are immune cells.Embodiment 102. The method of any one of embodiments 95-97, wherein the target cells are infected cells, autoimmune cells, or diseased cells.101IPTS / 2003972907
Claims
ATTORNEY DOCKET NO.: AZL-007WOCLAIMS1. A chimeric vesicular stomatitis virus glycoprotein G (VSV-G) comprising:a) one or more Indiana VSV-G domains; andb) one or more Cocal VSV-G domains.
2. The chimeric VSV-G of claim 1, wherein the chimeric VSV-G comprises an immature VSV-G comprising:a) a signal peptide (SG), a lateral domain (DI), a trimerization domain (DII), and a pleckstrin homology domain (Dill) from an Indiana VSV-G: andb) a fusion domain (DIV) and a transmembrane domain (TM) from a Cocal VSV-G.
3. The chimeric VSV-G of claim 1, wherein the chimeric VSV-G comprises a mature VSV-G comprising:a) a lateral domain (DI), a trimerization domain (DII), and a pleckstrin homology domain (Dill) from an Indiana VSV-G: andb) a fusion domain (DIV) and a transmembrane domain (TM) from a Cocal VSV-G.
4. A chimeric VSV-G comprising:a) one or more Indiana VSV-G domains;b) one or more Cocal VSV-G domains; andc) a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.
5. The chimeric VSV-G of any one of claims 1-4, wherein the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of the respective domains of the amino acid sequence of SEQ ID NO: 1.
6. The chimeric VSV-G of any one of claims 1-4, wherein the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of the respective domains of the amino acid sequence of SEQ ID NO: 307.
7. The chimeric VSV-G of any one of claims 1-6, wherein the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the 102IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOtrimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of the respective domains of the amino acid sequence of SEQ ID NO: 309.
8. The chimeric VSV-G of any one of claims 1-6, wherein the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of the respective domains of the amino acid sequence of SEQ ID NO: 13.
9. The chimeric VSV-G of any one of claims 1-8, wherein the chimeric VSV-G comprises a signal peptide (SG), a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM).
10. The chimeric VSV-G of any one of claims 1-8, wherein the chimeric VSV-G comprises a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM).
11. The chimeric VSV-G of any one of claims 1-10, wherein each respective domain comprises either an Indiana VSV-G domain or a Cocal VSV-G domain.
12. The chimeric VSV-G of any one of claims 1-11, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Indiana VSV-G.
13. The chimeric VSV-G of any one of claims 1-11, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Cocal VSV-G.
14. The chimeric VSV-G of any one of claims 1-11, wherein the chimeric VSV-G comprises 3 domains from Indiana VSV-G and 2 domains from Cocal VSV-G, not inclusive of the signal peptide (SG).
15. The chimeric VSV-G of any one of claims 1-14, wherein:(a) the Indiana VSV-G SG domain comprises amino acids 1-16 of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;(b) the Indiana VSV-G DI domain comprises two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;103IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(c) the Indiana VSV-G DII domain comprises three segments comprising amino acids 35- 52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (d) the Indiana VSV-G Dill domain comprises two segments comprising amino acids 53-69 and 198-275, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;(e) the Indiana VSV-G DIV domain comprises amino acids 70-197 of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; and(1) the Indiana VSV-G TM domain comprises amino acids 425-512 of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307.
16. The chimeric VSV-G of claim 15, wherein:(a) the Indiana VSV-G SG domain comprises SEQ ID NO: 3;(b) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5 or comprising SEQ ID NO: 4 and 311, respectively;(c) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively;(d) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10 or comprising SEQ ID NO: 312 and 10, respectively;(e) the Indiana VSV-G DIV domain comprises SEQ ID NO: 11; and(f) the Indiana VSV-G TM domain comprises SEQ ID NO: 12.
17. The chimeric VSV-G of any one of claims 1-16, wherein:(a) the Cocal VSV-G SG domain comprises amino acids 1-17 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13;(b) the Cocal VSV-G DI domain comprises two segments comprising amino acids 18-35 and 328-399, respectively, of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13;104IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(c) the Cocal VSV-G DII domain comprises three segments comprising amino acids 36-53, 277-327, and 400-425, respectively, of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; (d) the Cocal VSV-G Dill domain comprises two segments comprising amino acids 53-69 and 199-276, respectively, of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13;(e) the Cocal VSV-G DIV domain comprises amino acids 71-198 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; and(I) the Cocal VSV-G TM domain comprises amino acids 426-513 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13.
18. The chimeric VSV-G of claim 17, wherein:(a) the Cocal VSV-G SG domain comprises SEQ ID NO: 15;(b) the Cocal VSV-G DI domain comprises two segments comprising SEQ ID NO: 16 and 17 or comprising SEQ ID NO: 16 and 313, respectively;(c) the Cocal VSV-G DII domain comprises three segments comprising SEQ ID NO: 18, 19, and 20, respectively;(d) the Cocal VSV-G Dill domain comprises two segments comprising SEQ ID NO: 21 and 22 or comprising SEQ ID NO: 314 and 22, respectively;(e) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and(f) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
19. A chimeric VSV-G comprising:(a) an Indiana VSV-G SG domain comprising amino acids 1-16 of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;(b) an Indiana VSV-G DI domain comprising two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;105IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(c) an Indiana VSV-G DII domain comprising three segments comprising amino acids 35- 52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (d) an Indiana VSV-G Dill domain comprising two segments comprising amino acids 53- 69 and 198-275, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;(e) a Cocal VSV-G DIV domain comprising amino acids 71-198 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; and(1) a Cocal VSV-G TM domain comprising amino acids 426-513 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13.
20. The chimeric VSV-G claim 19, wherein:(a) the Indiana VSV-G SG domain comprises SEQ ID NO: 3;(b) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5 or comprising SEQ ID NO: 4 and 311, respectively;(c) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively;(d) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10 or comprising SEQ ID NO: 312 and 10, respectively;(e) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and(f) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
21. The chimeric VSV-G claim 19, wherein:(a) the Indiana VSV-G SG domain comprises SEQ ID NO: 3;(b) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5, respectively;(c) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7. and 8, respectively;(d) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10, respectively;106IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(e) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and(f) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
22. A chimeric VSV-G comprising:(a) an Indiana VSV-G DI domain comprising two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;(b) an Indiana VSV-G Dll domain comprising three segments comprising amino acids 35- 52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein, optionally wherein the hill-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (c) an Indiana VSV-G Dill domain comprising two segments comprising amino acids 53- 69 and 198-275, respectively, of a full-length Indiana VSV-G protein, optionally wherein the foil-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;(d) a Cocal VSV-G DIV domain comprising amino acids 71-198 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; and(e) a Cocal VSV-G TM domain comprising amino acids 426-513 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13.
23. The chimeric VSV-G of claim 22, wherein:(a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5 or comprising SEQ ID NO: 4 and 311, respectively;(b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively;(c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10 or comprising SEQ ID NO: 312 and 10, respectively;(d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and(e) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
24. The chimeric VSV-G of claim 22, wherein:(a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5, respectively;107IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively;(c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10, respectively;(d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and(e) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
25. The chimeric VSV-G of any one of the above claims, wherein the Indiana VSV-G domain has one or more of the sequences of any one of SEQ ID NO: 3-12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
26. The chimeric VSV-G of any one of the above claims, wherein the Cocal VSV-G domain has one or more of the sequences of any one of SEQ ID NOs: 15-24, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
27. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 139, 156, 158, 162, 164, 166, 141, 145, 147, 149, 153, 155, 161, 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
28. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 139, 156, 158, 162, 164, 166, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171, 173, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
29. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 139, 162, 153, 155, 182, 196, and 169, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
30. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G comprises the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.108IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO31. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G consists of the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
32. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G comprises the sequence of SEQ ID NO: 306, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
33. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G consists of the sequence of SEQ ID NO: 306, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
34. The chimeric VSV-G of any one of the above claims, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 2, optionally between 80% and 90% or between 85% and 90% sequence identity.
35. The chimeric VSV-G of any one of the above claims, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 14, optionally between 80% and 90% or between 85% and 90% sequence identity.
36. The chimeric VSV-G of any one of the above claims, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 2 and between about 70% and about 90% sequence identity with SEQ ID NO: 14, optionally between 80% and 90% or between 85% and 90% sequence identity with respect to both SEQ ID NO: 2 and SEQ ID NO: 14.
37. The chimeric VSV-G of any one of the above claims, wherein one or more of the Indiana VSV-G domains comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding Indiana VSV-G domain of SEQ ID NO: 1.
38. The chimeric VSV-G of any one of the above claims, wherein one or more of the Cocal VSV-G domains comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding Cocal VSV-G domain of SEQ ID NO: 13.
39. The chimeric VSV-G of any one of the above claims, wherein the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated.
40. The chimeric VSV-G of any one of the above claims, wherein the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine.109IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO41. The chimeric VSV-G of any one of the above claims, wherein the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine.
42. The chimeric VSV-G of any one of the above claims, wherein the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated to a residue wherein the chimeric VSV-G binding to a LDL receptor is reduced or eliminated.
43. The chimeric VSV-G of any one of the above claims, wherein the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated.
44. The chimeric VSV-G of any one of the above claims, wherein the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine.
45. The chimeric VSV-G of any one of the above claims, wherein the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 SEQ ID NO: 310 is substituted with a glutamine.
46. The chimeric VSV-G of any one of the above claims, wherein the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is mutated to a residue wherein the chimeric VSV-G binding to a LDL receptor is reduced or eliminated.
47. The chimeric VSV-G of any one of the above claims, wherein the lysine residue corresponding to residue number 47 and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 are each mutated, respectively.
48. The chimeric VSV-G of any one of the above claims, wherein the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine.
49. The chimeric VSV-G of any one of the above claims, wherein the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine.
50. The chimeric VSV-G of any one of the above claims, wherein the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with a glutamine.110IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO51. The chimeric VSV-G of any one of the above claims, wherein the lysine residue corresponding to residue number 47 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 is substituted with an alanine.
52. The chimeric VSV-G of any one of the above claims, wherein the lysine residue corresponding to residue number 47 and the arginine residue corresponding to residue number 354 of SEQ ID NO: 2 or SEQ ID NO: 310 are each mutated, respectively, to a residue wherein the chimeric VSV-G binding to a LDL receptor is reduced or eliminated.
53. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G has a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.
54. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G comprises a TS, T, or S substitution contained in any one of SEQ ID NO: 27-78, 133, 230, and 231.
55. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G comprises a TS pair contained in any one of SEQ ID NO: 27-78, 133, 230, and 231.
56. The chimeric VSV-G of any one of the above claims, wherein the chimeric VSV-G does not comprise an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2 and / or does not comprise a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.
57. A chimeric VSV-G comprising:a) one or more domains having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; and b) one or more domains having at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain, wherein the chimeric VSV-G has less than least 90% sequence identity with an Indiana VSV-G or a Cocal VSV-G, optionally between about 70% and about 90% sequence identity with SEQ ID NO: 2 and between about 70% and about 90% sequence identity with SEQ ID NO: 14, optionally between 80% and 90% or between 85% and 90% sequence identity with respect to both SEQ ID NO: 2 and SEQ ID NO: 14.
58. The chimeric VSV-G of claim 57, wherein the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain 111IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 1.
59. The chimeric VSV-G of claim 57 or 58, wherein the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 13.
60. The chimeric VSV-G of any one of claims 57-59, wherein the SG domain comprises SEQ ID NO: 3, the DI domain comprises SEQ ID NO: 4 and 5, the DII domain comprises SEQ ID NO: 6, 7, and 8, the Dill domain comprises SEQ ID NO: 9 and 10, the DIV domain comprises SEQ ID NO: 11, and / or the TM domain comprises SEQ ID NO: 12.
61. The chimeric VSV-G of any one of claims 57-60, wherein the SG domain comprises SEQ ID NO: 15, the DI domain comprises SEQ ID NO: 16 and 17, the DII domain comprises SEQ ID NO: 18, 19, and 20, the Dill domain comprises SEQ ID NO: 21 and 22, the DIV domain comprises SEQ ID NO: 23, and / or the TM domain comprises SEQ ID NO: 24.
62. The chimeric VSV-G of any one of claims 57-61, wherein the chimeric VSV-G comprises a signal peptide (SG), a lateral domain (DI), a trimerization domain (Dll), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM).
63. The chimeric VSV-G of any one of claims 57-62, wherein the chimeric VSV-G comprises a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM).
64. The chimeric VSV-G of claim 61 or 62, wherein each domain is an Indiana VSV-G domain or a Cocal VSV-G domain.
65. The chimeric VSV-G of any one of claims 57-64, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Indiana VSV-G.
66. The chimeric VSV-G of any one of claims 57-65, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Cocal VSV-G.
67. The chimeric VSV-G of any one of claims 57-66, wherein the Indiana VSV-G domain has the sequence of any one of SEQ ID NO: 3-12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
68. The chimeric VSV-G of any one of claims 57-67, wherein the Cocal VSV-G domain has the sequence of any one of SEQ ID NOs: 15-24, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.112IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO69. The chimeric VSV-G of any one of claims 57-68, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 141, 145, 147, 149, 153, 155, 161, 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
70. The chimeric VSV-G of any one of claims 57-69, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171, 173, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
71. The chimeric VSV-G of any one of claims 57-70, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 162, 139, 153, 155, 182, 196, and 169, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
72. The chimeric VSV-G of any one of claims 57-71, wherein the chimeric VSV-G comprises the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
73. The chimeric VSV-G of any one of claims 57-72, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 1.
74. The chimeric VSV-G of any one of claims 57-73, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 13.
75. The chimeric VSV-G of any one of claims 57-74, wherein the Indiana VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 1.
76. The chimeric VSV-G of any one of claims 57-75, wherein the Cocal VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 13.
77. The chimeric VSV-G of any one of claims 57-76, wherein the chimeric VSV-G has a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.113IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO78. The chimeric VSV-G of any one of claims 57-77, wherein the chimeric VSV-G has an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2.
79. The chimeric VSV-G of any one of claims 57-78, wherein the chimeric VSV-G has a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.
80. The chimeric VSV-G of any one of claims 57-79, wherein the chimeric VSV-G comprises a TS, T, or S substitution contained in any one of SEQ ID NO: 27-78, 133, 230, and 231.
81. The chimeric VSV-G of any one of claims 57-80, wherein the chimeric VSV-G comprises a TS pair contained in any one of SEQ ID NO: 27-78, 133, 230, and 231.
82. The chimeric VSV-G of any one of claims 57-81, wherein the chimeric VSV-G does not comprise an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2 and / or does not comprise a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.
83. An isolated nucleic acid, the isolated nucleic acid encoding the chimeric VSV-G of any one of the above claims.
84. A vector encoding the isolated nucleic acid of claim 83, optionally wherein the vector comprise a promoter operably linked to the isolated nucleic acid encoding the chimeric VSV-G.
85. A host cell comprising the isolated nucleic acid of claim 83 or the vector of claim 84.
86. A method of producing a delivery particle, the method comprising contacting a host cell with the isolated nucleic acid of claim 83 or the vector of claim 84 and one or more components for viral production or virus-like particle production, or plasmids encoding the same.
87. The method of claim 86, wherein the one or more components for viral production or viruslike particle production comprise one or more viral structural proteins, optionally wherein the one or more viral structural proteins comprise a Gag protein, a Pol protein, a Gag-Pol fusion protein, or a plasmid encoding the same, further optionally a plasmid encoding each of the Gag protein a Pol protein.
88. The method of claim 86 or 87, wherein the method produces an increased amount of the delivery particles relative to the amount of delivery particles produced using an Indiana VSV-G under equivalent conditions.114IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO89. The method of claim 88, wherein the method produces at least a 3-fold increase in the amount of the delivery particles relative to the amount of delivery particles produced using an Indiana VSV-G90. The method of any one of claims 86-89, wherein the delivery particle is a vims-like particle (“VLP”),91. A VSV-G trimer comprising the chimeric VSV-G according to any one of claims 1-82.
92. A viral envelope comprising the chimeric VSV-G according to any one of claims 1-82 or the VSV-G trimer of claim 91.
93. A delivery particle comprising the chimeric VSV-G according to any one of claims 1-82 or the VSV-G trimer of claim 91.
94. A delivery particle comprising a chimeric VSV-G comprising:a) one or more domains having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; and b) one or more domainshaving at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain.
95. A delivery particle comprising a chimeric VSV-G comprising:a) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain;b) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain; andc) a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.
96. A delivery particle comprising a chimeric VSV-G comprising:a) a lateral domain (DI), a trimerization domain (DII), and a pleckstrin homology domain (Dill) from an Indiana VSV-G; andb) a fusion domain (DIV) and a transmembrane domain (TM) from a Cocal VSV-G.
97. The delivery particle of claim 96, wherein:(a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5 or comprising SEQ ID NO: 4 and 311, respectively;(b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively;115IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10 or comprising SEQ ID NO: 312 and 10, respectively;(d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and(e) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
98. The delivery particle of claim 96, wherein:(a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5, respectively;(b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively;(c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10, respectively;(d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and(e) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
99. A delivery particle comprising:a) a chimeric VSV-G comprising:i) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; and ii) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain; b) a targeting moiety on the surface of the delivery particle; andc) a payload encapsidated within the particle.
100. A delivery particle comprising:a) a chimeric VSV-G comprising:i) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with an Indiana VSV-G domain; and ii) a domain having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with a Cocal VSV-G domain; b) a targeting moiety on the surface of the delivery particle; andc) a gene-editing system encapsidated within the delivery particle.116IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO 101. A delivery particle comprising:a) a chimeric VSV-G comprising:i) a lateral domain (DI), a trimerization domain (DII), and a pleckstrin homology domain (Dill) from an Indiana VSV-G; and ii) a fusion domain (DIV) and a transmembrane domain (TM) from a Cocal VSV-G;b) a targeting moiety on the surface of the delivery particle; andc) a payload encapsidated within the particle, optionally wherein the payload comprises a gene-editing system.
102. The delivery particle of claim 101, wherein:(a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5 or comprising SEQ ID NO: 4 and 311, respectively;(b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively;(c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10 or comprising SEQ ID NO: 312 and 10, respectively;(d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and(e) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
103. The delivery particle of claim 101, wherein:(a) the Indiana VSV-G DI domain comprises two segments comprising SEQ ID NO: 4 and 5, respectively;(b) the Indiana VSV-G DII domain comprises three segments comprising SEQ ID NO: 6, 7, and 8, respectively;(c) the Indiana VSV-G Dill domain comprises two segments comprising SEQ ID NO: 9 and 10, respectively;(d) the Cocal VSV-G DIV domain comprises SEQ ID NO: 23; and(e) the Cocal VSV-G TM domain comprises SEQ ID NO: 24.
104. The delivery particle of any one of claims 93-103, wherein the Indiana VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the117IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOtrimerization domain (DII), the pleckstrin homology domain (Dill), the fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 1.
105. The delivery particle of any one of claims 93-104, wherein the Cocal VSV-G domain is selected from the list consisting of: the signal peptide (SG), the lateral domain (DI), the trimerization domain (DII), the pleckstrin homology domain (Dill), fusion domain (DIV), and the transmembrane domain (TM) of SEQ ID NO: 13.
106. The delivery particle of any one of claims 93-105, wherein the chimeric VSV-G comprises a signal peptide (SG), a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM).
107. The delivery particle of any one of claims 93-106, wherein the chimeric VSV-G comprises a lateral domain (DI), a trimerization domain (DII), a pleckstrin homology domain (Dill), a fusion domain (DIV), and a transmembrane domain (TM).
108. The delivery particle of claim 106 or 107, wherein each domain is an Indiana VSV-G domain or a Cocal VSV-G domain.
109. The delivery particle of any one of claims 93-108, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Indiana VSV-G.
110. The delivery particle of any one of claims 93-109, wherein the chimeric VSV-G comprises 1, 2, 3, 4, or 5 domains from Cocal VSV-G.
111. The delivery particle of any one of claims 93-110, wherein the Indiana VSV-G domain has the sequence of any one of SEQ ID NO: 3-12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
112. The delivery particle of any one of claims 93-111, wherein the Cocal VSV-G domain has the sequence of any one of SEQ ID NOs: 15-24, or a sequence having at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
113. The delivery particle of any one of claims 93-112, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 141, 145, 147, 149, 153, 155, 161. 174, 178, 180, 182, 186, 188, 194, 196, 169, 171, 173, 177, 179, 185, and 193, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
114. The delivery particle of any one of claims 93-113, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 156, 158, 162, 164, 166, 139, 147, 153, 155, 161, 174, 178, 182, 186, 188, 194, 196, 169, 171, 173, 179, 185, and 193, or a sequence having 118IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WOat least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
115. The delivery particle of any one of claims 93-114, wherein the chimeric VSV-G comprises the sequence of any one of SEQ ID NO: 162, 139, 153, 155, 182, 196, and 169, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
116. The delivery particle of any one of claims 93-115, wherein the chimeric VSV-G comprises the sequence of SEQ ID NO: 139, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity thereto.
117. The delivery particle of any one of claims 93-116, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 1.
118. The delivery particle of any one of claims 93-117, wherein the amino acid sequence of the chimeric VSV-G has between about 70% and about 90% sequence identity with SEQ ID NO: 13.
119. The delivery particle of any one of claims 93-118, wherein the Indiana VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 1.
120. The delivery particle of any one of claims 93-119, wherein the Cocal VSV-G domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid mutations compared to the corresponding domain of SEQ ID NO: 13.
121. The delivery particle of any one of claims 93-120, wherein the chimeric VSV-G has a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.
122. The delivery particle of any one of claims 93-121, wherein the chimeric VSV-G has an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2.
123. The delivery particle of any one of claims 93-122, wherein the chimeric VSV-G has a deletion of the lysine amino acid corresponding to position 47 of SEQ ID NO: 2.
124. The delivery particle of any one of claims 93-123, wherein the chimeric VSV-G comprises a TS, T, or S substitution contained in any one of SEQ ID NO: 27-78, 133, 230, and 231.
125. The delivery particle of any one of claims 93-124, wherein the chimeric VSV-G comprises a TS pair contained in any one of SEQ ID NO: 27-78, 133, 230, and 231.119IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO126. The delivery particle of any one of claims 93-125, wherein the chimeric VSV-G does not comprise an alanine at the residue corresponding to residue number 354 of SEQ ID NO: 2 and / or docs not comprise a glutamine at the residue corresponding to residue number 47 of SEQ ID NO: 2.
127. The delivery particle of any one of claims 93-126, wherein the SG domain comprises SEQ ID NO: 3, the DI domain comprises SEQ ID NO: 4 and 5, the DII domain comprises SEQ ID NO: 6, 7, and 8, the Dill domain comprises SEQ ID NO: 9 and 10, the DIV domain comprises SEQ ID NO: 11, and / or the TM domain comprises SEQ ID NO: 12.
128. The delivery particle of any one of claims 93-127, wherein the SG domain comprises SEQ ID NO: 15, the DI domain comprises SEQ ID NO: 16 and 17, the DII domain comprises SEQ ID NO: 18, 19, and 20, the Dill domain comprises SEQ ID NO: 21 and 22, the DIV domain comprises SEQ ID NO: 23, and / or the TM domain comprises SEQ ID NO: 24.
129. The delivery particle of any one of claims 99-128, wherein the targeting moiety binds to a cell surface receptor, a T cell antigen, or a tumor antigen.
130. The delivery particle of claim 129, wherein the T cell antigen comprises one or more antigens selected from the group consisting of: CD2, CD3, CD4, CD5, CD7, CD8, CD 19, CD28, 4- IBB ligand, T cell receptor (TCR) a constant chain, TCR beta constant chain, major histocompatibility complex (MHC) presenting a T cell receptor (TCR) specific peptide.
131. The delivery particle of claim 129, wherein the targeting moiety binds to each of CD3, CD28, and CD2.
132. The delivery particle of any one of claims 99-131, wherein the pay load comprises a nucleic acid, a protein, a small molecule, or a combination thereof.
133. The delivery particle of any one of claims 99-131, wherein the pay load comprises a gene editing system, a polynucleotide encoding a transgene, a peptide, and / or a detectable marker.
134. The delivery particle of any one of claims 93-133, wherein the delivery particle exhibits fusogenic activity.
135. The delivery particle of any one of claims 93-134, wherein the delivery particle exhibits fusogenic activity comparable to or better than that of a delivery particle comprising Indiana VSV-G.120IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO136. The delivery particle of any one of claims 93-135, wherein the delivery particle exhibits low off-target activity.
137. The delivery particle of any one of claims 93-136, wherein the delivery particle exhibits reduced off-target activity compared to a delivery particle comprising Indiana VSV-G.
138. The delivery particle of any one of claims 93-137, wherein the delivery particle exhibits higher resistance to serum neutralization than a delivery particle comprising Indiana VSV- G.
139. The delivery particle of any one of claims 93-138, wherein the delivery particle exhibits 2- fold to 10-fold higher fusogenic activity in the presence of serum than a delivery particle comprising Indiana VSV-G.
140. The delivery particle of any one of claims 93-139, wherein the delivery particle is capable of being produced at a higher titer relative to a delivery particle comprising Indiana VSV-G under equivalent conditions.
141. The delivery particle of any one of claims 93-140, wherein the delivery particle is a viruslike particle (“VLP”).
142. A VLP comprising a chimeric VSV-G, wherein the chimeric VSV-G comprises:a) one or more Indiana VSV-G domains; andb) one or more Cocal VSV-G domains.
143. The VLP of claim 142, wherein the chimeric VSV-G comprises:(a) an Indiana VSV-G SG domain comprising amino acids 1-16 of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;(b) an Indiana VSV-G DI domain comprising two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;(c) an Indiana VSV-G DII domain comprising three segments comprising amino acids 35- 52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (d) an Indiana VSV-G Dill domain comprising two segments comprising amino acids 53- 69 and 198-275, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;121IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(e) a Cocal VSV-G DIV domain comprising amino acids 71-198 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; and(f) a Cocal VSV-G TM domain comprising amino acids 426-513 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13.
144. The VLP of claim 142, wherein the chimeric VSV-G comprises:(a) an Indiana VSV-G SG domain comprising SEQ ID NO: 3;(b) an Indiana VSV-G DI domain comprising two segments comprising SEQ ID NO: 4 and 5, respectively;(c) an Indiana VSV-G DII domain comprising three segments comprising SEQ ID NO: 6, 7, and 8, respectively;(d) an Indiana VSV-G Dill domain comprising two segments comprising SEQ ID NO: 9 and 10, respectively;(e) a Cocal VSV-G DIV domain comprising SEQ ID NO: 23; and(f) a Cocal VSV-G TM domain comprising SEQ ID NO: 24.
145. The VLP of claim 142, wherein the chimeric VSV-G comprises:(a) an Indiana VSV-G DI domain comprising two segments comprising amino acids 17-34 and 327-398, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;(b) an Indiana VSV-G DII domain comprising three segments comprising amino acids 35- 52, 276-326, and 399-424, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307; (c) an Indiana VSV-G Dill domain comprising two segments comprising amino acids 53- 69 and 198-275, respectively, of a full-length Indiana VSV-G protein, optionally wherein the full-length Indiana VSV-G protein is SEQ ID NO: 1 or SEQ ID NO: 307;(d) a Cocal VSV-G DIV domain comprising amino acids 71-198 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13; and122IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO(e) a Cocal VSV-G TM domain comprising amino acids 426-513 of a full-length Cocal VSV-G protein, optionally wherein the full-length Cocal VSV-G protein is SEQ ID NO: 309 or SEQ ID NO: 13.
146. The VLP of claim 142, wherein the chimeric VSV-G comprises:(a) an Indiana VSV-G DI domain comprising two segments comprising SEQ ID NO: 4 and 5, respectively;(b) an Indiana VSV-G DII domain comprising three segments comprising SEQ ID NO: 6, 7, and 8, respectively;(c) an Indiana VSV-G Dill domain comprising two segments comprising SEQ ID NO: 9 and 10, respectively;(d) a Cocal VSV-G DIV domain comprising SEQ ID NO: 23; and(e) a Cocal VSV-G TM domain comprising SEQ ID NO: 24.
147. The VLP of any one of claims 142-146, wherein the VLP is capable of being produced at a higher titer relative to a VLP comprising Indiana VSV-G under equivalent culturing conditions.
148. The VLP of any one of claims 142-147, wherein the VLP exhibits fusogenic activity equivalent to or better than that of a VLP comprising Indiana VSV-G at an equivalent viral titer.
149. The VLP of any one of claims 142-148, wherein the VLP exhibits activity equivalent to or better than that of a VLP comprising Indiana VSV-G following administration of an equivalent viral titer to a subject.
150. The VLP of claim 149, wherein the VLP comprises a payload comprising a gene editing system and the activity comprises genome editing efficiency.
151. The VLP of any one of claims 142-150, wherein the VLP comprises:a) a targeting moiety on the surface of the VLP; andb) a payload encapsidated within the VLP, optionally wherein the payload comprises a gene-editing system.
152. A method of delivering a payload to a population of target cells comprising contacting the population of target cells with the delivery particle of any one of claims 99-141 or the VLP of any one of claims 142-151.123IPTS / 2003972907ATTORNEY DOCKET NO.: AZL-007WO 153. A method of editing a population of target cells comprising contacting the population of target cells with the delivery particle of any one of claims 99-141 or the VLP of any one of claims 142-151.
154. A method of modifying a population of target cells to express a transgene comprising contacting the population of target cells with the delivery particle of any one of claims 99- 141 or the VLP of any one of claims 142-151.
155. The method of any one of claims 152-154, wherein the target cells are germ cells.
156. The method of any one of claims 152-154, wherein the target cells are somatic cells.
157. The method of any one of claims 152-154, wherein the target cells are cancer cells.
158. The method of any one of claims 152-154, wherein the target cells are immune cells.
159. The method of claim 158, wherein the immune cells are T cells, optionally wherein the T cells are naive T cells, stimulated T cells, primary T cells (e.g., uncultured), cultured T cells, immortalized T cells, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, or natural killer T cells.
160. The method of any one of claims 152-154, wherein the target cells are infected cells, autoimmune cells, or diseased cells.
161. The method of any one of claims 152-160, wherein the target cells are in vivo.124IPTS / 2003972907
